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Status of Alternative Approaches to Animal Testing
Abstract
EU legislation encourages a shift away from animal testing and the use of new advanced methodologies without reducing 
human and environment protection.
Cell and tissue-based methods are integrated with computational modelling in testing and assessment strategies for a more 
mechanistic-based safety assessment of chemicals and products. 
Alternative methods and approaches are also promoted and disseminated in areas of basic and applied research in life sciences.
Printed in Italy
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1Executive Summary
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) is 
an integral part of the European Commission's Joint Research Centre (JRC). Every year, EURL 
ECVAM produces a Status Report to inform its stakeholders about the progress being made in the 
development, validation and regulatory acceptance of alternative methods and approaches. The report 
describes primarily, but not exclusively, all the activities that EURL ECVAM has undertaken or has been 
involved in since the publication of the previous report (November 2016). 
The mandate of EURL ECVAM is described in Directive 2010/63/EU (EU, 2010) on the protection of 
animals used for scientific purposes and includes a number of duties (Article 48 and Annex VII) to 
advance the Replacement, Reduction and Refinement (the Three Rs) of animal testing. The current 
activities of EURL ECVAM build on over 25 years of JRC support to the Three Rs (EC, 1991) and include 
participation in research projects; coordination and undertaking of validation studies; dissemination 
and sharing of information on the Three Rs; and the promotion of dialogue towards the international 
acceptance and uptake of alternative methods and approaches. Besides Directive 2010/63/EU, EU 
chemicals legislation such as REACH (EC, 2008) and the Cosmetics Regulation (EC, 2009) have had an 
important impact on the Three Rs by increasing the pace and the number of methods being developed, 
validated and proposed for international adoption. 
Other pieces of EU chemicals and products legislation refer to alternative approaches and allow them 
to be used in hazard and risk assessment, including: Regulation (EC) No 1272/2008 on Classification, 
Labelling and Packaging of substances and mixtures (CLP); Regulation (EC) No 1107/2009 concerning 
the placing of plant protection products on the market; Regulation 283/2013 on data requirements for 
active substances; Regulation 284/2013 on data requirements for plant protection products; Regulation 
528/2012 concerning the making available on the market and use of biocidal products; Directive 
2001/83/EC (and its amendments) on the Community code relating to medicinal products for human 
use; and Directive 2001/82/EC (and its amendments) on the Community code relating to medicinal 
products for veterinary use. In addition, the Community Strategy on combined exposures ‘Mixtures’ 
(Bopp et al., 2015; Kienzler et al., 2016a) and the Community Strategy on Endocrine Disrupters (Bremer 
et al., 2012; Munn et al., 2016) are also important drivers of EURL ECVAM’s work since they present 
significant opportunities for the use of non-animal methods to address safety assessment challenges.
Research and development activities continue to be funded within large European collaborative 
programmes such as the H2020 flagship project EU-ToxRisk which is tackling complex health effects 
(endpoints) such as repeated-dose and reproductive toxicity. Research being undertaken aims to 
integrate scientific and technical advances in experimental and computational biology/toxicology to 
probe the complex chains of events that link chemical exposure to potential adverse outcomes in 
humans and environmental species. At international level, there is a growing impetus to explicitly use 
mechanistic reasoning to devise hypothesis-driven Integrated Approaches to Testing and Assessment 
(IATA) that incorporate multiple data streams derived from in vitro methods, 'omics techniques and 
computational modelling. In support of this, the Adverse Outcome Pathway (AOP) development 
programme at the OECD continues to play a key role in providing a framework to structure and 
synthesise scientific knowledge on toxicological processes to make it suitable and freely accessible for 
chemical risk assessment purposes. 
At the level of validation and standardisation of non-animal approaches, there is growing interest 
to evolve the definition and utility of performance standards for assessing classes of methods 
that provide similar (mechanistic) information, and to move towards evaluation frameworks for so-
called Defined Approaches (DA), that combine non-animal methods together with a rule-based data 
interpretation procedure to arrive at a conclusion in support of a regulatory decision. A related initiative 
at the OECD is exploring how scientifically valid DAs can be put on an equal footing with conventional 
in vivo Test Guidelines in order to satisfy requirements for the Mutual Acceptance of Data between 
OECD Member Countries. Mutual Acceptance of Data is the main instrument for ensuring global 
harmonisation of chemical testing to minimise the use of animals and reduce costs.
2For health effects such as skin irritation, skin corrosion, eye irritation, serious eye damage and 
skin sensitisation, IATA frameworks have already been adopted at international level. In addition, 
an informal working group was set up under the United Nations Sub-Committee of experts on the 
Globally Harmonised System of Classification and Labelling of Chemicals (GHS) to explore the use of 
non-animal methods for toxicological hazard classification. For other areas including non-genotoxic 
carcinogenicity, developmental neurotoxicity, endocrine disruption, fish bioaccumulation testing, 
repeated dose toxicity and reproductive toxicology, steady progress is being made and the work is at 
different stages of development or validation.
The EU flagship project VAC2VAC is progressing the development, optimisation and evaluation of non-
animal methods for routine batch testing of vaccines in order to avoid severe animal testing.
Finally, EURL ECVAM is working with its stakeholders to pursue opportunities to enhance knowledge 
sharing across sectors and communities to accelerate overall progress in the Three Rs in various domains 
including regulatory testing, basic, applied and translational research, and education and training. 
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1	 Introduction
Every year, EURL ECVAM prepares a Status Report with 
the primary purpose to inform its stakeholders and all 
interested parties (public, press, etc.) on updates on the 
status of alternative methods and approaches.
The EURL ECVAM status report provides updates on 
activities since the last report published in November 
2016. It reports on research, development and 
validation activities, as well as on activities which 
promote the regulatory and international adoption and 
use of alternative approaches and their dissemination. 
It describes primarily, but not exclusively, all the 
activities that EURL ECVAM has undertaken or has been 
involved in since the publication of the last report.
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2 Research and Development 
Activities on Alternative Methods
Under Horizon 2020, EURL ECVAM is collaborating 
on projects which develop animal-free strategies 
for the risk assessments of chemicals and chemical 
mixtures from different perspectives, evaluate the 
progress achieved in the area and identify further 
gaps to be still addressed.
The work of the EURL ECVAM laboratory directly 
supports the mandate given by Directive 
2010/63/EU on the protection of animals used for 
scientific purposes to coordinate and promote the 
development of alternative methods.
In this chapter current ongoing studies are 
described including collaborative work on projects 
for example with the consortium of the H2020 
project EU-ToxRisk and the US Environmental 
Protection Agency (US EPA). Several Research & 
Development projects related to fish toxicity and 
bioaccumulation, which are of specific interest to 
EURL ECVAM, are also described in this chapter.
The project "Vaccine batch to vaccine batch 
comparison by consistency testing" (VAC2VAC) 
focuses on the development and validation of non-
animal methods for vaccine quality control. 
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2 Research and Development 
Activities on Alternative Methods
2.1 SEURAT-1 Chemical Safety 
Assessment Workflow
In the framework of the European Commission 
and Cosmetics Europe 50 million euro-funded 
research initiative SEURAT-1, a workflow 
was designed to be applicable to cosmetic 
ingredients as well as to other types of 
chemicals, e.g., active ingredients in plant 
protection products, biocides or pharmaceuticals.
The intention was to develop an exposure driven 
workflow to assess chemical safety without 
relying on any animal testing, but instead 
constructing a hypothesis based on existing data, 
in silico modelling, biokinetic considerations and 
prove it through targeted non-animal testing. The 
outcome was recently published and is freely 
accessible on-line (Berggren et al., 2017).
The workflow is divided into tiers including a 
series of possible exit (decision) points, e.g., 
application of the Threshold of Toxicological 
Concern (TTC) approach might be used for 
low concentrations or read-across, in case 
the target chemical is "similar enough" to (an) 
already tested and assessed substance(s).
An evaluation and update of the TTC 
concept for application to cosmetics-related 
substances has also been carried out within 
one of the SEURAT-1 projects, COSMOS (Yang 
et al., 2017; Williams et al., 2016). If none 
of these "short cuts" (based on structural 
information and existing animal data) can be 
applied, the chemical safety is determined 
entirely by new approach methods and in 
vitro to in vivo extrapolation by means of 
mathematical modelling. 
READ MORE
SEURAT-1 - Towards 
the Replacement of in 
vivo Repeated Dose 
Systemic Toxicity 
Testing
www.seurat-1.eu
COSMOS project 
(part of SEURAT-1) 
- Integrated In Silico 
Models for the 
Prediction of Human 
Repeated Dose Toxicity 
of COSMetics to 
Optimise Safety
www.cosmostox.eu
Figure 2.1: Workflow for the safety assessment of chemicals without animal testing (From Berggren et al., 
2017, Computational Toxicology, 4, p. 33, under CC BY-SA 4.0).
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READ MORE
EU-ToxRisk - An 
Integrated European 
‘Flagship’ Programme 
Driving Mechanism-
based Toxicity Testing 
and Risk Assessment 
for the 21st century
www.eu-toxrisk.eu
Toxicology in the 21st 
Century (Tox21)
www.epa.gov/
chemical-research/
toxicology-testing-
21st-century-tox21
The workflow (see Figure 2.1) is a tool to inform 
targeted and toxicologically relevant in vitro 
testing, by structuring knowledge and data in 
a logical sequence for an integrated chemical 
safety assessment relying specifically on 
alternative methods and based on exposure 
considerations. Thus it is a means to gain 
confidence in safety decision making without 
the need for animal testing.
This "ab initio" workflow was also discussed 
from the perspective of "Integrated 
Approaches for Testing and Assessment (IATA)" 
in the OECD IATA Case Studies Project (see 
section 5.1.1). The chemical safety assessment 
workflow is thus an example of a living legacy 
from the SEURAT-1 Cluster, which has been 
taken up for further development by other 
ongoing research initiatives.
2.2 EU-ToxRisk 
EU-ToxRisk, the Integrated European ‘Flagship’ 
Programme Driving Mechanism-based Toxicity 
Testing and Risk Assessment for the 21st 
century, is a European collaborative project 
funded by the EU Framework Programme for 
Research and Innovation, Horizon 2020.
The project started on 1 January 2016 and 
will stay active for six years, with a budget of 
over 30 million €. The vision of EU-ToxRisk is to 
progress towards an animal-free toxicological 
assessment based on human cell responses and 
a comprehensive mechanistic understanding of 
cause-consequence relationships of chemical 
adverse effects.
EU-ToxRisk integrates advancements in cell 
biology, 'omics technologies, systems biology and 
computational modelling to define the complex 
chains of events that link chemical exposure to 
toxic outcome, and is a successful continuation 
of the prior FP7 research initiative SEURAT-1.
In fact, EURL ECVAM hosted in November 
2016 a workshop where SEURAT-1 got the 
opportunity to hand-over to EU-ToxRisk, 
communicating their main achievements and 
lessons learned (see section 4.11 and Box 2.1).
EU-ToxRisk presented their case studies 
and made a reality check of their regulatory 
relevance, by discussing with the EURL ECVAM 
regulatory network, PARERE, and its stakeholder 
forum, ESTAF, invited to the workshop.
The EU-ToxRisk first eight case studies have 
thereafter progressed considerably. Strong 
collaborations have been established with 
the US Tox21 programme and the European 
Commission, through the Joint Research Centre 
and its EURL ECVAM. There is a common 
belief that progress will be faster working 
together, and as much as possible ensure 
complementary and cross-fertilisation between 
different initiatives.
EURL ECVAM's PARERE network has officially 
been consulted on the four more advanced case 
studies within EU-ToxRisk and the outcome 
of that consultation will be discussed at the 
PARERE meeting on 27 to 28 November 2017. 
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EU-ToxRisk also organised its first winter school 
in February 2017.
2.3 European Research Projects 
on Chemical Mixtures
Several large research projects in the area of 
chemical mixtures have started in recent years 
in which EURL ECVAM is participating.
EuroMix is a Horizon 2020 project that 
started in 2015. EuroMix aims to develop an 
experimentally verified, tiered strategy for 
the risk assessment of mixtures of multiple 
chemicals derived from multiple sources. 
Important concepts for this new strategy are 
prioritisation criteria for chemicals based on 
their exposure and hazard characteristics 
and evaluation of the role of mode of action 
in grouping chemicals into cumulative 
assessment groups.
In silico and in vitro tools are developed and 
verified against in vivo experiments, with a 
focus on three selected endpoints (liver toxicity, 
hormonal disruption, and developmental 
toxicity) to provide a full proof-of-principle. 
EuroMix aims at developing an innovative 
platform for bioassays and a model toolbox for 
the exposure assessment.
EDC-MixRisk, which started in 2015, focuses 
on integrating epidemiology and experimental 
biology to improve risk assessment of exposure 
to mixtures of endocrine disruptive compounds 
(EDCs). EDC-MixRisk investigates risks for 
multiple adverse health outcomes based on 
molecular mechanisms involved after early life 
exposure to EDC mixtures.
The interdisciplinary project contributes to 
the: i) Identification of mixtures of EDCs that 
are associated with multiple adverse health 
outcomes; ii) Identification of molecular 
mechanisms and pathways underlying these 
associations; and iii) Development of methods 
for risk assessment of EDC mixtures to increase 
societal impact.
HBM4EU was launched in December 2016. It is 
a joint effort of 26 countries and the European 
Commission, co-funded by Horizon 2020. The 
READ MORE
EuroMix - A tiered 
strategy for risk 
assessment of mixtures 
of multiple chemicals
www.euromixproject.
eu
EDC-MixRisk - Safer 
Chemicals for future 
generations
edcmixrisk.ki.se
HBM4EU - The 
European Human 
Biomonitoring Initiative: 
science and policy for a 
healthy future
www.hbm4eu.eu
Exploring regulatory use of non-animal approaches in chemical 
safety assessment
On 9-10 November 2016 the JRC's EURL ECVAM hosted a workshop to explore 
the possible regulatory use of alternative approaches to systemic toxicity that 
are intended for the hazard and safety assessment of chemicals used in a 
variety of sectors.
The workshop was organised together with the recently concluded FP7 research 
initiative SEURAT-1 and the new Horizon 2020 
research project EU-ToxRisk. It brought together over 
70 participants from across the EU including experts 
from EURL ECVAM, the two research consortia, the 
EURL ECVAM regulatory network, PARERE, and the 
EURL ECVAM stakeholder forum, ESTAF.
The scope of the meeting was to address strengths 
and limitations of new approach methods (NAMs) 
emerging from scientific research and to understand 
how NAMs can be translated more efficiently and 
effectively into regulatory use. A selection of case 
studies exploring the utility of NAMs for different 
Box 2.1
predictive toxicology and safety assessment 
scenarios, which have been developed within the 
SEURAT-1 and EU-ToxRisk consortia, were used to fuel 
the discussions and trigger debate. There was general 
agreement that going forward, such case studies 
can serve as a very useful vehicle for continued 
engagement between developers, end-users and 
regulatory safety assessors.
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READ MORE
IMI 2 VAC2VAC 
project - Vaccine 
batch to vaccine 
batch comparison by 
consistency testing
www.vac2vac.eu
main aim of the initiative is to coordinate and 
advance human biomonitoring in Europe in 
order to provide better evidence of the actual 
exposure of citizens to chemicals and the 
possible health effects to support policy making.
One of the work packages is specifically on 
mixtures. This focuses on defining priority 
mixtures and real-life exposure patterns, and 
further developing practical approaches to 
identify and assess potential health risks and 
impacts of mixtures.
These projects, together with EU-ToxRisk 
(described in in section 2.2), linked up to discuss 
risk assessments of mixtures from the different 
perspectives, to evaluate the progress achieved 
and identify further gaps to be still addressed. 
A workshop on these projects involving several 
Commission services and EU agencies is 
currently being prepared with EURL ECVAM and 
will be hosted at JRC in May 2018.
2.4 The VAC2VAC Project
The VAC2VAC project - "Vaccine batch to 
vaccine batch comparison by consistency 
testing" is funded under the Innovative 
Medicines Initiative 2 (IMI 2), a joint 
undertaking of the European Union’s Horizon 
2020 research and innovation programme and 
the European Federation of Pharmaceutical 
Industries and Associations (EFPIA).
It was officially launched on 1 March 2016 and 
brings together 21 public and private partners 
including the JRC represented by EURL ECVAM.
The project is focused on the use of the 
consistency approach for quality control of 
established vaccines for human and veterinary 
use. The consistency approach moves away 
from the current focus on final product control 
often relying on animal testing. In the light 
of this, VAC2VAC partners are developing, 
optimising and evaluating non-animal methods, 
e.g., physicochemical and immunochemical 
methods, cell-based and other assays for 
routine batch quality, safety and efficacy testing 
of vaccines, in collaboration and consultation 
with regulatory agencies. 
EURL ECVAM is participating in the project as 
leader of the work package related to validation, 
and supports project activities related to 
international dissemination, harmonisation 
and regulatory acceptance of consistency 
approaches. In this role, EURL ECVAM organised 
with VAC2VAC partners a workshop to discuss 
ways of improving multi-centre validation 
studies and making use of the data generated 
for product-specific validation purposes.
The workshop was held at JRC (Ispra, Italy) on 
30 January to 1 February 2017 and involved 
30 experts from veterinary and human vaccine 
manufacturers, official medicines control 
laboratories, academia, translational research 
organisations, and vaccinology alliances (see 
Box 2.2). The summary of the discussions and 
recommendations will be published in 2018. 
2.5 In-house and Collaborative 
Experimental Studies in support 
of the EURL ECVAM Mandate
The EURL ECVAM Laboratory is designed 
to carry out typical cell biology/toxicology 
procedures which include cell banking 
(cryopreservation), cell culturing, cell 
characterisation (e.g., morphological or 
functional assessment), cell treatment (e.g., with 
reference toxicants), and cell-response analysis 
(e.g., a variety of technologies including high 
content cellular imaging, electrophysiological 
measurements, analytical (bio-) chemistry 
including Liquid Chromatography-Mass 
Spectrometry (LC-MS), and flow cytometry).
The Laboratory includes a number of 
automated (robotic) platforms for liquid 
handling and cell culturing which enable 
higher throughput and better reliability when 
testing larger sets of chemicals. The laboratory 
directly supports EURL ECVAM mandate as 
stated in Directive 2010/63/EU (EU, 2010) and 
also serves in collaboration projects such as 
those with the US Environmental Protection 
Agency (EPA) and the H2020 consortium 
EU-ToxRisk. Some examples of experimental 
studies are given below.
An in vitro metabolic hepatic clearance method 
(Lostia et al., 2016) was implemented to 
respond to the increasing demand to integrate 
kinetics information in toxicity testing. The 
results and experience gained in the project 
will support the drafting of an OECD Guidance 
Document with the objective to characterise 
and describe in vitro hepatic metabolic 
clearance methods (see section 5.2.11). 
vac2vac
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In the frame of the detection of chemicals 
with thyroid disrupting potential, EURL ECVAM 
is coordinating a validation study using a set 
of selected, mechanistically informative in 
vitro methods in collaboration with EU-NETVAL 
(see section 4.10 and Box 4.1). Some of these 
methods (e.g., the ANSA (8-anilino naphthalene 
sulfonic acid ammonium salt) displacement 
assay) have already been implemented in 
house and assessed.
A study on oxidative stress, one of the cellular 
responses determined at early stages of 
toxicity, was performed (Pistollato et al., 2016; 
Pistollato et al., 2017a,b). Nrf2 signalling 
activation upon induction of oxidative stress 
was assessed in neuronal and glial cells derived 
from hiPSCs treated with rotenone, an inhibitor 
of complex I of the mitochondrial respiratory 
chain. These studies indicate that analysis of 
Nrf2 signalling activation could serve as a basis 
for the establishment of a horizontal assay to 
assess oxidative stress induction (see Box 2.3).
2.6 Fish Toxicity and 
Bioaccumulation Research and 
Development Projects
Several R&D projects related to fish toxicity and 
bioaccumulation, which are of specific interest 
to EURL ECVAM, are described below. 
2.6.1 Use of a Fish Cell Line-Based 
Cytotoxicity Assay for Acute Fish 
Toxicity Testing
As a follow-up to the CEllSens project 
(Tanneberger et al., 2013) a ring trial evaluating 
the transferability and within-laboratory 
reproducibility of the RTgill-W1 (rainbow 
trout gill cell line) cytotoxicity assay has been 
organised by the Swiss Federal Institute of 
Aquatic Science and Technology (EAWAG; K. 
Schirmer; Cefic Long-Range Research Initiative 
[LRI] project ECO8.3-NC3Rs-EAWAG). A paper on 
the outcome of the ring trial is in preparation.
In addition, the method had been submitted 
to EURL ECVAM in early 2014 and the test 
submitter had been invited to provide a full 
submission (see Section 3.1 of EURL ECVAM 
Status Report 2015, Zuang et al., 2015).
An ISO guideline (ISO/CD 21115) "Water quality 
- Determination of acute toxicity of chemicals 
and water samples to a fish gill cell-line (RT 
gill-W1)" is in preparation.
2.6.2 Development of Adverse 
Outcome Pathways for Chronic Fish 
Toxicity Testing
Several research groups are working on the 
identification and description of potential 
Adverse Outcome Pathways (AOPs) relevant to 
READ MORE
CEllSens project
cefic-lri.org/projects/
eco8-development-
of-a-strategy-to-
predict-acute-fish-
lethality-using-fish-
cell-lines-and-fish-
embryos
ECO8.3-NC3Rs-EAWAG 
project
cefic-lri.org/projects/
eco8-3-nc3rs-eawag-
round-robin-test-of-
the-rtgill-w1-cell-
line-assay-to-study-
its-robustness-in-
establishment-and-
inter-laboratory-
comparability
VAC2VAC workshop on validation of non-animal 
methods for quality control of vaccines
The JRC's EU Reference Laboratory for alternatives to 
animal testing (EURL ECVAM) organised a workshop 
with VAC2VAC partners from 30 January to 1 
February 2017 to discuss ways of improving multi-
centre validation studies and making use of the data 
generated for product-specific validation purposes.
The VAC2VAC project aims to develop and validate 
non-animal based methods for the quality control 
of vaccines. In order to incorporate a new method 
into a monograph or a guideline used for regulatory 
purposes, the method has to be shown to be 
reproducible and to have the ability to detect vaccine 
batches of inferior quality.
Moreover, any new method introduced for the quality 
control of a vaccine needs to undergo product-specific 
validation. Both multi-centre validation studies and 
product-specific validation are technically demanding 
and time and resource intensive. In the light of this, the workshop focused on ways 
of improving multi-centre validation studies and making use of the data generated 
for product-specific validation purposes.
The workshop was held at JRC (Ispra, Italy) and involved 30 experts from veterinary 
and human vaccine manufacturers, official medicines control laboratories, 
academia, translational research organisations, and vaccinology alliances. The 
summary of the discussions and recommendations will be published during 2018.
Box 2.2
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chronic fish toxicity, which is currently assessed 
with a fish early life-stage (FELS) test (OECD 
TG 210, 2013a). As outcome of the Cefic 
LRI-funded project (LRI-ECO20-UA) two FELS-
relevant AOPs (AOP on AhR activation and AOP 
on thyroperoxidase and/or deiodinase inhibition 
leading to impaired swim bladder inflation in 
fish during early life stages) have been included 
into the OECD AOP work plan.
The overall objective of the recently started 
follow-up project LRI-ECO20.2 is the validation 
of the assays developed for the two most 
promising AOPs, the thyroid AOP and the 
narcosis AOP. It is planned to test around 25 
chemicals in vitro and to predict, based on 
the assay results, acute and chronic toxicity. 
The consortium further plans to perform, for 
a subset of the chemicals tested, acute (fish 
embryo toxicity test) and chronic fish toxicity 
tests (OECD TG 210, 2013a) to validate the 
predictions derived with the in vitro assays. 
2.6.3 Threshold of Toxicological Concern 
in Aquatic Toxicity Assessment
The ecological Threshold of Toxicological 
Concern (eco-TTC) has been proposed for 
environmental risk assessment as extension 
to the well-established human safety TTC 
concept (Belanger et al., 2015). An international 
collaboration/working group under the ILSI 
Health and Environmental Sciences Institute 
has been established who addressed over 
the last two years challenges relating to data 
collection, quality control, data characterisation 
and analysis as well as the development and 
application of useful eco-TTC concepts. 
The working group developed a database of 
approximately 110,000 unique ecotoxicological 
records, 6,200 chemicals and 1,900 species 
from three trophic levels (fish, invertebrates, 
algae/plants) and an on-line analytical tool that 
aims to calculate, based on those data, eco-TTC 
value according to particular research criteria.
 
A workshop held in September 2017 brought 
together participants representing academia, 
industry, national competent authorities, and 
regulatory bodies to discuss and evaluate 
the eco-TTC database and web-based tools 
through a series of presentations and case 
studies on potential use of the eco-TTC concept 
for environmental risk assessment. During this 
workshop, some potential improvements
were identified to make the tool more practical, 
Human relevant in vitro models for developmental 
neurotoxicity testing 
Exposure of developing organisms to chemicals may affect the development of 
the nervous system. In recent years, neurodevelopmental disorders in children 
have increased significantly. Therefore, the JRC's EURL ECVAM)is working with 
international partners to address the pressing need to implement reliable models 
to test potentially harmful effects of environmental chemicals and investigate 
mechanisms of developmental neurotoxicity (DNT) underlying chemical exposure.
Modern toxicity screening approaches are focused on reducing and replacing 
animal testing with alternative and human relevant models. In this context, human 
induced pluripotent stem cells (hiPSCs) represent important tools for toxicity 
screening because of their unique characteristics.
In a recent JRC study (Zagoura et al., 2017), hiPSC neuronal derivatives were used 
to assess the neurotoxic effects of rotenone - a broad-spectrum pesticide - after 
short-term exposure (24 hours). Rotenone induced the activation of the Nrf2 
signalling pathway*, which regulates cellular response to oxidative stress. Oxidative 
stress is an important hallmark of various neurodegenerative diseases, including 
Parkinson's disease.
In a new study (Pistollato et al., 2017a), JRC scientists investigated the effects of a 
prolonged rotenone exposure (14 days) on hiPSC-derived neural stem cells (NSCs) 
undergoing differentiation towards neurons and glia, assessing the expression and 
the activation of the Nrf2 pathway.
Box 2.3
Treatment with rotenone induced a progressive 
activation of Nrf2 signalling, together with an 
induction of astrocyte reactivity and neuronal 
cell death, in particular of dopaminergic neurons. 
Altogether these data indicate that hiPSC-neural 
models are relevant test systems for the evaluation 
of Nrf2 pathway activation upon induction of 
oxidative stress, allowing further understanding of 
the molecular mechanisms underlying exposure to 
developmental neurotoxicants.
*Signalling pathway describes a group of molecules in a cell that work 
together to control cell functions, such as cell division or cell death.
READ MORE
LRI-ECO20-UA project
cefic-lri.org/projects/
lri-eco20-ua-
development-of-an-
alternative-testing-
strategy-for-the-
fish-early-life-stage-
test-for-predicting-
chronic-toxicity
LRI-ECO20.2 project
cefic-lri.org/
projects/eco20-2-
development-of-an-
alternative-testing-
strategy-for-the-
fish-early-life-stage-
test-for-predicting-
chronic-toxicity-
assay-validation
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user friendly and fit for purpose. Those changes 
will be implemented shortly and the tool should 
be made publically available in 2018.
EURL ECVAM is contributing to this initiative, and 
worked in particular on the evaluation of the 
existing aquatic mode of action classification 
frameworks, their overlap and possibilities to 
move forward (Kienzler et al., 2017a).
2.6.4 Scientific Options for Avoiding 
Chronic Fish Testing on the Basis of Existing 
Data and Extrapolation Approaches
In the light of the EU Directive 2010/63/EU 
(EU, 2010) on the protection of animals used 
for scientific purposes and the EURL ECVAM 
strategy to replace, reduce and refine the use 
of fish in aquatic toxicity and bioaccumulation 
testing (Halder et al., 2014), EURL ECVAM 
explored whether interspecies extrapolations 
and acute-to-chronic relationships could be 
used to scientifically support the waiving of 
chronic fish tests.
For this purpose, acute and chronic toxicity 
data for Daphnia and fish were extracted from 
various databases and analysed to identify 
possible relationships taking into consideration 
different mode of actions. The results of 
this analysis indicate that several types of 
aquatic toxicity data can be used to assess the 
potential for chronic fish toxicity.
In particular, interspecies extrapolations based 
on invertebrate (Daphnia) data, and acute-to-
chronic extrapolations from existing acute fish 
toxicity data, are recommended as a means 
of deriving information on chronic fish toxicity 
without the need to perform additional fish 
tests (see Box 2.4).
More information is available in the JRC 
Technical Report (Kienzler et al., 2016b) and 
scientific paper (Kienzler et al., 2017b).
2.6.5 Development of a Tiered Testing 
Strategy for Fish Bioaccumulation 
Testing Based on in vitro Approaches 
This new Cefic LRI-funded project (LRI-ECO34) 
combines various in vitro approaches using 
fish cell lines to estimate chemical uptake 
and biotransformation with toxicokinetic and 
quantitative structure activity relationship 
models. The aim is to develop a tiered approach 
for the assessment of the bioaccumulation 
potential of chemicals.
READ MORE
LRI-ECO34 project
cefic-lri.org/projects/
eco34-a-tiered-
testing-strategy-for-
rapid-estimation-
of-bioaccumulation-
by-a-combined-
modelling-in-vitro-
testing-approach
A modelling approach to avoid chronic fish toxicity tests 
The assessment of aquatic toxicity is an important component of the 
environmental hazard and risk assessment of all types of chemicals. Aquatic 
toxicity is usually determined by testing on organisms representing the three 
trophic levels: plants (or algae), invertebrates (crustaceans such as Daphnia spp.) 
and vertebrates (fish). 
Whereas acute aquatic toxicity testing is a basic requirement in most pieces of EU 
chemicals legislation, chronic aquatic toxicity testing may be required on a case by 
case basis, for example when the outcome of the acute testing indicates a risk, or 
when long-term exposure to the chemical is expected. 
However, in accordance with EU Directive 2010/63/EU on 
the protection of animals used for scientific purposes, 
all available information should be considered before 
testing on vertebrates, including fish, is carried out.
In this context, the JRC has explored the utility of simple 
extrapolation approaches, based on existing aquatic 
toxicity data, for avoiding chronic fish testing (Kienzler 
et al.,, 2016b; Kienzler et al., 2017b). Acute and chronic 
toxicity data for Daphnia and fish were extracted from 
various databases and analysed to identify possible 
relationships taking into consideration the chemical 
mode of action.
Box 2.4
The results of this analysis indicate that interspecies 
extrapolations based on invertebrate (Daphnia) data 
could support the waiving of chronic fish toxicity test 
in low-tier risk assessments, especially for chemicals 
acting by unspecific reactivity and non-polar narcosis. 
Acute-to-chronic extrapolations from existing acute 
fish toxicity data are also recommended as a means 
of deriving information on chronic fish toxicity without 
the need to perform additional fish tests, irrespective 
of the chemical’s mode of action.
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2.6.6 Development of a 
Biotransformation Database
The biological fate of a substance in an 
organism plays an important role in exposure 
and risk assessment of chemicals in general. 
Four underlying processes: absorption, 
distribution, metabolism and excretion (ADME), 
determine the time-course of internal or 
systemic exposure, e.g., chemical half-life. 
For hydrophobic, low volatility chemicals, the 
chemical half-life is largely determined by the 
biotransformation (metabolism) rate constant. 
Biotransformation is usually determined with 
animal models or in vitro using intact cells or 
subcellular fractions from the liver.
The availability of a curated and quality 
assured database containing in vivo and in 
vitro biotransformation data will contribute to 
several EURL ECVAM in-house activities (e.g., 
comparative predictive toxicity, development 
of adverse outcome pathways) and support 
the work carried out in collaboration with 
external partners, e.g., prediction of in vivo fish 
bioconcentration factor (BCF) using information 
on metabolism derived with in vitro methods 
(see section 5.2.4).
EURL ECVAM launched this project in 2016 
involving an external contractor and plans 
to make the database publicly available in 
2018. It will provide a valuable data source for 
model developers (e.g., for in vitro to in vivo 
extrapolation models, kinetic models, models to 
predict exposure and internal concentration in 
an organism) and chemical assessors.
2.7 Activities in Basic, Applied 
and Translational Research
In the seventh Commission report on the 
number of animals used in the EU in 2011 for 
experimental and other scientific purposes, 
it was highlighted that more than 60% of 
the animals were used for research and 
development in the fields of human medicine, 
veterinary medicine, dentistry and in biological 
studies of fundamental nature.
Ethical concerns, as well as the cost, maintenance 
and relative inefficiency of animal research, 
have encouraged the development of alternative 
methods for the study of diseases.
Major efforts are needed to identify and 
promote the use of non-animal tools in 
biomedical research, particularly in developing 
ambitious education and training programmes, 
as well as improving communication and 
dissemination. Furthermore, Directive 
2010/63/EU (EU, 2010) reinforced and extended 
EURL ECVAM's central role in promoting the 
use, validation and acceptance of alternative 
approaches that originally focused on regulatory 
testing of chemicals or biological agents.
At the Joint PARERE-ESTAF meeting in 
November 2016, some selected ESTAF 
members (e.g., those involved in research, 
education and training activities) had been 
asked to give 10-minutes flash presentations 
on their activities related to alternatives used 
for basic, applied and/or translational research 
purposes and/or education and training (see 
also section 4.11).
ESTAF and PARERE members were also asked 
to contribute their ideas and initiatives to 
reduce animal use in biomedical research taking 
the priorities proposed at an EURL ECVAM - 
European 3Rs Centres meeting (held in April 
2015, see Zuang et al., 2015, section 5.13) as a 
basis to establish common goals and strategic 
aims for the network to collaborate on. 
These priorities were i) more systematic 
and effective critical assessment of animal-
based studies, ii) improve communication 
about all aspects of the Three Rs including 
the development of ambitious education 
and training programmes, iii) understand 
and describe organisational and institutional 
obstacles to the Three Rs and iv) facilitate more 
extensive input from Three Rs centres in the 
project evaluation process.
The adoption of methods using human tissue 
has the potential to replace some of the animal 
models, improving predictivity and reducing 
animal use. In this context, EURL ECVAM 
participated in a two-day workshop organised 
by NC3Rs that brought together cancer 
researchers working with human tissue from 
across academia and industry.
New activities which have the potential to be 
translated to compound testing and mechanistic 
studies currently carried out by academia and 
industry could be identified at the workshop. 
EURL ECVAM will continue to participate in this 
type of meetings where the research focus is 
mainly on the use of human in vitro models in 
biomedical research.
READ MORE
EU statistical reports 
on the use of animals 
for	scientific	purposes
europa.eu/!pf93Wq
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Moreover, JRC's EURL ECVAM launched a call for 
tender on 11 August 2017 on a "Review of Non-
animal Methods in Use for Biomedical Research".
The outcome of the project will contribute to 
the uptake, implementation and promotion 
of non-animal methodologies in biomedical 
sciences by performing reviews in selected 
human disease areas.
The review should cover in vitro methods and 
in silico approaches, and in particular, human-
specific (sub)cell and tissue-based models 
including two or three dimensional cultures/
organotypic models; stem-cell technologies, 
such as human-induced pluripotent stem 
cells (iPSC), lab-on-a-chip devices with 
microfluidic systems, (ex) vivo approaches 
and computational modelling, indicating their 
applications and development status.
2.8 EURL ECVAM/ESTIV 
Workshop on Moving Forward in 
Carcinogenicity Assessment
A joint ESTIV-EURL ECVAM workshop on "Moving 
forward in carcinogenicity assessment" took 
place in October 2016 in conjunction with the 
European Society of Toxicology In vitro (ESTIV) 
congress in Juan Les Pins, France.
The workshop addressed current progress in the 
area of carcinogenicity and how this, together 
with technological advances, can be exploited to 
move away from the two-year rodent bioassay 
(Corvi et al., 2017, see Figure 2.2).
The workshop was opened with an introduction 
on a recent analysis of carcinogenicity testing 
for regulatory purposes in the EU (Madia et al., 
2016). This was followed with presentations 
of a number of international initiatives ranging 
from the ICH approach for pharmaceuticals 
to waive the cancer study, the recent revised 
approach for the systematic classification 
of carcinogens by the International Agency 
for Research on Cancer (IARC), to integrating 
different 'omics and high throughput 
technologies together with disease knowledge 
into more traditional testing. 
Despite a seemingly diverse range of strategic 
developments, commonalities are emerging. 
First, providing insight into carcinogenicity 
mechanisms is an increasingly essential aspect 
of hazard assessment applicable to all types 
of substances. Second, there is a need to direct 
efforts towards the integration of all available 
information on relevant endpoints, including 
from epidemiology, traditional and alternative 
toxicology test systems, and from novel data 
streams (e.g., 'omics, high through technologies).
2.9 Analysis of Mechanistic 
Information in the Context of 
Acute Systemic Toxicity
The development of Integrated Approaches 
to Testing and Assessment (IATA) for acute 
systemic toxicity is hampered by our incomplete 
knowledge of the numerous toxicity pathways 
and/or modes-of-action that lead to acute 
systemic toxicity. In fact, the importance of 
improving the understanding of toxicological 
mechanisms in this area is well recognised 
Figure 2.2: Integration of data, application of new technologies and approaches, regulatory relevance and 
acceptance across sectors can warrant a better carcinogenicity safety assessment (From Corvi et al., 2017, 
Toxicology in Vitro, under CC BY-SA 4.0).
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Review of current alternatives approaches 
for acute systemic toxicity testing
Chemical substances may have negative effects on 
human health at sufficiently high doses. Therefore, 
regulatory authorities require the assessment of their 
toxicity to categorise such substances and indicate 
on product labels precautions to be taken while 
handling them. The current animal tests included 
in regulatory test guidelines generate an LD50, 
which is the dose that produces death in 50% of the 
animals tested. However, more recent efforts have 
been directed at identifying non-animal alternatives 
for acute toxicity testing with the aim of reducing 
and refining the use of animals.
Scientists from the JRC's EURL ECVAM participated 
to a specific workshop on "Alternative Approaches 
for Identifying Acute Systemic Toxicity: Moving from 
Research to Regulatory Testing" which took place in 
September 2015 and was hosted by the US National 
Institute of Environmental Health Sciences (NIEHS) 
and cosponsored by NTP Interagency Center for the 
Evaluation of Alternative Toxicological Methods, the 
PETA International Science Consortium Ltd., and the Physicians Committee for 
Responsible Medicine.
There was a conclusion on the need to have a better insight of variability 
in current animal data in order to evaluate new approaches. Experts also 
highlighted the importance of understanding the mechanisms of acute toxicity, 
which could be facilitated by the development of Adverse Outcome Pathways 
(AOPs). Compiling and making available high-quality reference data, training 
on use and interpretation of in vitro and in silico approaches, and global 
harmonisation of testing requirements are considered crucial for a progress in 
implementing alternatives (Hamm et al., 2017).
Box 2.5
(Hamm et al., 2017; NRC, 2015; Prieto et al., 
2014) (see Box 2.5).
Therefore, in line with the objectives outlined in 
the EURL ECVAM strategy to replace, reduce and 
refine the use of animals in the assessment 
of acute mammalian systemic toxicity (Prieto 
et al., 2014), EURL ECVAM has centered its 
in-house activities in this area on the collection 
and evaluation of mechanistic information 
on eight organs identified as relevant for 
acute systemic toxicity (central and peripheral 
nervous system, cardiovascular system, liver, 
kidney, lung, blood, gastrointestinal system and 
immune system) (Gennari et al., 2004).
Information was derived from published 
literature, toxicology handbooks, short 
descriptions of reference compounds
used in the ACuteTox project and internet 
databases (e.g., HSDB).The aim was to identify 
properties that are required for in vitro test 
methods for target organ toxicity testing which 
are not covered by cytotoxicity assays. The 
outcome of the analysis of the information 
collected is under finalisation and a manuscript 
is under preparation.
Briefly, the nervous system and the 
cardiovascular system appear as the most 
frequent targets. For chemicals acting 
on the nervous system, interference with 
neurotransmitters and/or neurotransmission and 
impairment of propagation of electrical activity 
are among the main reported mechanisms.
Chemicals that target the cardiovascular 
system often interfere with ion balance/
signalling/membrane potential of the cell and 
with intracellular signalling mechanisms.
General cytotoxicity is confirmed as an 
important determinant of acute systemic 
toxicity. The false negative prediction obtained 
with the cytotoxicity assay can, in some cases, 
be explained by specific target organ effects.
Nevertheless, it is difficult to explain in 
vitro misclassifications only on the basis of 
mechanistic information. Other factors, such as 
the variability of the in vivo and in vitro data 
and in vivo kinetics may have an impact, which 
deserves further in depth investigation.
READ MORE
ACuteTox - Research 
Project for Alternative 
Testing
www.acutetox.eu
HSDB - A TOXNET 
database
toxnet.nlm.nih.gov/
newtoxnet/hsdb.htm
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3 Test Method Submissions
Since the last EURL ECVAM status report published 
in October 2016 (Zuang et al., 2016), five test 
submissions have been evaluated by EURL ECVAM.
The results of the PARERE consultation on a test 
method for bioaccessibility (bioelution) testing were 
evaluated and the test submitter was asked to 
complete a full submission (see section 3.1).
Similarly, the test submitter of the Toxtracker® assay 
was invited to provide a full submission further 
to the EURL ECVAM assessment and the PARERE 
consultation on the pre-submission (see section 3.2).
Additional data were submitted to EURL ECVAM
at the end of 2016 on the SENS-IS assay and 
the evaluation process is currently under 
finalisation (see section 3.3).
Based on the feedback received from the PARERE 
members, the assessment of the EDITOX pre-
submission was completed in June 2017 and 
the test submitter was invited to complete a full 
submission (see section 3.4).
Finally, a pre-submission for the assessment of a 
method	based	on	γH2AX/pH3	biomarkers	for	the	
prediction of genotoxic potential was submitted to 
EURL ECVAM in August 2017 (see section 3.5). The 
assessment is on-going. 
The EURL ECVAM database (TSAR11) that tracks 
the status of a test method from its submission 
through its final adoption into a regulatory 
framework (EU, OECD and related standards) will 
be updated by the end of the year 2017.
1 https://eurl-ecvam.jrc.ec.europa.eu/test-submission
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READ MORE
Classification	and	
Labelling (CLP/GHS)
europa.eu/!fh39Yd
Registration, Evaluation, 
Authorisation and 
Restriction of Chemicals 
(REACH)
echa.europa.eu/
regulations/reach/
understanding-reach
CARACAL - Competent 
Authorities for REACH 
and CLP
europa.eu/!kc97Mr
3.1 Bioelution
The bioelution test method is not a toxicity 
test. It provides the fraction of a substance 
that dissolves under surrogate physiological 
conditions (e.g., simulated gastric fluid) and is 
potentially available for absorption into systemic 
circulation (bioaccessible concentration).
In the pre-submission received in summer 
2016 from the European non-ferrous metal 
association (Eurometaux) on the bioelution 
in vitro method (see section 3.2 in Zuang et 
al., 2016), the test method was proposed 
to support read across and grouping under 
REACH for systemic endpoints and to assign 
CLP classifications.
In the context of hazard classification, 
the test method has been proposed as a 
refinement to the current approach to alloy 
classification. Alloys are defined as special 
preparations under REACH in recognition of 
the fact that they do not behave as simple 
mixtures (EC, 2006).
Thus, the rationale provided in the pre-
submission was that using the gastric 
bioaccessible concentration of a metal in an 
alloy appears more informative and relevant 
for predicting the toxicity than simply using 
the concentration of the metal ingredient.This 
assumes that the dissolved metal ion is the 
cause of toxicity.
The issue on how to classify alloys under CLP 
for human health endpoints was triggered 
at the REACH Committee in relation to the 
inclusion of a new harmonised classification 
of lead in Annex VI of the CLP Regulation. 
Member States raised concerns and questions 
around the applicability and interpretation of 
Article 12(b) [specific cases requiring further 
evaluation] in the case of mixtures/alloys. 
An Expert Group established by the European 
Chemicals Agency (ECHA) in September 2016 
further debated the regulatory application of 
the bioelution test method. This group limited 
the discussions to alloys and their systemic 
effects after oral exposure in the context of 
hazard assessment related to CLP.
EURL ECVAM actively participated in the 
meetings and teleconferences organised by 
ECHA. The group drafted a document that 
was shared and discussed at the Competent 
Authorities for REACH and CLP (CARACAL) 
meeting in June 2017.
Following the pre-submission of the bioelution 
in vitro method, EURL ECVAM launched a 
consultation within the PARERE network in 
November 2016. The purpose was to get their 
views with regard to 1) the interpretation 
of the CLP legal text, 2) the regulatory 
applicability of the bioelution test method, 3) 
its limitations and scientific relevance, 4) the 
potential further validation of the test method, 
and 5) the impact on animal testing.
Overall, there was a general opinion among 
PARERE members that the bioelution test 
method is interesting and might be of 
potential use in a regulatory context. However, 
no clear picture emerged of how the test 
method could be used.
On the basis of the evaluation of the information 
retrieved from the test method pre-submission 
and the feedback received from PARERE 
members, the test submitter has been invited 
to submit a full submission and to provide 
clarifications and more detailed information on 
a number of questions that emerged from the 
assessment, the PARERE consultation and the 
ECHA expert group discussions.
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3.2 Toxtracker® Assay
A test pre-submission was received in late 
November 2016 on an in vitro method 
intended for testing genotoxicity called the 
ToxTracker® Assay.
The ToxTracker® was presented as a 
genotoxicity assay that also includes a number 
of non-genotoxic endpoints associated with 
human carcinogenicity hazards. It was proposed 
by the test submitter as an additional in vitro 
test able to allow an accurate genotoxicity 
assessment, providing insight into the 
mechanisms of (geno)toxicity and reducing 
the frequency of misleading positive in vitro 
test results that would trigger in vivo follow-up 
testing in the current genotoxicity strategy.
The test method consists in a microplate format 
including a set of six different mouse Embryonic 
Stem (mESC) green fluorescent protein (GFP) 
reporter cell lines for four distinct biological 
responses: i) DNA damage; ii) Cellular stress; 
iii) Oxidative stress and iv) Protein damage as 
unfolded protein response.
Cells are simultaneously treated in a 96-well 
plate and detection of GFP reporter genes 
induction and cytotoxicity by flow cytometry is 
performed after 24 hours exposure to at least 
four different concentrations. The relative GFP 
induction of the reporter cell lines is measured 
in function of each chemical concentration as 
a proportional assessment of genome damage 
and other stress responses.
The test method underwent prevalidation and 
the information and data, compiled in the EURL 
ECVAM pre-submission template together with 
a well standardised protocol, were submitted to 
EURL ECVAM for a preliminary assessment. 
In November 2016, the test submitter also 
submitted to the OECD a new project proposal on 
a Detailed Review Paper on the "ToxTracker assay: 
a stem cell-based reporter assay for mechanistic 
carcinogenicity hazard assessment" which will 
include the results of the validation study.
Based on the information received, EURL ECVAM 
has considered that the possibility to provide 
insight into the mechanism of genotoxicity by 
the combination of various endpoints could 
make the ToxTracker® a promising method 
potentially suited to cover human genotoxic 
effects, and judged the test as biologically and 
mechanistically relevant.
The above consideration has been confirmed by 
the positive feedback from OECD WNT members 
and positive comments received following 
consultation (March, 2017) with PARERE.
In June 2017, EURL ECVAM asked the test 
submitter to complete a full submission when the 
data from the validation study becomes available.
3.3 SENS-IS
As reported in the EURL ECVAM status report 
2016 (Zuang et al., 2016, Section 3.6), the 
SENS-IS assay is a reconstructed human skin 
model-based method for identifying potential 
skin sensitising substances and for classifying 
them into four potency classes (weak, moderate, 
strong and extreme) on the basis of the analysis 
of the expression of three groups of genes.
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Following the evaluation of the full submission 
of July 2016, reporting the validation of the 
SENS-IS coordinated by ImmunoSearch (Grasse, 
France), EURL ECVAM requested the test 
developer to provide additional information on 
the method and recommended to analyse the 
ability of the method for classifying substances 
according to the GHS classification scheme. 
Additional data were submitted to EURL ECVAM 
at the end of 2016 and in 2017 and the 
evaluation process is currently under finalisation.
3.4 EDITOX
In June 2016, EURL ECVAM assessed the pre-
submission of an in vitro cell based method, 
EDITOX, to assess the risk for chemical 
compounds to induce psychiatric adverse side 
effects, (e.g., depression and/or suicide).
This test method quantitatively analyses 
variations of the relative proportion of the 
32 mRNA editing isoforms of the serotonin 
receptor (5-HT2cR) using a next generation 
sequencing approach in SH-SY5Y cells (human 
neuroblastoma cell line).
The information provided in the test pre-
submission form was considered sufficient 
enough to understand the principle of the 
test method, and its biological and general 
mechanistic relevance.
In October 2016, PARERE members were asked 
to evaluate the potential use of EDITOX for 
regulatory purposes. Based on the feedback 
received from the PARERE members, in June 
2017 EURL ECVAM completed the assessment 
of the EDITOX pre-submission and invited the 
test submitters to progress the test method to 
a full submission, taking into account a list of 
questions raised by EURL ECVAM.
In particular, since this assay is entirely 
based upon one mode of action (e.g., editing 
of 5-HT2cR), this method, as a standalone, is 
not expected to fully replace in vivo testing 
for depression.
Therefore, EURL ECVAM asked the submitter to 
provide with their full Test Submission a review 
of other possible modes of action of drugs (and 
potentially environmental chemicals) with the 
risk of causing depression and/or pro-suicidal 
side effects, and of in vitro test methods (e.g., 
battery of tests) that may be available to 
potentially cover these other modes of action, 
highlighting their relation to currently available 
in vivo methods.
3.5 γH2AX/pH3 Biomarkers
In August 2017, EURL ECVAM received a pre-
submission for the assessment of a method 
based	on	γH2AX/pH3	biomarkers	for	the	
prediction of genotoxic potential of different 
different substances.
The combination of the two biomarkers is 
proposed to detect early events in the DNA 
damage response and to discriminate structural 
and numerical chromosome damage. Increased 
levels	of	γH2AX	phosphorylation	at	serine	
139 measure the recruitment of DNA repair 
machinery to DNA double strand breaks.
The induction of Histone 3 (pH3) serves as an 
indicator of mitotic index and cell proliferation 
status. Specifically, aneugenic chemicals often 
elevate the mitotic index, thus pH3 tends to 
be reduced by cytotoxic conditions, including 
cytotoxicity associated with many DNA-
reactive chemicals.
The submitter declared the integration of 
information derived by the two biomarkers 
detection to be more predictive of genotoxicity 
than common Micronucleus in vitro and Ames 
tests. For this reason, the test method is 
intended to be used as i) screening and early 
selection test of candidate molecules before 
entry into drug development or ii) as a follow-up 
of positive results within the current available 
regulatory battery of in vitro genotoxicity 
assays to provide insight into the mechanism of 
action and help read across approaches. 
The	assessment	of	the	γH2AX/pH3	test	method	is	
ongoing and will be finalised by the end of 2017.
Figure 3.1: SH-SY5Y neuroblastoma cell line.
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4 Validation of Alternative Methods
This section refers to validation studies which are 
either carried out by EURL ECVAM or for which 
EURL ECVAM has been consulted. It is a non-
exhaustive list of all possible validation studies 
carried out around the world.
Nonetheless, EURL ECVAM is aware of external (to 
EURL ECVAM) validation studies that are carried 
out by companies/industry on methods which 
are intended to be submitted to EURL ECVAM for 
evaluation and peer review. 
These studies are mentioned under section 3 (Test 
Method Submissions) and section 4.8 (EURL ECVAM 
Scientific Advisory Committee Peer Reviews). 
The validation studies undertaken with EURL ECVAM's 
international partners in the framework of the 
International Cooperation on Alternative Methods 
(ICATM) are described in Annex 2. 
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Methods
4.1 Endocrine Disruption -
AR-CALUX Test Method
EURL ECVAM has the lead in developing an 
OECD Performance Based Test Guideline (PBTG) 
for Androgen Receptor Transactivation Assays 
(ARTAs) and related Performance Standards.
This PBTG will be based on ARTAs either already 
validated (the AR STTA using the AR-EcoScreen 
cell line, led by Japan and issued as TG 458) or 
in the process of a validation (the ARTA using 
the 22Rv1/MMTV cell line, led by Korea) and the 
EURL ECVAM ongoing validation study of the in 
vitro method AR-CALUX.
The latter method is a reporter-based assay 
where an increase or decrease in expression 
of luminescence is measured in osteosarcoma 
cells, stably transfected with a human androgen 
receptor, when presented with chemicals 
that have (anti)androgenic potential. The 
method was submitted by the Dutch company 
BioDetection Systems (BDS). The validation 
study is carried out with three participating 
laboratories of EURL ECVAM's network of 
specialised laboratories, the European Union 
Network for the Validation of Alternative 
Methods (EU-NETVAL).
So far, EURL ECVAM has carried out an 
experimental assessment of the method; 
conducted a GLP study in order to refine the 
assay and established transfer criteria; provided 
a training for the three partner facilities at the 
JRC laboratories; and coordinated all the phases 
of the validation study.
Validation study to assess in vitro methods for the detection of 
chemicals which disrupt thyroid function
There is global concern about substances, natural and man-made, which have 
the potential to interfere with the endocrine system. The thyroid’s main role in the 
endocrine system is to regulate metabolism through the action of thyroid hormone, 
by extracting iodine from the blood and incorporating it into thyroid hormones.
Cells and human body systems depend on the thyroid to manage their metabolism 
and for regulating vital body functions, including 
breathing, heart rate, central and peripheral nervous 
systems, body weight, muscle strength, menstrual 
cycles, body temperature and cholesterol levels. Some 
man-made chemicals have the potential to interfere 
with the functioning of the thyroid and related hormone 
signalling processes, which can result in adverse health 
effects in humans and other organisms that have been 
sufficiently exposed.
A total of 17 in vitro methods have been identified by 
EURL ECVAM as candidates for a validation study which 
will be carried out in collaboration with the European 
Box 4.1
Union Network of Laboratories for the Validation of 
Alternative Methods (EU-NETVAL) (see section 4.10).
Those methods which perform well may be selected 
for further assessment with a view to their eventual 
use in a regulatory context, in support of EU initiatives 
to address the potential risks to human health and 
the environment posed by endocrine disruptors.
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READ MORE
OECD Conceptual 
Framework for the 
Testing and Assessment 
of Endocrine Disruptors
www.oecd.org/env/
ehs/testing/oecd-
workrelatedtoendo-
crinedisrupters.htm
The transfer phase, where the three 
participating laboratories have applied the 
method in their own laboratories, has been 
successfully finalised. The phases to assess 
between-laboratory reproducibility and 
predictive capacity are ongoing.
4.2 Thyroid Hormone Disruption
EURL ECVAM launched a call to EU-NETVAL 
members for participation in the validation study 
of in vitro methods for the detection of thyroid 
disruptors (see section 4.10 and Box 4.1).
Due to concerns about the potential of 
chemicals to interfere with the endocrine 
system in humans and animals, a number 
of OECD Test Guidelines (TGs) have been 
developed for the screening and testing of 
potential endocrine disrupting chemicals, as 
listed in the OECD Conceptual Framework 
for the Testing and Assessment of Endocrine 
Disruptors. TGs for the screening of chemicals 
that disturb the thyroid hormone signalling are 
however lacking, largely due to the complexity 
of the thyroid system.
In 2014, OECD published a scoping document on 
in vitro and ex vivo assays for the identification 
of modulators of thyroid hormone signalling 
(OECD, 2014a). Several key biological 
mechanisms of thyroid system disruption 
were reviewed and the corresponding methods 
evaluated for their state of readiness as 
candidates to enter the validation process. 
Relevant in vitro and ex vivo methods were 
identified and recommendations were given for 
their development/use. 
EURL ECVAM collected information on 17 
methods, taking primarily into account the 
information reported in the OECD review (OECD, 
2014a) but also the OECD Detailed Review 
Paper (OECD, 2006), and feedback received 
at various meetings (e.g., the EU NETVAL 
meeting of 2016 (see Box 4.4), OECD Validation 
Management Group-Non-Animal meeting 
2016 and the DG ENV/ANSES Thyroid Disruptor 
workshop in 2017 (DG ENV, 2017)).
Further information has been retrieved for 
each of these in vitro methods, and on the 
basis of this information, a set of in vitro 
methods, covering all of the eight blocks 
identified as known targets of thyroid 
disruption (except epigenetic changes) and 
described in the OECD review (OECD, 2014a), 
have been selected for the EURL ECVAM 
coordinated validation study.
This validation study will consist of two parts: 
part one will define the methods and assess 
their transferability and reliability, and part 
two will assess the overall relevance based on 
the underlying mechanisms of the selected in 
vitro methods using the same set of reference 
chemicals (test items) for all test methods. 
4.3 Developmental Neurotoxicity 
Deficiencies in the testing methodology for 
developmental neurotoxicants represent a 
significant gap in the regulatory testing and 
assessment of chemicals and increases the 
uncertainties in the establishment of safe 
levels of exposure to developing humans (Bal-
Price et al., 2015a).
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The existing OECD TG 426 on Developmental 
Neurotoxicity (DNT) Study is entirely based on 
in vivo studies and is very resource intensive in 
terms of animals, time and overall cost (Tsuji 
and Crofton, 2012). It is therefore rarely used, 
resulting in a small amount of chemicals being 
tested for their DNT potential.
Based on the conclusions of two recent 
workshops on developmental neurotoxicity 
(October 2016 and January 2017) organised 
by EFSA/OECD and CAAT Europe/OECD, 
respectively, it was decided to develop a testing 
battery of alternative DNT methods that 
could be applied right now in a fit-for-purpose 
manner for different regulatory purposes.
EFSA, OECD and US EPA support the development 
of an integrated in vitro neurotoxicity testing 
strategy which could serve as complementary to 
the rodent in vivo method (OECD TG 426) in order 
to speed up screening of the high number of 
chemicals for their DNT potential and to prioritise 
chemicals for further testing.
One way to fulfil this goal is through more 
targeted data production, focusing on DNT-
specific endpoints using in vitro methods 
and non-mammalian models (e.g., zebrafish). 
Therefore, development of an Integrated 
Approach to Testing and Assessment (IATA) 
has been proposed as a practical solution, 
composed of in vitro assays anchored to key 
neurodevelopmental processes and key events 
identified in the existing DNT AOPs (Bal-Price 
and Meek, 2017).
In parallel, further development of Adverse 
Outcome Pathways (AOPs) relevant to DNT will 
take place, providing mechanistic information 
on the causal links between molecular 
initiating events (MIEs), key events (KEs) and 
adverse outcomes (AOs) of regulatory concern. 
Mechanistic knowledge built during AOP 
development will provide the biological context 
for the in vitro assays anchored to AOP(s) key 
events, facilitating development of AOP-
informed IATA for various regulatory decision-
making (Bal-Price and Meek, 2017). 
4.4 Vaccine Quality Control – 
EDQM Biological Standardisation 
Programme
Most of the validation studies on alternative 
methods for vaccine quality control are carried 
out within the framework of the Biological 
Standardisation Programme (BSP) of the 
European Directorate for the Quality of Medicines 
& HealthCare (EDQM; Council of Europe) and co-
sponsored by the European Commission. 
Several validation studies are currently ongoing 
which assess alternative methods for the safety 
and potency testing of human and veterinary 
vaccines, e.g., a serological assay for the 
potency testing of whole-cell pertussis vaccines; 
the BINACLE assay for in vitro detection of 
toxicity in tetanus vaccines, and, in collaboration 
with EPAA, BSP130 Phase III Validation of in 
vitro methods for the testing of Clostridium 
septicum vaccine (see see section 5.6.4) and 
BSP148 Validation of a rabies in vitro potency 
assay (see section 5.6.5). 
4.5 Skin Sensitisation - Genomic 
Allergen Detection Test Method
As described in the EURL ECVAM status report 
of 2015, the Genomic Allergen Detection 
(GARD) test method (Johansson et al., 2011; 
Johansson et al., 2013; Johansson et al., 2014) 
for the binary classification of chemicals into 
skin sensitisers and non-sensitisers is based on 
global transcriptomic analysis of differential 
expression in a human myeloid cell line, induced 
by sensitising chemicals in comparison to non-
sensitising controls.
The resulting biomarker signature, the GARD 
prediction signature (GPS), consists of 200 
transcripts, which are used as input into a support 
vector machine (SVM) model trained on a set of 
reference chemicals (Johansson et al., 2011).
The GARD is currently undergoing a validation 
study under the umbrella of the OECD. The 
method was recently further developed to 
predict three sensitiser potency classes according 
to the European Classification, Labelling and 
Packaging (CLP) Regulation, targeting categories 
1A (strong), 1B (weak) and no category (non-
sensitiser). Using a random forest approach 
and 70 training samples, a potential biomarker 
signature of 52 transcripts was identified for this 
purpose (Zeller et al., 2017).
4.6 Genotoxicity Testing - 
Micronucleus Test and Comet 
Assay in Reconstructed Skin Models 
The experimental phases of the validation 
studies of methods for genotoxicity 
testing in reconstructed human 3D skin 
models, coordinated by Cosmetics Europe 
READ MORE
Biological 
Standardisation 
Programme (BSP)
www.edqm.eu/en/
work-programme-bsp
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(CosEU), have been finalised (manuscripts 
in preparation). In April 2017, CosEU 
organised a workshop aimed at informing 
different stakeholders on the validation 
status of 3D-skin based genotoxicity assays 
(micronucleus test and comet assay).
The presentations of the results of the two 
studies were followed by a more strategic 
discussion on how to use the tests within the 
testing battery. For the time being the assays are 
considered for the assessment of genotoxicity 
caused by substances applied topically.
There was agreement that both the 
micronucleus and the comet assays in 
reconstructed skin models are promising 
assays. However, they are not to be considered 
as stand-alone assays, but are foreseen to be 
used within a testing strategy for genotoxicity 
without animals to follow-up the positive results 
in the in vitro testing battery.
Further discussion on the specific use of 
these assays and how to proceed in order to 
accelerate their implementation took place at the 
International Workshops on Genotoxicity Testing 
(IWGT) held in Tokyo on 8 to 10 November 2017.
4.7 Genotoxicity Testing - 
Hen's Egg test for Micronucleus 
Induction (HET-MN)
The hen's egg test for micronucleus induction 
(HET-MN) has also been proposed as a follow-
up test method for in vitro positives in a testing 
strategy for genotoxicity. The HET-MN combines 
the use of the commonly accepted genetic 
endpoint “formation of micronuclei” with the 
well-characterised and complex model of the 
incubated hen's egg, which mimics systemic 
exposure, thus not needing the addition of S9. 
A validation study is currently under finalisation 
by a German consortium (Greywe et al., 2012). 
4.8 EURL ECVAM Scientific 
Advisory Committee Peer Reviews
Between April and June 2016, the EURL ECVAM 
Scientific Advisory Committee (ESAC, see Box 4.2) 
reviewed five test methods and their respective 
validation studies that had been submitted to 
EURL ECVAM for evaluation and peer-review.
These were: 
(i) the validation of the Ocular Irritection® test 
method for assessing serious eye damage/eye 
irritation potential of chemicals submitted by 
Secam Services & Consultation on Alternative 
Methods Sagl.,
(ii) the validation study of the SkinEthic™ 
Human Corneal Epithelium (HCE) Eye Irritation 
Test (EIT) submitted by L'Oréal,
(iii) the validation study of the U-SENS™ 
test method for skin sensitisation testing 
submitted by L'Oréal,
(iv) the Performance Standards-based validation 
study of the LuSens test method for skin 
sensitisation testing submitted by BASF, and
(v) the Performance Standards-based validation 
study of the epiCS® Skin Irritation Test (SIT) 
submitted by CellSystems GmbH.
Two ESAC Rapporteurs coordinated the 
peer-review of the epiCS® SIT, whereas the 
peer-reviews of the other four methods were 
coordinated by two newly appointed ESAC 
Working Groups composed of ESAC members 
and experts on eye irritation or skin sensitisation 
nominated by EURL ECVAM and ICATM partners.
EURL ECVAM's Scientific Advisory 
Committee (ESAC) 
The EURL ECVAM's Scientific Advisory Committee 
(ESAC) advises EURL ECVAM on scientific issues.
Its main role is to conduct independent peer review of 
validation studies of alternative test methods and to 
assess their scientific validity for a given purpose.
The peer review is normally prepared by 
specialised ESAC Working Groups and, at the end 
of the peer review, ESAC's advice to EURL ECVAM 
is formally provided as 'Working Group Reports' 
and 'ESAC Opinions'. More information is available 
http://europa.eu/!nd68pq
Box 4.2
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The ESAC Working Group on eye irritation met 
at EURL ECVAM on 11-13 May 2016 to conduct 
the review of the SkinEthic™ HCE EIT and of the 
Ocular Irritection® assay.
The ESAC Working Group on skin sensitisation 
met at EURL ECVAM on 17-19 May 2016 to 
conduct the review of the U-SENS™ and of 
the LuSens test methods. Working Group/
Rapporteur reports and ESAC Opinions on 
each individual method were discussed and 
endorsed by ESAC at its 42nd meeting (ESAC42) 
on 9-10 June 2016.
A sixth ESAC Opinion on the use of Performance 
Standards to evaluate test methods similar to a 
Validated Reference Method was also issued at 
ESAC42. The six ESAC Opinions were published 
by the JRC in November 2016.
They are:
• Ocular Irritection® (ESAC, 2016a) 
• SkinEthic™ HCE EIT (ESAC, 2016b)
• U-SENS™ (ESAC, 2016c)
• LuSens (ESAC, 2016d)
• epiCS® SIT (ESAC, 2016e)
• Performance Standards (ESAC, 2016f)
Also available is an earlier related ESAC Opinion 
on the EURL ECVAM/Cosmetics Europe Eye 
Irritation Validation Study (EIVS) on EpiOcular™ 
EIT and SkinEthic™ HCE and a Cosmetics Europe 
study on HPLC/UPLC-spectrophotometry as an 
alternative endpoint detection system for MTT-
formazan (ESAC, 2014).
4.8.1 Renewal of the ECVAM Scientific 
Advisory Committee 
EURL ECVAM launched on 14 December 
2016 an open call for the renewal of the 
core membership of its Scientific Advisory 
Committee, ESAC, with closing date for 
submitting an application on 31 January 2017.
Twenty-five candidates submitted an application 
by the deadline for nine available positions. A 
Selection Committee, comprising EURL ECVAM 
staff and representatives from other Commission 
services (external members) with experience 
in managing expert groups, was established 
to assess the candidates, as described in the 
"Information on the Call for Applications 2016".
All 25 applicants were deemed eligible for 
selection by the Selection Committee on the 
basis of the eligibility criteria published in the 
"Information on the Call for Applications 2016", 
and were therefore evaluated against the 
selection criteria described in the same document.
In its selection process, the Selection Committee 
also considered the candidates' independence 
(potential conflicts of interest), representation 
from different geographic regions and gender 
balance. The official appointment of the nine 
selected candidates is expected to occur before 
the end of 2017.
4.9 EURL ECVAM Recommendations
4.9.1 Non-animal Approaches for 
Skin Sensitisation 
The EURL ECVAM Recommendation (EURL ECVAM, 
2017) for skin sensitisation (see Box 4.3) builds 
on the progress made in the area since the 
publication of the EURL ECVAM strategy document 
for this endpoint in 2013 (Casati et al., 2013).
The document illustrates EURL ECVAM views on 
the regulatory use of individual OECD adopted 
test methods, including two in vitro methods, 
the LuSens and the U-SENS™, that underwent 
ESAC peer review in 2016 (ESAC, 2016c,d) and 
on Defined Approaches (DAs) integrating data 
from various non-animal sources e.g., in silico, 
in chemico and in vitro methods.
In relation to the individual methods, EURL 
ECVAM recommends using the qualitative and 
quantitative mechanistic information generated 
by the in chemico and in vitro methods 
adopted by the OECD, together with other 
relevant information, within DAs and Integrated 
Approaches to Testing and Assessment (IATA) 
for assessing skin sensitisation hazard and for 
hazard classification purposes.
In addition EURL ECVAM supports using the 
LuSens and U-SENS™ as valid scientific 
methods for generating information 
respectively on KE2 and KE3 of the skin 
sensitisation AOP and to be considered 
together with other relevant information in 
the context of DAs and IATA. EURL ECVAM also 
fully supports the inclusion of the LuSens as 
similar method to the KeratinoSens™ in OECD 
TG 442D and the development of an OECD TG 
on the U-SENS™.
As concerns predictions generated with valid 
DAs12, EURL ECVAM recommends using them, 
2 Examples of DAs which are considered for further 
evaluation are reported in Annex I to OECD GD 256.
READ MORE
Call for experts to 
serve on EURL ECVAM's 
Scientific	Advisory	
Committee (ESAC)
europa.eu/!Jy43bu
Information on the Call 
for Applications 2016 
- ESAC
europa.eu/!uy48WT
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where applicable and adequate, instead of LLNA 
data or in conjunction with such data if they 
already exist, in the context of IATA for assessing 
skin sensitisation hazard and for hazard 
classification purposes and to properly document 
new DAs applied for regulatory purposes using 
the templates provided in OECD GD 255.
EURL ECVAM also recommends that in view 
of promoting international applicability 
and acceptance of alternative non-animal 
approaches to skin sensitisation, future work 
should focus on the definition of internationally 
agreed standards (e.g., OECD TGs) for DAs and 
individual test methods that provide equivalent 
or better level of information than the current 
animal tests for skin sensitisation.
4.9.2 Cytochrome P450 Induction
EURL ECVAM is preparing an EURL ECVAM 
Recommendation on the human cytochrome 
P450 (CYP) activity n-fold induction in vitro 
test methods. The CYP induction method is 
important as the metabolism of a test item 
may (i) be increased by the test item itself 
(auto-induction) or by another concurrently 
administrated/exposed substance (e.g., mixture), 
(ii) perturb the endogenous metabolism by 
induction or inhibition of enzymes involved in 
the process, or (iii) lead to toxicity by reactive 
metabolite formation. Metabolism is thus 
increasingly recognised as a key element in 
chemical hazard and risk assessment. 
Mechanistic information on CYP induction 
should be considered in the context of IATA for 
adverse effects. This information is relevant 
when the induction of the specific CYP isoform 
is directly related to a (downstream) adverse 
outcome or it serves as a surrogate for the 
upstream transcription factor activation leading 
to adverse effects through other parallel (non-
CYP activity-dependent) pathways, such as 
Aryl Hydrocarbon Receptor (AhR), Constitutive 
Androstane Receptor (CAR) and Pregnane X 
Receptor (PXR) response pathways.
4.10 Update on EU-NETVAL
The European Network of Laboratories for the 
Validation of Alternative Methods (EU-NETVAL) 
was set up by EURL ECVAM in response to 
the provision of Directive 2010/63/EU on 
the protection of animals used for scientific 
purposes, which requests that EU Member 
The EURL ECVAM recommendation on the 
use of non-animal approaches for skin 
sensitisation (allergy) testing
This recommendation builds on the progress made 
in the area since the publication of the EURL ECVAM 
strategy in 2013 (Casati et al., 2013) and provides 
EURL ECVAM views on the latest two methods for 
skin sensitisation, the LuSens and the U-SENS™, 
peer-reviewed by the EURL ECVAM Scientific Advisory 
Committee (ESAC), and on Defined Approaches which 
are based on the integration of different kinds of 
non-animal data.
Three recommendations were issued by EURL ECVAM 
on non-animal methods for skin sensitisation testing, 
the DPRA, the KeratinoSensTM and the h-CLAT. A 
major achievement was the OECD adoption of these 
first three in vitro methods (OECD Test Guidelines 
442C, 442D and 442E) based on key chemical and 
biological mechanisms of the process that leads to 
development of skin allergies. Following independent 
peer review by ESAC, EURL ECVAM now supports 
the use of two additional methods, the LuSens and 
the U-SENS™ when used in combination with other 
relevant information.
Box 4.3
Since none of the regulatory adopted methods provides the same level of 
information as the traditional animal tests, a number of defined approaches, i.e., 
approaches based on the use of different type of non-animal data, have been 
proposed for the identification of chemicals that may cause skin allergy.
On behalf of the European Commission, the JRC's EURL ECVAM led the development 
of international guidance on the harmonised reporting of these approaches.
The defined approaches for skin sensitisation have comparable performance to the 
standard animal test, the Local Lymph Node Assay (LLNA), for identifying potential 
skin allergens. In addition some of them provide useful information to distinguish 
between strong and weak sensitisers. In the light of this evidence EURL ECVAM 
recommends these defined approaches be used where applicable and adequate 
instead of LLNA data or together with the animal data if these are already available.
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States assist the European Commission in the 
validation of alternative methods.
Currently, there are 37 members of EU-NETVAL 
representing fifteen countries in the network, 
selected against pre-defined eligibility criteria23 
(including the European Commission's own in 
vitro GLP test facility) and endorsed by the 
National Contact Points.
EU-NETVAL is coordinated by EURL ECVAM, in 
close collaboration with the EC Directorate-
General for Environment.
EU-NETVAL's mission is to provide support for 
EURL ECVAM validation studies to assess the 
reliability and relevance of alternative methods 
that have a potential to replace, reduce 
or refine the use of animals for scientific 
purposes and the tasks are outlined in the 
terms of reference34. 
 
The most recent call for membership of 
EU-NETVAL closed in September 2015. The 
current network holds a range of expertise 
and competences and includes laboratories 
experienced in advanced in vitro procedures, 
test systems and measurement techniques 
which are considered important to address 
specific aims and objectives identified in EURL 
ECVAM's strategies or in accepted conceptual 
frameworks to achieve Three 3Rs impact in 
different areas of regulatory safety testing.
The network contributes to the development 
of guidance documents and training materials 
supporting good in vitro method development. 
Furthermore, it promotes practices that 
ensure scientific integrity and quality of the 
data generated with in vitro methods in order 
3 https://eurl-ecvam.jrc.ec.europa.eu/eu-netval/Annex-1-
EU-NETVAL-EligibilityCriteria-January-2015.pdf
4 https://eurl-ecvam.jrc.ec.europa.eu/eu-netval/EU-NETVAL-
tor-november-2013.pdf
to stimulate trust by decision makers and 
industrial end-users.
EU-NETVAL has provided input in the drafting of 
an OECD technical guidance document (led by 
EURL ECVAM) on Good In Vitro Method Practices 
for the development and implementation of in 
vitro methods for regulatory use in human safety 
assessment (see section 5.2.9) which is currently 
undergoing a second commenting round.
With the EU-NETVAL activities and applying 
the modular approach to validation (Hartung 
et al., 2004), EURL ECVAM demonstrates that 
validation is a flexible scientific process aiming 
to establish the confidence that the method(s) 
are fit for a particular purpose.
The first pilot validation project involves 
three selected EU-NETVAL test facilities from 
Sweden, UK and France for the generation of 
experimental data using the in vitro AR-CALUX 
method to support the development of an OECD 
Performance-Based Test Guideline (PBTG) and 
associated performance standards for Androgen 
Receptor Transactivation Assays (ARTA) for the 
detection of compounds with (anti)androgenic 
potential (see section 4.1). 
During this validation, mechanisms were 
developed to ensure efficient communication 
and transfer from the test developer of the 
method to the validation partner EU-NETVAL 
facilities and to run the in vitro method under 
GLP conditions since the method would be part 
of an OECD PBTG.
In June 2017, EURL ECVAM launched a 
validation study (see Box 4.1) within the 
EU-NETVAL network to assess 17 in vitro 
methods for the detection of thyroid disruptors. 
EU-NETVAL test facilities interact during the 
validation study with the in vitro method 
READ MORE
EURL ECVAM Strategy 
Papers
europa.eu/!NF94PD
Figure 4.1: Knowledge sharing and training session during the EU-NETVAL meeting in 2016.
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developers to define the methods and establish 
SOPs that can run in a GLP environment. They 
will also assess within-laboratory reproducibility 
followed by relevance assessment of the 
methods using a set of reference compounds. 
The ultimate goal is to combine several 
methods in a testing strategy.
The 17 methods were selected based on the 
OECD review paper (OECD, 2014a) and with 
input from previous meetings and workshops 
(see section 4.2 and section 5.2.17). Those 
methods which perform well may be selected 
for further relevance assessment using a set 
of selected reference items with a view to 
their eventual use in a regulatory context. In 
vitro method developers and experts that have 
shown interest or have in-depth knowledge 
on in vitro method best scientific and quality 
practices are involved.
Upon request by the OECD, an EU-NETVAL 
survey was carried out to embrace advances 
in technologies applied to existing in vitro 
OECD TG methods, like e.g., the OECD TG 471 
on the Ames bacterial gene mutation (see 
section 5.2.14). The survey on the uptake 
by EU-NETVAL members of the throughput 
miniaturised Ames bacterial gene mutation test 
collected information to support the decisions 
of the OECD Expert Working Group for the 
development of a Detailed Review Paper (DRP).
Thirty-four EU-NETVAL facilities replied to the 
survey including the current nine EU-NETVAL 
test facilities using already the miniaturised 
Ames. Fifty-four percent of the responders 
showed interest for future testing purposes 
while 61% showed interest in training 
opportunities, put into practice at the EU-
NETVAL meeting on 10 and 11 October 2017. 
At the EU-NETVAL meeting in October 2016, a 
training and knowledge-sharing session on new 
in vitro skin sensitisation OECD TGs (including 
DPRA, h-CLAT, KeratinoSens™ and LuSens) 
took place. In addition, a follow-up to assess 
the impact of the training in terms of practical 
implementation in more EU-NETVAL facilities has 
been assessed by a dedicated survey discussed 
at the EU-NETVAL meeting in October 2017.
4.11 Meeting of the Preliminary 
Assessment of Regulatory 
Relevance (PARERE) network and 
the EURL ECVAM Stakeholder 
Forum (ESTAF)
EURL ECVAM hosted the annual meeting of 
the Preliminary Assessment of Regulatory 
Relevance (PARERE) network followed by a joint 
Meeting of the EU-NETVAL: Sharing practical 
expertise and knowledge on in vitro methods 
The JRC's European Union Reference Laboratory 
for Alternatives to Animal Testing (EURL ECVAM) 
hosted a two-day meeting with the members of the 
European Union Network of Laboratories for the 
Validation of Alternative Methods (EU-NETVAL) on 
10-11 October 2016.
In 2016 EURL ECVAM welcomed 13 new test facilities 
to the network bringing the total to 37 facilities from 
15 different countries across Europe.
The network holds a wide range of expertise and 
competences and includes laboratories experienced 
in advanced in vitro procedures, biological test 
systems and measurement techniques which are 
considered important to address specific aims and 
objectives identified in EURL ECVAM's strategies 
to achieve impact in the Replacement, Reduction, 
and Refinement of animal testing (the 'three Rs') in 
different areas of regulatory safety assessment.
Box 4.4
Representatives from test facilities engaged in a workshop related to the 
development of Good In vitro Method Practice (GIVIMP) (see Box 5.2), an 
international project being led by JRC (EURL ECVAM) on behalf of the EU at the 
OECD. The purpose of this guidance is to contribute to increased standardisation, 
harmonisation and overall quality of in vitro studies that inform chemical and 
product safety assessment in a regulatory context.
The second day of the meeting was dedicated to knowledge sharing and training 
sessions organised in the EURL ECVAM laboratory. These practical sessions covered 
in vitro methods for assessing the skin sensitisation potential of chemicals and 
included the DPRA, KeratinoSensTM/LuSens and h-CLAT OECD TG methods. 
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meeting of PARERE and the ECVAM Stakeholder 
Forum (ESTAF) Networks on 8 November 2016, 
which includes stakeholder organisations from 
academia, industry and civil society/animal 
welfare (see Box 4.6).
The trans-sectorial PARERE network provides 
advice to EURL ECVAM on the regulatory 
relevance and suitability of alternative 
approaches proposed for validation, whilst both 
PARERE and ESTAF networks contribute to EURL 
ECVAM strategies and recommendations as part 
of the validation process (see Box 4.5). 
During the PARERE meeting, members provided 
feedback on their experiences in carrying out 
their roles and highlighted the work they have 
done within their Member States to engage the 
relevant people to support the implementation 
of Directive 2010/63/EU (EU, 2010). New test 
method submissions were also presented to 
PARERE members, who gave valuable input to 
the consultation preparation.
The joint meeting with both PARERE and 
ESTAF focused on the promotion of non-
animal approaches in basic, applied and 
translational research and education and 
training as well as updates from several of 
the stakeholder organisations.
The meeting was followed by a workshop which 
brought together experts from the Horizon2020 
project EU-ToxRisk (see section 2.2), FP7 
research initiative SEURAT-1 (see section 2.1) 
with PARERE and ESTAF members. The scope 
of the meeting was to address strengths and 
limitations of new approach methodologies 
(NAMs45) and to explore the possible regulatory 
use of alternative (non-animal) approaches 
to systemic toxicity that are intended for the 
hazard and safety assessment of chemicals 
used in a variety of sectors.
Further details can be found in the summary 
records of the PARERE meeting and the joint 
PARERE ESTAF meeting.
The PARERE meeting which will take place 
at the JRC on 27 to 28 November 2017 
will provide updates on test submissions 
related to the Bioelution (see section 3.1), the 
ToxTracker (see section 3.2) and the EDITOX 
(see section 3.4) methods on which PARERE 
had been consulted.
It will also include a session on toxicokinetic 
data in regulatory frameworks where EFSA, 
EMA and ECHA will provide their perspectives 
on the use and integration of toxicokinetic 
data in regulatory safety decisions. EURL 
ECVAM will present its current activities in 
the toxicokinetics area which will be followed 
by a Q&A session on Absorption, Distribution, 
Metabolism and Excretion (ADME).
In the morning of 28 November, the more 
advanced case studies of the EU ToxRisk 
5 In general, new approach methodologies (NAMs) 
means the same as alternative methods/approaches 
and more recently in certain fora, people tend to use 
it interchangeably. The only difference between the 
terms NAMs and alternative methods is that in the 
term NAM emphasis is given to the fact that they 
are newer and better technologies (when compared 
to traditional animal tests) rather than replacement 
(alternative) methods of the traditional animal 
tests. However in areas where animal tests do not 
exist (e.g., in the area of hazard/risk assessment 
of mixtures) the term NAM (instead of alternative 
method) may be more appropriate.
Preliminary Assessment of Regulatory Relevance (PARERE)
PARERE is a trans-sector network of regulators from EU Member States which 
provides EURL ECVAM with expert advice regarding the potential application of 
alternative methods for safety assessment that have been proposed for validation. 
The PARERE network also inclides relevant EU regulatory agencies such as ECHA, 
EMA, EFSA and Commission services (DG ENV, DG GROW, DG RTD, DG SANTE).
EURL ECVAM Stakeholder Forum (ESTAF)
ESTAF comprises stakeholder organisations from academia, industry and civil 
society (e.g., animal welfare groups) and provides input in a number of areas 
including EURL ECVAM strategies to implement the three Rs and EURL ECVAM 
Recommendations that are typically issued on conclusion of a validation study.
Box 4.5
READ MORE
Preliminary Assessment 
of Regulatory Relevance 
(PARERE)
europa.eu/!yn37DP
EURL ECVAM 
Stakeholder Forum 
(ESTAF)
europa.eu/!PR99kF
Summary records of 
the PARERE meeting 
2016
europa.eu/!NP38kf
Summary records of 
the joint PARERE-ESTAF 
meeting 2016
europa.eu/!Qw34BD
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project (see section 2.2) will be presented 
as well as the outcome of the PARERE 
consultation on the preliminary regulatory 
relevance of these case studies.
The joint PARERE ESTAF meeting (28 to 29 
November 2017) will build on the conclusions of 
the study on 3Rs knowledge sharing (Holley et 
al., 2016) by exploring the status of 3Rs relevant 
knowledge sources and sharing practices in 
three specific areas, namely research, education 
and training, and regulatory testing. Participants 
will take part in a workshop to identify good 
practices, explore opportunities and propose 
solutions for better knowledge sharing.
EURL ECVAM meets with its networks of 
regulators and stakeholders
On 8 November the JRC's EURL ECVAM hosted a 
meeting of its network for the Preliminary Assessment 
of Regulatory Relevance (PARERE) of alternative 
methods, followed by a joint meeting of PARERE and 
the EURL ECVAM Stakeholder Forum (ESTAF).
During the PARERE meeting, members highlighted the 
work they have done within their Member States to 
engage relevant experts to support its role and the 
implementation of Directive 2010/63/EU. Discussions 
also focused on two consultations recently launched 
by EURL ECVAM concerning in vitro methods 
for detecting potential neuro-toxicants and for 
measuring the potential release of toxic substances 
from solid materials such as metal alloys.
This year the joint PARERE-ESTAF meeting 
focused primarily on the promotion of non-animal 
Box 4.6
approaches in education and training and in basic, applied and translational 
research. Several stakeholder organisations reported on their own activities 
and initiatives in this area. An overview of EURL ECVAM's activities was also 
presented, which have also been described in the 2016 EURL ECVAM Status 
Report (Zuang et al., 2016).
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5 Promoting the Regulatory 
Acceptance and International 
Adoption of Alternative Methods 
and Approaches
As well as promoting the development and 
dissemination of alternative methods and 
approaches, EURL ECVAM also promotes their 
international recognition and acceptance by 
regulators through numerous activities, many of 
which are detailed in this chapter.
Much of this international work is undertaken 
together with OECD partners where essential 
experience and knowledge is exchanged through 
expert groups and guidance and harmonised 
approaches are agreed, ensuring the 3Rs are 
always taken into account where possible. 
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Acceptance and International 
Adoption of Alternative Methods 
and Approaches
5.1 Activities in the OECD Working 
Party on Hazard Assessment 
In the OECD Working Party on Hazard Assessment 
(WPHA), Member Countries work together to 
improve and harmonise chemical assessment 
methods using the most current science.
These include integrated approaches to testing 
and assessment (IATA) and (quantitative) 
structure activity relationships, or (Q)SARs.
This results in the publication of OECD 
monographs that illustrate general 
considerations drawing from example cases, 
with the overall goal of moving towards 
technical convergence. 
5.1.1 OECD Integrated Approaches to 
Testing and Assessment Case Studies Project
The IATA Case Studies Project under the OECD 
WPHA aims to support efforts of the OECD 
member countries to increase the use of 
alternative methods within IATA.
The project is investigating the practical 
applicability of IATA by discussing case studies, 
based on a draft template (based on OECD, 
2014b,c), to create a common understanding 
of using the approaches. Findings and 
conclusions are summarised in considerations 
documents, which highlight the major issues 
discussed and lessons learned from the IATA 
approaches of the case studies, to contribute 
to the development of further guidance and 
respective tools.
The first cycle in 2015 comprised four case 
studies focused on grouping and read-
across for different hazard endpoints (OECD, 
2016a-e). Five case studies were reviewed 
in the second cycle in 2016, including three 
read-across case studies (OECD, 2017a-b), 
one specifically supported by toxicogenomics 
data (OECD, 2017c), a pesticide cumulative 
risk assessment and assessment of lifestage 
susceptibility (OECD, 2017d), as well as the 
JRC/BIAC chemical safety assessment workflow 
based on exposure considerations and focusing 
on non-animal methods (OECD, 2017e), based 
on the SEURAT-1 cross-cluster ab initio case 
study (Berggren et al., 2017). This workflow 
aims to structure knowledge and data in a 
logical sequence for an integrated chemical 
safety assessment considering multiple data 
streams for safety assessment decisions.
The five case studies of the 2016 cycle and 
its considerations document (OECD, 2017f), 
updating the learnings with new experience 
from the second cycle, were endorsed at the 
WPHA meeting in June 2017 and published on 
the OECD IATA website in September 2017. 
The third cycle, that started in 2017, is 
reviewing a case study on read-across with 
metabolism playing a key role in toxicity16 
(led by ICAPO), an IATA workflow using inter-
chemical comparison (read-across) and intra-
chemical comparison of data from traditional 
and alternative approaches27 (led by Canada/
US), the prioritisation of chemicals using 
an IATA-based Ecological Risk Classification 
(led by Canada) and the JRC case study on 
grouping and read-across for nanomaterials 
- genotoxicity of nano-TiO2, based on the 
Nanocomput project carried out at EURL ECVAM 
(see section 5.9).
The aim of this case study was to determine 
the genotoxic hazard potential of two nano-
TiO2 target substances by reading across in 
vitro comet assay results. It is illustrating the 
applicability of the workflow for grouping and 
6 Use of Integrated Approaches for Testing and 
Assessment for sub-chronic repeated-dose toxicity of 
simple aryl alcohol alkyl carboxylic esters
7 Estrogenicity of substituted phenols
READ MORE
Integrated Approaches 
to Testing and 
Assessment (IATA) - 
Case studies project
www.oecd.org/
chemicalsafety/
risk-assessment/
iata-integrated-
approaches-to-
testing-and-
assessment.
htm#casestudies
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read-across proposed in the REACH guidance 
update for nanomaterials (ECHA, 2017a) and 
identifying sources of uncertainty, exploring the 
extent to which ECHA's Read-Across Assessment 
Framework (RAAF) (ECHA, 2017b) captures the 
different sources of uncertainty for nanoforms, 
pointing out nanospecificities to be considered. 
Furthermore, the relevance of computational 
methods in grouping of nanoforms was explored.
5.1.2 Chemical Mixtures and Combined 
Exposure
Humans and the environment are continuously 
exposed to a multitude of substances via 
different routes of exposure.
The toxicological risk of chemical mixtures, 
relates both to intentional mixtures (e.g., 
known compositions, such as personal care 
products, food additives and pesticides) and 
unintentional ones (e.g., the combination of 
dozens to hundreds of substances in surface 
water, drinking water or air). For the latter, the 
assessment is much more challenging because 
the compositions are various and complex, 
many of the substances are unidentified and 
toxicity data are lacking.
The current risk assessment approach of 
chemicals, for regulatory purposes, does 
not generally take into account this complex 
situation of exposure to multiple substances 
and mainly relies on the assessment of 
individual substances. Moreover, although 
the current EU regulations identify different 
types of mixtures, there is no harmonised 
methodological approach to their assessment.
In follow-up to the Commission Communication 
on the Combined Effects of Chemicals (EC, 2012), 
EURL ECVAM started its activities in the area 
of mixture risk assessment with a review of 
regulatory requirements, available guidance and 
approaches (Kienzler et al., 2014; Kienzler et al., 
2016a). Furthermore, EURL ECVAM investigated 
the applicability of novel, non-animal tools in the 
assessment of combined effects of chemicals 
on humans and the environment.
New approaches and methods, such as the AOP 
concept, in vitro methods, 'omics techniques, 
quantitative structure activity relationships 
(QSARs), read-across, toxicokinetic and dynamic 
energy budget (DEB) modelling, and IATA 
can help achieve a more effective regulatory 
assessment and at the same time reduce the 
reliance on animal testing (Bopp et al., 2015).
Their main strengths lie in their integrated 
use in smart combination, finally allowing a 
better, mechanistically based prediction of 
mixture effects.
In order to gain further insight into the issues 
linked to the risk assessment of chemical 
mixtures, EURL ECVAM reviewed relevant case 
studies from the peer-reviewed literature (Bopp 
et al., 2016), which provided further evidence 
that chemicals need to be further addressed 
not only in single substance risk assessments 
but also in mixture risk assessments that 
cover multiple chemical classes and legislative 
sectors (see Box 5.1).
Currently, EURL ECVAM is performing several own 
case studies that will become available in 2018.
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As international harmonisation is essential in this 
context, EURL ECVAM plays an active role in the 
OECD project on combined exposure (led by the 
OECD WPHA in collaboration with the Working 
Party on Exposure Assessment) and supports 
the development of consistent assessment 
approaches for combined exposure to chemical 
mixtures at international level. The draft guidance 
document was completed in June 2017 and is 
expected to be finalised by the end of 2017.
5.1.3 Guidance Document on 
Physiologically Based Mathematical Models
The EURL ECVAM Strategy Document on 
Toxicokinetics (TK) (Bessems et al., 2015) 
outlines objectives to enable prediction of 
systemic toxicity by applying new approach 
methods (NAM) that consider TK.
The aim of the EURL ECVAM strategy is to 
replace, reduce and refine animal testing in 
the assessment of toxicokinetics and systemic 
toxicity of substances, showing a significant 
short to mid-term Three Rs impact, and at 
the same time laying the foundation for a 
risk assessment approach that is increasingly 
based on human ADME/TK data. In order to 
facilitate the generation, acceptance and use 
of TK data and in vitro and in silico methods 
in the regulatory domain, four main objectives 
were identified.
The first concerns the development of 
standards to characterise in vitro methods that 
measure individual Absorption, Distribution, 
Metabolism and Excretion (ADME) processes. 
The second objective aims to establish good 
kinetic modelling practices (GMP). The third 
objective expresses the need for publicly 
available databases to facilitate access 
information to create and deploy Physiologically 
Based Kinetic (PBK83) models. The fourth 
objective expresses the need to develop 
guidance on how to generate, use and integrate 
these data in a regulatory setting. 
Concerning GMP (objective two), PBK models are 
used widely throughout a number of working 
sectors to provide insight into the dosimetry 
related to observed adverse health effects in 
humans and other species. Despite significant 
advances in GMP for model development and 
evaluation, there remains some reluctance 
among regulatory agencies to use such models 
during the risk assessment process.
The results of the EURL ECVAM international 
survey disseminated to the modelling 
community (93 respondents from 19 
countries) in January 2017 are presented 
in Paini et al., (2017a) and inform on the 
frequency of use and applications of PBK 
models in science and regulatory submission, 
on the increased use of new approaches, on 
the need to peer review the models and on the 
need for guidance (see Box 5.2).
8 PBK is synonymous of PBPK, PBBK, PBTK.
Assessing potential risks from exposure to chemical mixtures - 
case study review
Humans and wildlife can be exposed to an almost infinite number of different 
combinations of chemicals in mixtures via food, consumer products and 
the environment, which raises concerns for possible impacts on public and 
environmental health.
A review of recent literature by the JRC's EURL ECVAM (Bopp et al., 2016) 
summarises the outcome of case studies covering several chemical classes. 
Parameters that could lead to an over- or underestimation of potential risks were 
identified. Case study results need to be interpreted with caution, considering the 
underlying assumptions, model parameters and related uncertainties.
However, there is clear evidence that chemicals need to be further addressed not 
only in single substance risk assessments but also in mixture assessments that 
cover multiple chemical classes and legislative sectors.
Furthermore, several issues hampering mixture risk assessments are identified. 
In order to perform a mixture risk assessment, the composition of the mixture in 
terms of chemical components and their concentrations need to be known, and 
information on their uptake and toxicity are required. 
Screening level assessments based on conservative 
assumptions are generally possible. However, 
refining such assessments to more realistic exposure 
scenarios is often not feasible due to data gaps. In 
particular, relevant exposure and toxicity data as well 
as information on modes of action are often lacking.
Box 5.1
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During a JRC workshop in November 2016 
on the use of PBK models in risk assessment, 
twenty-two experts unanimously agreed that 
there is a need for a guidance document for the 
new generation of PBK models that integrate in 
vitro, in silico and NAM data (Paini et al., 2017b). 
Thus, the ultimate aim of the endorsed OECD 
guidance document is to address such a need 
so that the credibility of this new generation of 
models can be established in order to promote 
their acceptance and use in a regulatory context.
The intention is to provide harmonised guidance 
to model developers, reviewers, and risk 
assessors on i) characterisation of PBK models 
using non-animal ADME data, ii) assessment 
of the model performance and iii) reporting 
and documentation of model characterisation, 
evaluation/validation, and intended applications.
Additionally EURL ECVAM was active in 
knowledge transfer of the COSMOS/SEURAT-1 
outputs to the EU-ToxRisk partners. On 3 March 
2017, a webinar was provided on the COSMOS 
database and KNIME workflows.
In terms of dissemination, a special issue on 
the Virtual Cell Based Assay (VCBA), which 
simulates the in vitro fate and toxicity of 
chemicals, was published (Comenges et al., 
2015; Graepel et al., 2017; Paini et al., 2017c, 
d; Sala Benito et al., 2017; Whelan et al., 2017; 
Worth et al., 2017a). A JRC technical report 
covering application of the VCBA for simulation 
of chemical fate following acute exposure 
was also published (Proenca et al., 2017). A 
traineeship on the evaluation of the applicability 
of PBK modelling for mixtures also resulted in a 
publication (Desalegn et al., submitted).
The work carried out under objective 2, on 
GMP for PBK models, of the EURL ECVAM TK 
Strategy was disseminated during several 
meetings and events: at the NC3Rs workshop 
on IVIVE, the ECETOC meeting on Advances in 
Exposure Modelling, the ICCA-LRI/JRC workshop 
on exposure assessment and at a session at the 
Figure 5.1: Participants in the PBK Modelling Workshop.
Biologically based mathematical models 
in toxicology: current use and regulatory 
acceptance
Scientists from the JRC and US Environmental 
Protection Agency examined how and to what extent 
mathematical models of biological organisms are used 
in toxicology, and identified a number of challenges 
that need to be overcome for wider use and regulatory 
acceptance of these non-animal approaches.
The survey focused on the use of physiologically based 
kinetic (PBK) models which provide a mathematical 
representation of how chemicals are distributed in 
the body following exposure (Paini et al., 2017a). This 
information - what the body does to a chemical – is 
used along with additional information, e.g., from in vitro 
toxicity experiments, to determine the potential health 
risks resulting from realistic exposure conditions.
The results of the survey indicate that PBK models are 
used widely in academia, industry, and government.
Box 5.2
Moreover, significant scientific and technical advances have been made in their 
development and application. There remains some reluctance, however, among 
regulatory agencies to apply these models to their full potential. One reason 
for this is the lack of appropriate guidance. The findings were based on the 
responses of 93 individuals (modelling experts and end-users) from 19 countries. 
The individual results are publicly accessible at: http://bolegweb.geof.unizg.hr/
questionaire/pbk
READ MORE
COSMOS - Integrated 
In Silico Models for the 
Prediction of Human 
Repeated Dose Toxicity 
of COSMetics to 
Optimise Safety
www.cosmostox.eu
Figure 5.2: Geographic distribution of the PBK questionnaire results (From Paini et al., 2017a, 
Regulatory Toxicology and Pharmacology, 90, p. 107, under CC BY-SA 4.0).
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Society of Toxicology (SOT) meeting 2017 on 
exposure science.
Since March 2017, EURL ECVAM has 
participated in the HESI PBPK working group, 
to discuss and advance the utilization of PBK 
models, by improving PBK model platforms 
and model evaluation, where results from 
the survey were presented. Since May 2017, 
EURL ECVAM has also participated in the 
EU-ToxRisk biokinetic group, providing an 
overview of the tools developed in COSMOS 
(PBK models and VCBA).
5.2 Activities in the OECD Test 
Guidelines Programme
The OECD Test Guidelines (TG) for the testing 
of chemicals are a collection of internationally 
agreed testing methods used by governments, 
industry, research or contract laboratories and 
academia to assess the safety of chemical 
products. They are primarily used in regulatory 
safety testing and subsequent chemical 
notification and registration.
The set of TG is updated on a regular basis to 
keep pace with scientific developments and 
Member Countries’ regulatory needs. OECD-
wide networks of national coordinators and 
national experts provide input from scientists in 
government, academia and industry. OECD TG 
should not be confused with data requirements, 
which are the prerogative of supra-national (EU) 
or national authorities.
The OECD Test Guidelines Programme (TGP), 
with the Mutual Acceptance of Data Agreement 
(MAD) is the main instrument to promote 
a globally harmonised regulatory safety 
testing of chemicals. This supports an open 
global market for the chemicals industry and 
protection of the safety of workers, consumers 
and the environment. OECD also considers 
animal welfare and is committed to the 
implementation of the 3Rs principles in the 
development of TGs.
Historically, acting on behalf of the EU with 
a mandate from the European Commission 
(DG ENV), the JRC's EURL ECVAM has taken a 
leading role in the development of OECD TG 
and GD based on alternative approaches. Annex 
1 of this report summarises the status of 
adoption of OECD TGs on alternative methods 
from 2011 to 2017.
5.2.1 Summary of the Outcome of the 
29th Meeting of the Working Group of 
National Coordinators of the OECD Test 
Guidelines Programme
At the 29th meeting of the Working Group of 
National Coordinators of the OECD TGP held 
at the OECD headquarters in Paris on 25 to 
28 April 2017, eleven Test Guidelines were 
approved of which six were new TGs and five 
were updated TGs.
None of the new TGs were based on in vitro 
methods but there was one refinement method, 
namely TG 433 on a Fixed Concentration 
Procedure (FCP) for Acute Inhalation Toxicity.
The updated TGs included:
• SkinEthic™ HCE EIT in TG 492 on Serious 
Eye Damage/Eye Irritation using Reconstructed 
human Cornea-like Epithelium (RhCE)
• IL8-Luc and U-SENSTM (addressing the 3rd 
KE on the AOP for skin sensitisation, e.g., the 
activation of dendritic cells) in TG 442E. The 
TG was renamed as "Key Event Based Test 
Guideline 442E" and is composed of a general 
introduction and a detailed description of each 
of the three methods in three separate annexes.
Nine Guidance Documents or supporting 
documents were approved as well. TG 415 on 
one generation reproduction toxicity testing 
was deleted. The WNT agreed the new work 
plan that includes now nineteen new projects, 
thirteen of which are of relevance to the field 
of alternative methods/approaches.
Furthermore, the WNT supported the 
development of guiding principles and good 
practice regarding Intellectual Property (IP) and 
Licensing in TGs.
A workshop took place on 21 to 22 September 
2017 and an OECD advisory group for future 
issues was created. It was also decided to 
expand the Standard Project Submission 
Form (SPSF) with a more broad description of 
IP under point 8 and to introduce a penalty/
return-to-start clause in case IP elements 
are not transparently communicated upfront 
during project proposal and are only raised 
later during project development or after 
approval of the TG.
Regarding the outcome of the WNT 
consultation on the OECD policy on similar 
(me-too) assays in the TGP, the WNT pointed 
READ MORE
NC3Rs workshop on 
IVIVE
www.nc3rs.
org.uk/events/
workshop-applying-
exposure-science-
increase-utility-
non-animal-data-
efficacy-and-safety
ECETOC meeting on 
Advances in Exposure 
Modelling
www.ecetoc.org/
event/workshop-
advances-exposure-
modelling-bridging-
gap-research-
application
ICCA-LRI/JRC 
workshop on exposure 
assessment 
cefic-lri.org/events/
icca-lri-workshop-
2017-which-fit-for-
purpose-exposure-
science-for-risk-
assessment-needs-
for-priority-setting-
screening-and-next-
gen-evaluation
Exposure science at the 
Society of Toxicology 
(SOT) meeting 2017
www.toxicology.org/
events/am/AM2017/
program.asp
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out that the issue was not limited to similar 
methods, but was a question of priorities 
within the TGP. The WNT supported the option 
to have a modified SPSF template for similar 
methods, require an up-front submission 
package, develop a modified process for peer-
review, and a simplified process for adding 
similar methods to existing TG.
More information can be found on the OECD 
website of the TGP.
The following chapters mainly focus on TGs 
for which the EC (through JRC-EURL ECVAM) 
has the lead or co-lead. However, some 
projects with relevance to the alternative 
field led by other Member Countries are also 
briefly described. Beside those, EURL ECVAM 
participated in numerous OECD expert groups 
and validation management groups and 
commented on several other draft TGs and GDs 
led by other OECD Member Countries.
5.2.2 Guidance Document on Integrated 
Approaches to Testing and Assessment 
for Serious Eye Damage/Eye Irritation
The assessment of serious eye damage/eye 
irritation is a basic information requirement in 
international regulations for the classification 
and/or safety assessment of chemicals, 
pesticides, and medicines. Under some 
regulations (e.g., EU Cosmetics Regulation, 
REACH) this information is required to be 
generated without the use of animal tests.
In 2002, a supplement describing a sequential 
testing and evaluation strategy was added to 
OECD TG 405 on in vivo "acute eye irritation/
corrosion". This strategy recommended that, 
prior to undertaking the described in vivo test, 
a weight-of-evidence analysis be performed 
on all existing relevant data and that, where 
insufficient data were available, new data be 
developed through application of a sequential 
testing strategy, starting first with alternative 
methods, in order to avoid unnecessary testing 
in laboratory animals. 
Since publication of the supplement in 2002, 
several in vitro methods for serious eye 
damage/eye irritation have been developed, 
validated and accepted by the OECD. Depending 
on country requirements and the results 
obtained with the OECD accepted methods 
(e.g., BCOP, ICE, FL, STE, EpiOcular™ EIT and 
SkinEthic™ HCE EIT), they may in many cases 
satisfy all information requirements for serious 
eye damage/eye irritation.
In addition, non-standard methods (e.g., not 
yet validated and/or accepted by OECD) may 
provide further information (e.g.,, persistence vs. 
reversibility of effects, direct identification of 
Category 2 chemicals) that could contribute to 
the full replacement of the in vivo rabbit eye test.
Although the suitability of such data for 
regulatory purposes needs to be judged case by 
case, they should be considered before conducting 
animal studies. For these reasons, guidance 
in relation to the use and generation of data 
for serious eye damage/eye irritation required 
updating and, therefore, the EC JRC's EURL 
ECVAM and the United States Environmental 
Protection Agency (U.S. EPA) proposed to jointly 
lead the development of a Guidance Document 
(GD) on an Integrated Approach on Testing and 
Assessment (IATA) for serious eye damage and 
eye irritation at the OECD. 
The objective was to provide guidance on the 
possible use and usefulness of individual test 
methods and on how to best combine them to 
reach a scientifically sound conclusion in an 
effective way, at the same time minimising 
animal testing to the extent possible. The 
project was approved by WNT in April 2015. 
The final GD was adopted by the WNT in April 
2017 following two commenting rounds, and 
was published by the OECD in July 2017 (OECD, 
2017g). TGs 405, 437 (BCOP), 438 (ICE), 460 
(FL), 491 (STE) and 492 (EpiOcular™ EIT and 
SkinEthic™ HCE EIT) were also revised and 
adopted at the same time to include a new 
reference to the GD and delete the Supplement 
from TG 405 (see also Annex 1).
5.2.3 Adoption of New Test Guidelines 
for Skin Sensitisation
Two new TGs for skin sensitisation testing were 
approved by the WNT at its April meeting in 2017, 
OECD TG on the U937 cell line activation Test 
(U-SENS™) and OECD TG on the IL-8 Luc assay.
The U-SENS™ method is proposed to address 
the third key event (dendritic cell activation) 
of the skin sensitisation AOP by quantifying 
the change in the expression of a cell surface 
marker associated with the process of 
activation of monocytes and DC (e.g., CD86), in 
the human histiocytic lymphoma cell line U937, 
READ MORE
Mutual Acceptance of 
Data (MAD)
www.oecd.org/env/
ehs/mutualacceptan-
ceofdatamad.htm
OECD Test Guidelines 
Programme (TGP)
www.oecd.org/
chemicalsafety/
testing/oecd-
guidelines-testing-
chemicals-related-
documents.htm
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following exposure to sensitisers (Piroird et al., 
2015). The measured expression levels of CD86 
cell surface marker in the cell line U937 is then 
used for supporting the discrimination between 
skin sensitisers and non-sensitisers.
The U-SENS™ method has been evaluated in a 
validation study and subsequently independently 
peer reviewed by the EURL ECVAM Scientific 
Advisory Committee (ESAC) (ESAC, 2016c, see 
section 4.8). Considering all available evidence 
and input from regulators and stakeholders, the 
U-SENS™ was recommended by EURL ECVAM 
(EURL ECVAM, 2017) to be used as part of an 
IATA to support the discrimination between 
sensitisers and non-sensitisers for the purpose 
of hazard classification and labelling.
The IL-8 Luc assay addresses the third key event 
(dendritic cell activation) of the skin sensitisation 
AOP. In contrast to the h-CLAT, which follows 
the expression of cell surface markers, it 
quantifies changes in IL-8 expression, a cytokine 
associated with the activation of DC. In the 
THP-1-derived IL-8 reporter cell line (THP-G8, 
established from the human acute monocytic 
leukemia cell line THP-1), IL-8 expression is 
measured following exposure to sensitisers 
(Takahashi et al., 2011). The expression of 
luciferase is then used to aid discrimination 
between skin sensitisers and non-sensitisers.
The IL-8 Luc method has been evaluated in 
a validation study (OECD, 2017h) conducted 
by the Japanese Centre for the Validation of 
Alternatives Methods (JaCVAM), the Ministry 
of Economy, Trade and Industry (METI), and 
the Japanese Society for Alternatives to 
Animal Experiments (JSAAE) and subsequently 
subjected to independent peer review (OECD, 
2017i) under the auspices of JaCVAM and 
the Ministry of Health, Labour and Welfare 
(MHLW) with the support of the International 
Cooperation on Alternative Test Methods 
(ICATM). The IL-8 Luc assay is considered useful 
as part of IATA to discriminate sensitisers 
from non-sensitisers for the purpose of hazard 
classification and labelling.
Based on a proposal made by the EC at the 
meeting of the OECD expert group on skin 
sensitisation held on 2 and 3 November 2016 
in Paris, the OECD decided to develop key 
event-based TGs for non-animal test methods 
addressing a specific key event within an 
existing AOP. This approach would facilitate 
organising the various test methods into single 
documents and simplify locating methods that 
address the same key event.
The first example of key event based TG 
(TG 442E) describes in vitro assays that 
address mechanisms under the 3rd Key 
Event of the AOP for skin sensitisation, i.e., 
activation of dendritic cells (OECD, 2012a). 
The TG comprises test methods to be used for 
supporting the discrimination between skin 
sensitisers and non-sensitisers in accordance 
with the UN GHS. The test methods described 
in this TG are: the Human Cell Line Activation 
test (h-CLAT), the U937 cell line activation 
Test (U-SENS™) and the Interleukin-8 Reporter 
Gene Assay (IL-8 Luc assay).
The test methods included in this TG differ 
in relation to the procedure used to generate 
the data and the readouts measured and can 
be used indiscriminately to address countries’ 
requirements for test results on the 3rd Key 
Event on the AOP for skin sensitisation while 
benefiting from the Mutual Acceptance of Data.
5.2.4 Development of OECD Test 
Guidelines on in vitro Fish Hepatic 
Metabolism
The OECD project on the development of new 
OECD TGs on in vitro Fish Hepatic Metabolism 
(under the lead of USA and the EC represented 
by JRC's EURL ECVAM) aims at standardising 
two in vitro methods using either rainbow 
trout S9 fraction (Johanning et al., 2012) or 
cryopreserved rainbow trout hepatocytes (Fay 
et al., 2015) to determine in vitro fish intrinsic 
hepatic clearance rates.
The project builds on work carried out within 
the framework of the ILSI HESI project 
"Bioaccumulation". ILSI HESI coordinated 
a multi-laboratory ring trial to assess the 
reliability, transferability, and predictive value of 
the two in vitro methods (2014-2016). Building 
on the protocols used, two OECD TGs and a 
guidance document have been developed and 
published for consultation with WNT experts in 
April and August 2017 (OECD, 2017j-m).
The fish intrinsic hepatic clearance rate derived 
with in vitro methods can be extrapolated to a 
whole-body metabolism rate constant. Inclusion 
of measured biotransformation rates enhances 
the reliability of models to estimate the 
Bioconcentration Factor (BCF) (Laue et al., 2014; 
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Nichols et al., 2013). The BCF is either predicted 
or measured (typically in fish, but if necessary, 
also in invertebrates). 
The bioconcentration potential of a chemical is 
important information that is required in many 
pieces of chemical legislation. It is used for 
hazard classification and for the assessment 
of persistent, bioaccumulative and toxic (PBT) 
substances. More reliable BCF prediction models 
have the potential to reduce uncertainty and 
thus avoiding unnecessary testing on fish. 
In order to support this project, EURL ECVAM 
has launched the development of a curated 
database containing in vivo and in vitro 
biotransformation data (see section 2.6.6).
5.2.5 Update of OECD Guidance 
Document 23 on Aquatic Toxicity Testing 
of Difficult Substances
This project initiated by the International Council 
on Animal Protection in OECD Programmes 
(ICAPO) and co-led by the EC (JRC-EURL ECVAM) 
addresses the use of solvents in fish toxicity 
tests. When solvents are used, e.g., for the 
testing of poorly soluble chemicals, OECD test 
guidelines require two control groups - a water 
control and a solvent control. 
Part 1 of the project initially aimed at updating 
specific sections of OECD Guidance Document 
23 on Aquatic Toxicity Testing of Difficult 
Substances and Mixtures (OECD, 2000) with 
advanced methodology for media preparation 
and exposure systems, and by that minimising 
the use of solvents. 
At the WNT meeting in 2016, OECD member 
countries agreed upon the complete revision of 
GD 23 (under the lead of USA) to adequately 
address the many comments received on 
all sections of GD 23 during the 1st WNT 
commenting round. During 2016-2017, the 
three parties worked closely together and the 
revised draft GD 23 has been published for WNT 
consultation in August 2017 (OECD, 2017n).
Part 2 of the project aims at determining 
whether it is possible to use only one control, 
the solvent control, when solvents are used in 
aquatic toxicity tests on fish. A retrospective 
review of existing data generated according 
to OECD test guidelines in the presence of a 
solvent will be used to determine if the use 
of only one control would impact the outcome 
of the study. It is anticipated that a Detailed 
Review Paper (DRP) will be prepared. 
5.2.6 Revision of OECD Guidance 
Document 126
The project aims at updating OECD GD 126, the 
threshold approach for acute fish toxicity (OECD, 
2010), and integrate the fish embryo acute 
toxicity test (OECD, 2013b) into the step-wise 
approach for determining acute fish toxicity.
The project started in 2015 under the lead 
of Austria and ICAPO and the evaluation of 
data is ongoing.
Figure 5.2: Members of OECD.
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5.2.7 Revision of OECD Test Guideline 203
OECD TG 203 fish acute toxicity test (OECD, 1992) 
determines the concentration of a chemical at 
which 50% of the fish die (LC50) and is one of the 
few guidelines still using death as an endpoint.
The project (led by Switzerland and UK) aims 
at including the use of non-lethal endpoints 
(moribund state) to reduce the suffering of the 
fish. The evaluation of non-lethal endpoints and 
their predictivity is ongoing.
5.2.8 OECD Test Guideline on CYP Induction
The human cytochrome P450 (CYP) activity 
n-fold induction in vitro test method assesses 
the potential of test items to induce three 
cytochrome P450 (CYP) enzyme activities 
(CYP1A2, CYP2B6, and CYP3A subfamily) in two 
human-derived metabolically competent hepatic 
in vitro test systems: the cryopreserved human 
primary hepatocytes and the cryopreserved 
human HepaRG (HepaRG).
The method has been validated and peer 
reviewed (EURL ECVAM, 2014; Zuang et al., 
2015) and an EURL ECVAM Recommendation is 
currently being prepared (see section 4.9.2).
A PBTG, prepared by EURL ECVAM, including 
both the CryoHepaRG™ and the human primary 
hepatocytes test methods, underwent a first 
commenting round in 2015. Subsequently, a 
first meeting of the OECD Expert Group on 
Biotransformation Assays took place in Paris, 
France, on 11 to 12 May 2015.
Considering the need for TGs on in vitro 
metabolism, the expert group suggested that 
a TG based on the CryoHepaRG™ model should 
be developed in the short-term and that 
other methods, based e.g., on human primary 
hepatocytes, could be included in the medium-
term, while keeping in mind the development of 
AOP/IATA in the long-term.
It was considered that for the regulatory early 
screening phase of substances, a reproducible 
and easy to use model for the evaluation of the 
induction properties of a chemical was needed. 
The cryoHepaRG™ is likely to deliver more 
consistent results and the test system itself is 
more readily available than the cryopreserved 
human primary hepatocytes model.
In addition, it was suggested to prepare an 
explanatory background review document 
(BRD) that describes the context of use of 
this type of methods in a regulatory hazard 
and risk assessment framework for a better 
understanding of the value of information on 
the CYP inducing properties of a chemical.
The need for an accompanying GD was also 
raised at the OECD WNT meeting in April 2017. 
5.2.9 OECD Guidance Document on 
Good In Vitro Method Practices for the 
Development and Implementation of 
In vitro Methods for Regulatory Use in 
Human Safety Assessment
A Guidance Document (GD) on Good In Vitro 
Method Practices (GIVIMP) for the development 
and implementation of in vitro methods for 
regulatory use in human safety assessment 
was identified as a high priority requirement 
by the OECD. 
The GD aims at reducing the uncertainties in 
cell and tissue-based method predictions by 
the application of good scientific, technical and 
quality practices from method development to 
method implementation for regulatory use.
The draft GIVIMP GD is coordinated by EURL 
ECVAM and was accepted on the work plan of 
the OECD test guidelines programme in April 
2015 as a joint activity between the Working 
Group on Good Laboratory Practice (GLP) and 
the Working Group of the National Coordinators 
of the Test Guideline Programme (WNT). 
During the first stage, expert input was received 
from European regulatory agencies [the 
European Food Safety Authority (EFSA), the 
European Medicine Agency (EMA), the European 
Chemicals Agency (ECHA)], the European Union 
Network of Laboratories for the Validation of 
Alternative Methods (EU-NETVAL), the EU and 
OECD Working Groups on GLP, 3Rs Centres, 
a regulatory agency (RIVM), from scientists 
of large industries and SMEs and from 
international scientists with expertise in stem 
cells, cell biology, GLP and in vitro methods.
The GIVIMP GD is divided into 10 sections 
covering: (1) roles and responsibilities, (2) 
quality considerations, (3) facilities, (4) 
apparatus, material and reagents, (5) test 
systems, (6) test and reference/control items, 
(7) standard operating procedures (SOPs), (8) 
performance of the method, (9) reporting of 
results, (10) storage and retention of records 
and materials. 
READ MORE
GLP -Good Laboratory 
Practice
ec.europa.eu/growth/
sectors/chemicals/
good-laboratory-
practice_en
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This guidance is not intended to duplicate or 
replace existing OECD Guidance Documents 
but rather to complement them by addressing 
specific gaps and collecting available references 
and information on best scientific, technical and 
quality practices in one document.
On 23 and 24 March 2017, EURL ECVAM hosted 
a meeting with the OECD GIVIMP expert group 
to discuss some outstanding issues see (see 
Box 5.2). Following on from this meeting a new 
draft version of GIVIMP (v05) incorporating 
the feedback received during the meeting was 
prepared. On 4 August, 2017 this GIVIMP GD 
draft was sent to the OECD for the second 
commenting round. The GD is expected to be 
adopted at the 30th WNT meeting to be held on 
24 to 27 April 2018.
5.2.10 New Project Proposal on a 
Performance-based Test Guideline for 
Defined Approaches relating to Skin 
Sensitisation
In 2017, the OECD endorsed a project 
proposal jointly submitted by the EC (through 
JRC's EURL ECVAM), US (NICEATM/EPA/
CPSC) and Canada (Health Canada) for the 
development of a Performance Based Test 
Guideline (PBTG) for Defined Approaches (DAs) 
for skin sensitisation.
This proposal for the development of a PBTG 
in the area of skin sensitisation builds on 
discussions held during an International 
Cooperation on Alternative Test Methods 
(ICATM) workshop on the regulatory 
applicability and acceptance of alternative 
approaches to skin sensitisation, hosted by 
EURL ECVAM in October 2016 (see section 
7.1 and Box 7.1). More than 20 regulatory 
authorities from the US, EU, Korea, Japan, 
China, Canada, and Brazil were represented.
One major outcome of the ICATM workshop 
was the proposal to develop assessment 
criteria for non-animal DAs for skin 
sensitisation that will serve as alternatives 
to the current animal tests, namely the LLNA 
(OECD TGs 429, 442A and 442B) and the 
guinea pig tests (OECD TG 406), in the context 
of IATA (e.g., always considering other existing 
reliable and relevant information). 
A set of criteria were already proposed by 
the regulatory experts at the workshop, and 
will be used by ICATM as a basis to propose 
assessment criteria within the OECD, in 
consultation with the relevant expert group 
and the WNT to evaluate a number of existing 
DAs (Annex 1 to OECD GD 256) and individual 
test methods (if available/applicable). These 
JRC meets with OECD experts to define 
good practices for in vitro methods
Safety testing of chemicals is required to assess 
the hazards and potential risks of chemicals 
to humans. To accommodate the demand of 
regulatory authorities, a number of in vitro 
methods, often based on the use of human cells 
and tissues, have been submitted to international 
validation bodies during the last two decennia.
However, validation studies have revealed 
that many in vitro methods need serious 
improvements in design, robustness and reliability 
in order to be successfully implemented and 
generate data sets which can be used to support 
regulatory decisions.
In this respect, the OECD asked the JRC's 
EURL ECVAM to coordinate the drafting of a 
guidance document on Good In Vitro Method 
Practices (GIVIMP) for the development and 
implementation of in vitro methods for regulatory 
use in human safety assessment.
The OECD expert group met at the JRC in Ispra on 23 and 24 March 2016 to 
discuss in detail the feedback received on the draft OECD guidance document from 
EU-NETVAL and the first OECD commenting round. EURL ECVAM prepared the final 
GIVIMP version, which will be submitted for adoption by the OECD in April 2018.
The purpose of the GIVIMP guidance document is taking into account all necessary 
good scientific, technical and quality practices, to ensure that the overall process - 
from in vitro method development to in vitro method implementation for regulatory 
use - becomes more efficient and effective.
Box 5.2
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assessment criteria will be based on key 
criteria such as biological plausibility, inclusion 
of existing validated in vitro methods covering 
AOP key events, consideration of the known 
applicability domain of the DAs, potential of 
the DAs to generate data that may inform 
potency sub-categorisation, accessible data 
interpretation procedures, and performance 
against reference chemicals.
Performance criteria will be derived from, for 
example, a comprehensive analysis of current 
animal test (LLNA) data to determine thresholds 
for acceptance based on i) reproducibility of 
the animal test and ii) concordance with human 
data where available.
The assessment framework will also 
provide criteria for selection of appropriate 
reference chemicals to be used to compare 
the performance of DAs (and individual test 
methods) to the LLNA. The ultimate goal will 
be to use the assessment framework to draft 
a PBTG including those DAs (and individual test 
methods) able to meet the acceptance criteria.
A special meeting of the OECD WNT will take 
place from 13 to 15 December 2017 at the 
JRC. On occasion of this meeting preliminary 
assessment criteria as well as potential ways 
for analysing the in vivo (LLNA and human) 
data will be proposed for discussion.
5.2.11 New Project Proposal on a 
Guidance Document for Human Hepatic 
Metabolic Clearance Methods
The published EURL ECVAM Toxicokinetics (TK) 
Strategy (Bessems et al., 2015) aims to promote 
the use of TK/ADME data in chemical risk 
assessment considering due to the increasing 
demand (from researchers, test method 
developers, regulators and end-users) to integrate 
TK information in chemical risk assessment.
This is based on the fact that exposure to a 
chemical does not automatically mean that all 
of the dose will be bioavailable and therefore 
able to cause a specific toxicity. Hence the 
knowledge of the chemical's human kinetics can 
contribute to the better design of toxicity tests 
(both in vivo and in vitro) and the interpretation 
of toxicological findings.
Consequently, the EC-EURL ECVAM has proposed 
the development of an OECD GD to characterise 
and describe a specific class of in vitro methods 
for measuring hepatic metabolic clearance as a 
first practical step to promote the use of kinetics 
information. The underlying rationale is that 
hepatic metabolic clearance represents in many 
cases the main driving process of kinetics and 
that there are already several non-guideline in 
vitro methods to measure hepatic metabolic 
clearance which can significantly vary in their 
experimental settings, stage of development, 
intended use, reliability and relevance, etc.
With a view to enhancing the use of in vitro 
methods for hepatic metabolic clearance in 
chemical hazard and risk assessment, the 
objective of this GD is to establish a consistent 
and transparent framework. This framework will 
be focused on identifying the relevant elements 
to be considered when characterising and 
describing in vitro hepatic metabolic clearance 
methods in order to facilitate the assessment 
of their performance, method comparison and 
increase confidence in their use. 
The framework and its elements are intended 
to be descriptive rather than prescriptive. 
They do not define how a method should 
be designed, how it should be used, or 
what performance it should have. Instead 
they provide a standardised means of 
characterising, describing and reporting the 
salient attributes of a method.
In addition, the GD is expected to enhance 
the communication between in vitro methods 
developers, end-users and regulators, by 
increasing the understanding of how in vitro 
hepatic metabolic clearance data have been 
generated and therefore what uncertainties 
need to be taken into account when applying 
the method for specific applications.
5.2.12 Workshop and New Project 
Proposal on Developmental Neurotoxicity
A clear overall consensus has been reached 
among the participants of the recent 
workshops on developmental neurotoxicity 
(DNT; October 2016, January 2017) that DNT 
is a highly relevant toxicological measure, 
and that the amount of data generated to 
date is not sufficient to provide confidence 
on the safety of the thousands of untested 
chemicals to which pregnant women, infants 
and children may be exposed, nor to be 
informative or supportive of epidemiological 
observations on neurodevelopmental 
disturbances (Fritsche et al., 2017). 
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The workshop participants emphasised 
that there is an urgent need for a problem 
formulation-driven, fit-for-purpose testing 
paradigm to supply data for risk assessment to 
support risk management decisions.
Such a testing strategy should be developed 
and implemented to achieve two aims, 
conducted simultaneously.
The first aim is to begin using the battery of 
currently available alternative test methods to 
generate data that could be used to prioritise 
chemi¬cals for further testing. The second 
aim is to generate data that informs risk 
assessment and management decisions.
Priority for the first aim should be given, where 
possible, to a human cell-based testing battery 
covering basic neurodevelopmental processes 
and key events identified in the existing DNT 
AOPs to be put into place immediately for 
screening and prioritisation purposes. It was 
suggested that the testing strategy should be 
flexible, able to incorporate new technologies, 
and adaptable to the different problem 
formulations. The testing battery should be part 
of an IATA strategy, and the process should 
result in an OECD GD on DNT.
Currently, the main task is to establish 
performance standards and readiness criteria 
for individual in vitro DNT assays evaluation 
to understand which in vitro assays are ready 
to be used and which test methods need 
further optimisation and standardisation. 
The evaluation of such assays will lead to 
development of a guidance on principles for 
the building of an in vitro DNT testing strategy 
followed by challenging not a single assay, but 
a battery of in vitro assays by chemical testing. 
These efforts should result in development 
of an OECD GD on available in vitro DNT test 
methods and principles of building DNT testing 
strategy(ies) for various regulatory purposes. 
This task has been included in the OECD Work 
programme 2017 and the GD will be developed 
in collaboration with EFSA, EU (including JRC) 
and US DNT experts.
5.2.13 Integrated Approach to Testing 
and Assessment of Non-genotoxic 
Carcinogens
Non-genotoxic carcinogens contribute to 
an increased cancer risk through a variety 
of mechanisms that are not yet included in 
international regulatory approaches. To address 
this need, an OECD expert working group has 
been set up to develop an integrated approach to 
testing and assessment (IATA) of non-genotoxic 
carcinogens internationally (Jacobs et al., 2016). 
Among other activities the working group 
has so far: agreed on the definition of non-
genotoxic carcinogenicity, examined the current 
international regulatory requirements for non-
genotoxic carcinogenicity risk assessment and 
has conducted an analysis of uncertainty in the 
rodent cancer bioassay (Paparella et al., 2017).
One objective of this latter analysis is to 
transparently illustrate the complexity 
associated with the in vivo approach currently 
used and its actual performance in order to 
define a benchmark that new approaches 
should overcome.
The working group is also tasked to review, 
describe and assess relevant in vitro assays 
with the aim of tentatively organising them 
into levels of testing, following the AOP 
format, such as that possible structure(s) of 
the future IATA(s) can be created. A workplan 
for taking forward the identification of assays 
for non-genotoxic carcinogenicity is currently 
under development.
5.2.14 OECD Detailed Review Paper on 
the Miniaturised Ames Test
An OECD Expert Working Group on the 
development of the miniaturised Ames test 
was established in November 2016 with the 
aim to perform a retrospective analysis of data 
obtained from the different miniaturised versions 
of the Ames test and comparative evaluation 
with Ames results from the classic Ames test.
A Detailed Review Paper will be drafted in view 
of an eventual incorporation of these methods 
into an updated version of OECD TG 471.
 
Several miniaturised versions of the Ames test 
are used routinely as early screening method 
in product development. The added value 
for the miniaturised versions of the test is 
mainly based on significant reduction of test 
material and of costs and on the possibility 
for simultaneous analyses of large number 
of samples. The inclusion of these versions of 
the Ames test in an updated version of the TG 
would eventually allow more regulatory use and 
integration in genotoxicity testing. 
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During its kick-off meeting in February 2017, 
the Expert Working Group decided to first 
launch an exploratory survey in order to obtain 
better insights in (i) the use, (ii) the amount of 
data available for the different miniaturised 
Ames tests and (iii) the extent to which these 
data can ultimately be shared. In a second 
phase, this initial survey will be followed with a 
request for actual data sharing and then with 
the analysis of the data.
In this first phase, EURL ECVAM contacted its 
EU-NETVAL (see section 4.10) for the extension 
of the exploratory survey, launched in May 
2017, to the 37 members.
5.2.15 Survey on Acute Systemic 
Toxicity
At the last OECD WNT meeting the proposal 
made by ICAPO, the US (through NICEATM), 
and the EC (through JRC-EURL ECVAM) to 
launch a new acute toxicity survey to complete 
our understanding of the international 
requirements for acute systemic toxicity has 
been approved. 
The survey is also meant to gather information 
about the level of acceptance of alternative 
approaches such as read-across, (Q)SAR, 
potential for waiving tests, in vitro methods, or 
a combination of such approaches. The survey 
builds on previous efforts from OECD (OECD, 
2001), EPAA (Seidle et al., 2010) and EURL 
ECVAM (Graepel et al., 2016, see Box 5.3) and 
intends to cover all industry sectors for oral, 
dermal, and inhalation acute toxicity endpoints.
The outcome of the survey will be published 
in a peer-reviewed journal and will hopefully 
be useful in guiding activities worldwide 
of stakeholders working to replace acute 
systemic in vivo tests.
5.2.16 Update of OECD Guidance 
Document 150
The OECD GD 150 on the assessment of 
chemicals for endocrine disruption was published 
in 2012 (OECD, 2012b).
The objectives of the Guidance Document are to 
support regulatory authorities’ decisions on the 
hazard of specific chemicals and toxicologically-
relevant metabolites when they receive test 
results from a TG or draft TG for the screening/
testing of chemicals for endocrine disrupting 
properties by providing guidance on how to 
interpret the outcome of individual tests and 
how to increase evidence on whether or not a 
substance may be an endocrine disruptor (ED).
In the context of this document, an ED has 
Opportunities to prevent new animal testing in the area of 
acute toxicity
Acute systemic toxicity testing is one in vivo test that always has generated and 
still generates a lot of debate due to scientific and ethical considerations. In view 
of the upcoming final registration deadline for chemicals under the EU REACH 
Regulation, in May 2018, and in line with the EURL ECVAM strategy to replace, 
reduce and refine the use of animals in the assessment of acute mammalian 
systemic toxicity, JRC scientists conducted a survey directed to experts in the field 
of toxicity testing with the ultimate aim of understanding how data from acute 
systemic toxicity tests are used in practice, and whether non-animal methods 
and/or existing in vivo data could provide the information needed. The results of 
the survey were complemented with a retrospective data analysis of acute and 
repeated-dose toxicity studies from ECHA registration dossiers.
The overall outcome of these investigations (Graepel et al., 2016) supported the 
use of data from 28-day toxicity tests in order to identify non-classified chemicals 
under the EU CLP Regulation. The strength of this approach lies in the fact that 
non-classified chemicals make-up the majority of chemicals currently registered 
under REACH. In particular, JRC scientists have shown in their analysis that with 
the use of a previously established threshold of 200 mg/kg b.w./day (Bulgeroni 
et al., 2009), both NOAEL and LOAEL values can be used in order to identify non-
classified chemicals. A higher threshold of 1000 mg/kg b.w./day, as proposed by 
Box 5.3
ECHA in the revision of their guidance document 
on acute toxicity, would give greater confidence 
in the predictions. Importantly, the answers 
to the survey questionnaire showed also 
willingness to adopt waiving opportunities.
to chemical pesticides, they could be extended 
to the assessment of other chemicals, 
formulations and biological materials on a case-
by-case basis.
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been defined according to WHO (2002), i.e.,
"An ED is an exogenous substance or mixture 
that alters function(s) of the endocrine system 
and consequently causes adverse health 
effects in an intact organism, or its progeny, or 
(sub) populations."
The original version of this GD was focusing on 
four endocrine modalities; estrogen receptor 
mediated, androgen receptor mediated, thyroid 
hormone mediated, and steroidogenesis 
interference, both for human health and 
wildlife populations. 
In order to take into account the evolution of 
science and the development of new TGs, the 
GD 150 is being updated. The revised version 
includes some coverage of juvenile hormone, 
ecdysone or retinoid modalities as well as new 
sections on e.g., cross-species extrapolations, 
integrated approaches and systems, sources 
of uncertainties in in vitro assays, the aspect 
of multiple simultaneous modes of endocrine 
actions, and regulatory experience of endocrine 
assessment.
5.2.17 New Endpoints and Assays for 
the Identification of Endocrine Disruptors 
In support of the EU Community Strategy for 
Endocrine Disruptors and the OECD programme 
on testing and assessment of endocrine 
disruptors, the JRC has been supporting the 
European Commission's Directorate General 
Environment over a wide range of activities 
aimed at improving ED detection.
The first step was to conduct a survey (Bopp 
et al., 2017) to solicit views of academia, 
regulators, industry and civil society 
organisations on perceived gaps in test 
methods and priorities for addressing the gaps 
followed up by three projects focused on the 
following specific aspects:
• Thyroid disruption;
• Retinoid signalling pathway;
• Temporal aspects.
Thyroid disruption is linked to neurodevelopment 
and cognitive impairment with maternal 
hypothyroidism associated with delayed 
language development, lower intelligence 
scores, hippocampal abnormalities and higher 
autism scores. Thyroid cancers are the fastest 
rising in both men and women (6% increase 
per year) and thyroid disruption also impacts on 
cardiovascular health. 
Identification of thyroid disruption was 
considered to be insufficiently covered by 
current test methods. A specific workshop (DG 
ENV, 2017) was held to discuss a number of 
different aspects of improving test method 
design and interpretation including the need 
for screening a number of relevant targets with 
in vitro methods (see section 4.2) combining 
methods to cover multiple mechanisms of 
thyroid disruption in a testing battery.
The scoping of a detailed review paper on the 
retinoid signalling pathway, to feed into the 
EC/Sweden co-led OECD project, was a first 
step in investigating the need for development 
of methods for assessing retinoid signalling 
disruption. There are currently no in vitro 
methods in the OECD Conceptual Framework 
for the testing and assessment of endocrine 
disruptors relevant to the retinoid pathway 
although there are a number of effects such as 
hypospadias, cryptorchidism, effects on testes 
development or spermatogenesis, oogenesis, 
oestrus cycle, craniofacial and skeletal system 
defects measured in current in vivo test 
guidelines that may have a retinoid component.
The temporal aspects project focused on what 
are considered to be sensitive windows of 
exposure such as embryo-foetal development, 
post-natal period and early childhood, puberty 
and senescence and the extent to which 
current in vivo test guidelines might not cover 
such aspects and how such gaps might be 
addressed in the future. 
All of these concerns were brought together 
in a workshop on setting priorities for further 
development and validation of test methods 
and testing approaches for evaluating endocrine 
disruptors at the end of May 2017. The 
workshop report is in preparation. Participants 
from academia, regulatory authorities, civil 
society organisations and industry were asked 
to identify endocrine-related diseases/disorders 
and pathways of concern, gaps in current 
approaches to identify substances which may 
be contributing to the disease burden in human 
and wildlife populations, ideas to address the 
gaps, criteria for prioritising the proposals and 
application of criteria to identify the priorities in 
the short and long term.
The conclusions confirmed the outcome of the 
JRC survey in that the diseases/disorders of 
highest concern were related to thyroid disruption, 
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specifically neurodevelopmental impacts, female 
reproduction and metabolic disturbances. It was 
indicated that there was a need for further in 
vitro assays to investigate pathways outside of 
the Estrogenic, Androgenic and Steroidogenic 
(EAS) modalities measuring more downstream 
effects and accounting for metabolism. 
5.2.18 OECD Harmonised Template 201 
The OECD Harmonised Templates for reporting 
chemical test summaries (OHTs) are standard 
data formats which are publicly available. 
They are designed to report information used 
for the risk assessment of chemicals, mainly 
studies done to determine the chemical 
properties or effects on human health and 
the environment, and also (since 2016) to 
describe their use and related exposure to 
workers, consumers and the environment.
The 2016 OECD revision of the OHTs included 
a set of updates, technical improvements and 
completions identified by OECD and template 
users over the past years. The changes 
contributed to harmonising the elements 
considered, the picklists and the terminology 
used in the OHTs. The template format was 
simplified, and new templates made available 
including the one on intermediate effects (OHT 
201), which was developed by the JRC-EURL 
ECVAM, by applying its in-house knowledge 
(predictive toxicology, toxicity pathways and 
assay validation), and involving ECHA as well as 
external stakeholders.
This OHT on ‘Intermediate effects’ allows 
reporting of non-apical observations during 
in vitro testing, e.g., intermediate effects at 
molecular, subcellular, cell, tissue or organ level 
which can be relevant when studying the hazard 
posed by a compound (and possibly inform the 
adverse outcome pathways).
In 2016 OHT 201 was published on the 
OECD website.
The JRC is currently collaborating with the OECD 
and ECHA to endorse the use of OHT 201 for 
all in vitro test results, especially those that are 
currently stored in less suitable "apical" (in vivo 
test–oriented) templates.
5.2.19 eChemPortal
The OECD eChemPortal provides free public 
access to information on chemical properties 
and direct links to collections of information 
prepared for governmental chemical review 
programmes at national, regional, and 
international levels. Access to information on 
existing chemicals, new industrial chemicals, 
pesticides and biocides is provided.
eChemPortal also makes available national/
regional classification results according 
to national/regional hazard classification 
schemes or according to the Globally 
Harmonised System of Classification and 
Labelling of chemicals (GHS). In addition, 
eChemPortal provides also exposure and use 
information on chemicals.
The JRC is a member of the Steering Group 
for the management and further development 
of the eChemPortal and as such provides 
expertise in both the subject matter (e.g., 
chemical risk assessment and study results) 
and the Information and Communications 
Technology (ICT) aspect.
READ MORE
eChemPortal -The 
Global Portal to 
Information on 
Chemical Substances
www.echemportal.
org
Figure 5.3: New OECD Harmonised Template as from April 2016.
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In April 2017, the JRC hosted the annual face to 
face meeting of the Steering Group, and experts 
from the OECD secretariat, Germany, USA, 
Canada, Japan, the Russian Federation, and 
ECHA discussed the upcoming development of 
new eChemPortal features.
5.3 Activities in the Extended 
Advisory Group on Molecular 
Screening and Toxicogenomics 
The OECD AOP Development Programme was 
launched in 2012 and is managed by the 
Extended Advisory Group for Molecular Screening 
and Toxicogenomics (EAGMST), a large group of 
experts from various areas of toxicology.
Experts are designated by governmental or non-
governmental affiliations (academia, agencies, 
industry, animal welfare groups, scientific 
societies, etc.). They meet once a year face-to-
face and hold a teleconference after six months 
to keep pace with new developments.
Together with US EPA, JRC/EURL ECVAM is co-
chairing this group, which is leading the AOP 
development plan, issuing regularly updated 
GD for standardising the development and 
assessment of AOPs and supporting the build-
up of an AOP knowledgebase (AOP-KB) as 
described in the following chapters.
5.3.1 Update on the Adverse Outcome 
Pathway-Knowledge Base
AOPs are the central element of a toxicological 
knowledge framework being built to support 
chemical risk assessment based on mechanistic 
reasoning. To enable the scientific community 
to share, develop and discuss their AOP-related 
knowledge in one central location, the OECD 
has, in parallel to the instigation of the overall 
AOP initiative, started the AOP-KB project. 
Within this project EURL ECVAM contributes ICT 
design and analysis know how and co-manages 
the project together with the US EPA.
AOP-KB consists of several modules, each 
tailored to specific needs; a module titled 
e.AOP.Portal is the uniform search interface 
to retrieve AOPs from all other modules; the 
data interchange format to be used between 
the AOP-KB modules, named AOP-XML, was 
developed by EURL ECVAM. 
The first AOP-KB module available to the public 
was the AOP-KB Wiki, a system that organises, 
via crowd-sourcing, the available knowledge 
and published research into a verbal description 
of individual pathways, via a user friendly wiki 
interface. Controlled-vocabulary drop-down 
lists from which to select methods, actions, 
biological objects, life stages, species, etc., 
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related to the AOP had already simplified the 
entry of standardised information.
In early 2016, the introduction of ontologies to 
further harmonise the naming of AOP objects 
was discussed, and ontologies were then 
implemented in the AOP-KB Wiki in the second 
half of 2016 and first half of 2017.
The AOP-Wiki always combined both free 
text fields and closed vocabulary to describe 
mechanistically linked Key Events (KEs) and 
their Relationships (KERs). A new version of the 
Wiki (version 2.0) was released in December 
2016 with a completely revisited website 
style and upgraded functionalities such as a 
facilitated search of AOPs elements through 
keywords and unique identification numbers. 
Due to the increasing number of AOPs and the 
lack of a harmonised controlled terminology, 
a joint effort to incorporate ontology-based 
information in the AOP-Wiki has been carried 
out by JRC/EURL ECVAM and the US EPA 
throughout the second half of 2016 and 2017.
The new version of the AOP-Wiki now introduced 
the concept of "event component" which 
provides a structured representation of the KEs 
using terms from a selected series of existing 
biological ontologies (Ives et al., accepted).
One or more event components can be assigned 
to each KE to represent main features as 
Process, Object and Action through a controlled 
vocabulary. Biological Process and Object are 
used to portray the biological system whose 
perturbation described in the AOP is captured by 
the Action term. In addition, a separate Context 
term can be defined to represent the biological 
environment where the KE occurs in relation to 
the level of biological organisation. 
As a result, all the individual KEs present in 
the AOP-Wiki as of December 2016 have been 
annotated using ontologies. In the future, AOP 
authors will be able to independently annotate 
their new KEs using the controlled terminology 
provided in drop-down lists.
The ontology-based annotations are aimed to 
facilitate and improve the systematic re-use 
of KEs by minimising redundancy and also 
allowing for more flexibility in naming the 
KEs according to their AOP-specific context. 
Ontologies as computer readable descriptions 
of the biological components will drive the 
possibility to find connections and make 
inferences between KEs at different levels of 
granularity thereby facilitating the automatic 
development of AOP networks. 
Overall, the introduction of a controlled 
terminology in the AOP-Wiki represents a 
significant advancement for the progress and 
optimisation of the AOPs and it will ultimately be 
beneficial also for other modules of the AOP-KB.
The introduction of the AOP concept into the 
area of chemical risk assessment is a major 
milestone towards the goal of identifying, 
assessing and ultimately accepting alternatives 
to animal tests for regulatory purposes. Without 
the AOP-KB tool, the AOP concept would remain 
a theoretical idea without any real-life impact. 
By facilitating the collection and also discussion 
of AOP-related information, the AOP-KB anchors 
this novel concept firmly in the scientific and 
regulatory environments, which is a prerequisite 
for a world with less animal testing. The new 
concept of IATA profits from the AOP concept as it 
informs scientists and regulators about the biology 
behind a chemical's mode of action which needs 
to be modelled in in vitro and in silico methods.
5.3.2 Update of OECD Guidance 
Document on Developing and Assessing 
Adverse Outcome Pathways
The revised OECD Guidance Document on 
developing and assessing AOPs has been 
approved by the Extended Advisory Group 
on Molecular Screening and Toxicogenomics 
(EAGMST) at their annual meeting in June 2016. 
Following this revision and to keep up with the 
ongoing development of the AOP framework 
the OECD handbook writing group, in which 
EURL ECVAM is involved, prepared proposal 
for changes/amendments to the existing 
User's Handbook, including a new section 
called "Lessons Learned in Application of the 
AOP Framework to Challenging Examples" for 
approval at the 2017 EAGMST meeting.
New findings from the Society of Environmental 
Toxicology and Chemistry (SETAC) Pellston 
workshop in April 2017 were already integrated 
in this new handbook version. Three EURL 
ECVAM staff members participated in this 
Pellston Workshop for advancing the AOP 
framework that dealt with various key 
questions, which have been identified during a 
READ MORE
e.AOP.Portal
aopkb.org
AOP Wiki
aopwiki.org
Adverse Outcome 
Pathway Knowledge 
Base (AOP-KB)
aopkb.org/index.html
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preceding horizon scanning exercise among the 
global scientific and regulatory communities.
5.3.3 Development of Adverse Outcome 
Pathways relevant to Neurotoxicity
Two AOPs relevant to neurotoxicity developed 
by EURL ECVAM have already been endorsed 
by WNT and WPHA and published by OECD 
(Sachana et al., 2017a,b) and another two are 
the OECD review process:
• Inhibition of the mitochondrial complex I 
of nigra-striatal neurons leads to parkinsonian 
motor deficits (in collaboration with EFSA; AOP-
Wiki: https://aopwiki.org/aops/3)
• Sodium Iodide Symporter (NIS) inhibition 
and subsequent adverse neurodevelopmental 
outcomes in mammals (AOP-Wiki: https://
aopwiki.org/aops/54)
The first AOP relevant to Parkinson disease 
passed an internal and an external OECD 
reviewing process and after introducing the 
relevant comments, it will be forwarded 
to WNT for a final endorsement in 2018. 
The second AOP (NIS inhibition) is currently 
being amended taking into consideration the 
comments of the OECD internal reviewers and 
shortly will undergo the reviewing process by 
the external OECD reviewers.
EURL ECVAM has undertaken the first 
steps in applying the AOP framework for 
understanding and predicting developmental 
and adult neurotoxicity (Bal-Price et al., 
2015b; Bal-Price et al., 2017) including more 
holistic and mechanistic understanding of 
the pathophysiological pathways involved in 
complex neurodegenerative disorders such as 
Parkinson disease (Bal-Price and Meek, 2017). 
The current AOPs are mainly qualitative 
pathway descriptions, and further experimental 
work is required to develop the relationships 
between key events in quantitative terms.
These AOPs follow publically available 
conventions adopted in the OECD AOP 
development programme to permit tailored 
application of AOPs for a range of different 
regulatory purposes.
5.3.4 Activities on "Omics"
EURL ECVAM participated in an European 
Chemical Industry Ecology and Toxicology 
Center (ECETOC) workshop on "Applying ‘Omics 
Technologies in Chemicals Risk Assessment" 
organised in October 2016 to directly discuss 
how to overcome the obstacles that limit 
regulatory uptake of ‘omics data.
The workshop focused on best practices in the 
collection, storage, analysis and interpretation 
of 'omics data. As follow up of the meeting, 
a series of peer reviewed papers have been 
published (Buesen et al., 2017; Sauer et al., 
2017; Kauffmann et al., 2017; Gant et al., 2017; 
Bridges et al., 2017).
A proposal was also brought to the EAGMST to 
develop a series of guidance documents dealing 
with the processing of data from collection to 
interpretation of results. 
Finally, a project proposal on the "Construction 
of a series of guidance documents for 
consistent reporting of 'omics data from 
various sources" has been submitted to the 
OECD WNT. This project aims to develop 
reporting frameworks for the standardisation 
of reporting of 'omics data generation and 
analysis, to ensure that all of the information 
required to understand, interpret and 
reproduce an 'omics experiment and its 
results are reported. The project will initially 
focus on transcriptomics.
5.4 VICH Guidelines on Vaccines: 
Harmonisation of Criteria for Waiving 
of Target Animal/Laboratory Animal 
Batch Safety Testing of Vaccines for 
Veterinary Use
The requirements on batch safety testing differ 
between the various geographic regions. For 
example, general safety tests for batch release 
of human and veterinary vaccines are no longer 
required in Europe and were deleted from 
European Pharmacopoeia monographs several 
years ago (abnormal toxicity test; Schwanig 
et al., 1997) or recently (target animal batch 
safety test; EDQM, 2012).
Since these tests may still be required outside 
of Europe, European manufacturers may need 
to carry out these tests when exporting to 
third countries.
Since 2008, EURL ECVAM is working on behalf 
of EMA with VICH experts on the development 
of VICH guidelines on harmonisation of criteria 
to waive the target animal batch safety testing 
for inactivated and live vaccines for veterinary 
use. VICH GL50 for inactivated veterinary 
READ MORE
J3RsWG - Working 
Group on the 
Application of the 3Rs 
in Regulatory Testing of 
Medicinal Products
www.ema.europa.
eu/ema/index.
jsp?curl=pages/
contacts/CVMP/peo-
ple_listing_000094.
jsp&mid=W-
C0b01ac05803a9d6d
 52
CHAPTER 5
vaccines was adopted in 2013 and is in force 
since 1 March 2014 (VICH, 2013). It will be 
superseded by the recently revised VICH 
GL50(R) and the comparable new VICH GL55 
for live veterinary vaccines published in May 
2017 and coming into force in May 2018 (VICH, 
2017a,b) (see Box 5.4).
A third guideline is under development aiming at 
the harmonisation of criteria to waive the general 
batch safety test in laboratory animals (e.g., 
abnormal toxicity test) for veterinary vaccines.
5.5 Promoting Regulatory 
Acceptance in the Frame of EMA: 
J3Rs Working Group
In 2016, the European Medicines Agency 
(EMA) published the final guidance on the 
acceptance of Three Rs testing approaches 
in pharmaceuticals testing (EMA, 2016a) 
and several other documents (guidelines, 
reflection papers) drafted by the joint CVMP/
CHMP expert group on the application of the 
3Rs (within the former JEG 3Rs) underwent 
public consultation (EMA, 2016b-d). 
After the mandate of the JEG 3Rs terminated 
at the end of 2016, EMA established the joint 
CVMP/CHMP working group on the application of 
the Three Rs in regulatory testing of medicinal 
products (J3RsWG ), which will finalise the 
guidelines and reflection papers drafted by 
the JEG3Rs, work on 3Rs issues related to 
batch release testing of vaccines and other 
biologicals, and support the implementation of 
Directive 2010/63/EU (EU, 2010).
The J3RsWG consists of a core group of 
European experts from each of the existing 
CVMP and CHMP Working Parties for which 
animal testing is relevant, experts on 3Rs and 
representatives from EDQM and the European 
Commission (e.g., EURL ECVAM). 
5.6 Activities of EPAA to Promote 
the Regulatory Acceptance of 
Alternative Methods 
The European Partnership for Alternative 
Approaches to Animal Testing (EPAA) is a 
public-private collaboration between the 
European Commission, European trade 
associations and companies from eight 
business sectors. 
The partners are committed to pooling 
knowledge and resources to accelerate 
alternative approaches to animal use in 
regulatory testing.
Two new guidelines for the reduction of animal tests for quality 
control of veterinary vaccines
JRC scientists supported the development of two guidelines released by the 
International Cooperation on Harmonisation of Technical Requirements for 
Registration of Veterinary Medicinal Products (VICH) on the harmonisation of 
criteria to waive target animal batch safety tests for inactivated and live veterinary 
vaccines. Their implementation (from May 2018 onwards) is a major step towards 
international harmonisation and will reduce the number of animals used for batch 
release testing. The JRC's EURL ECVAM has been working on behalf of EMA with 
VICH experts on the development of these guidelines.
Each batch of a vaccine has to undergo strict quality control before it is released 
on the market. Some of these batch release tests are carried out in animals, 
for example the target animal batch safety test (TABST). Since 1 April 2013, the 
TABST is no longer required in Europe and has been deleted from the European 
Pharmacopoeia monographs for veterinary vaccines. However, outside of Europe and 
European Pharmacopoeia countries the TABST is still requested for batch release.
With the new VICH GL55 and the revised GL50(R), European manufacturers have 
the possibility to apply for a waiver of the TABST when exporting to the other VICH 
regions (Japan, North America) or countries following the VICH guidelines.
EURL ECVAM had been a driving force for this change. In 1997, EURL ECVAM 
launched a retrospective study analysing TABST data provided by manufacturers 
and control authorities. The ECVAM Scientific Advisory Committee (ESAC) peer-
Box 5.4
reviewed the results of the study and stated in 2002 
that the TABST was no longer relevant and should be 
omitted for routine batch control.
This had been incorporated into the European 
Pharmacopoeia and from 2004 onwards (until its 
deletion in 2013) manufacturers had the possibility to 
waive the TABST provided that their vaccines fulfilled 
the waiving criteria, i.e., the manufacturer had to 
demonstrate to the control authorities that at least 10 
batches of the given product had not failed the TABST.
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The overall aim is the replacement, reduction 
and refinement (Three Rs) of experiments on 
animals. The JRC, represented by EURL ECVAM, 
is one of the Commission services that are 
members of EPAA.
In the reporting period, EPAA has focused 
mainly on the promotion of regulatory and 
user acceptance. In this context, EPAA runs a 
number of projects that are described in the 
sections below. The partnership also engages in 
dissemination activities (see section 6.7).
A former EPAA activity regarding the consistency 
approach for various vaccines set the ground 
for the current Horizon 2020 project "VAC2VAC 
- Vaccine batch to vaccine batch comparison by 
consistency testing" (see section 2.4).
5.6.1 Optimised Evaluation of Skin 
Sensitisation 
As described in the previous EURL ECVAM report 
(Zuang et al., 2016), in December 2015, the 
EPAA skin sensitisation team started a new 
project aimed at comparing the performance 
of in vitro skin sensitisation methods based 
on 3D-epidermis to predict a set of "difficult" 
reference chemicals.
Data for twelve chemicals have been generated 
with the reconstructed human Epidermis 
(epiCS®), IL-18 test method and the SenCeeTox. 
Such data have been complemented with SENS-
IS results from the Cosmetics Europe evaluation 
program. The analysis of the data is ongoing.
5.6.2 Waiving of the Two-year 
Carcinogenicity Studies
The University of Wageningen in collaboration 
with the Dutch Medicines Evaluation Board 
has finalised the compilation and analysis of a 
database on active pharmaceutical ingredients. 
The aim was to confirm and expand previous 
investigations by Sistare et al., (2011) to 
identify opportunities for waiving the two-
year carcinogenicity studies based on in vitro 
genotoxicity testing and the results of (sub-)
chronic toxicity studies. This approach is now 
under consideration by the ICH.
Moreover, the combination of the 
histopathological approach as proposed 
by Sistare and colleagues with the 
pharmacological approach (van der Laan et al., 
2016a) has been investigated. The data for this 
evaluation were obtained from reports from the 
Medicines Evaluation Board of the Netherlands. 
This approach resulted in an ability to predict 
non-carcinogens and carcinogens at a success 
rate of 92% and 98%, respectively. 
These findings show that by taking the 
results of the three to six month rat studies 
and the pharmacological properties of a 
pharmaceutical product into account, a reliable 
prediction of a carcinogen can be made 
without the need for two-year carcinogenicity 
studies (van der Laan et al., 2016b).
A new project has been awarded aiming at 
evaluating whether a similar approach as 
described above for pharmaceuticals can be 
translated and adapted to the assessment 
of agrochemicals. The objective of the 
project is to provide evidence that data from 
three-month repeated dose toxicity studies 
together with mechanistic-based parameters 
can be leveraged to predict human relevant 
carcinogenic potential of agrochemicals 
with reduced or no need for a two-year 
carcinogenicity study. 
5.6.3 Acute Toxicity 
The data mining exercise aimed to enable 
the identification of clinical signs predictive 
of mortality that was initiated in 2015 is still 
ongoing (Zuang et al., 2016, section 5.9.2). 
After completion of the statistical analysis and 
based on the results obtained, the team plans 
to finalise a decision framework document that 
aims to replace animals in acute toxicity testing 
and in those cases where animal usage cannot 
be avoided, to substitute clinical signs predictive 
of mortality at higher dose levels and thereby 
replace mortality as the principal endpoint.
The document will ultimately facilitate discussions 
with regulators and industry regarding acceptance 
and implementation of the new results.
A peer review publication of the overall data 
READ MORE
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evaluation, which is carried out by NC3Rs in 
collaboration with the UK Chemicals Regulation 
Directorate (CRD), is foreseen.
5.6.4 Clostridial Vaccine Project
The EPAA clostridial vaccines group evaluated 
Vero cell based assays to replace the Minimum 
Lethal Dose and Total Combining Power assays 
required for in-process control of Clostridium 
septicum vaccines.
The collaborative study was carried out in 
collaboration with the EDQM BSP and the results 
of BSP130 were discussed with the study 
participants at a workshop in September 2015.
The results show that the in vitro assays are 
repeatable and reproducible and that there is 
excellent overall concordance with the mouse 
tests (Sinitskay et al., 2016). However, in order 
to fully exploit the advantage of the Vero cell 
assays, further work is needed.
A follow-up study (BSP130 III) with 14 
participants started in 2016 aiming at the 
further optimisation of the Vero cell assays 
to increase their sensitivity and accuracy. The 
experimental phase will be finalised in 2017.
Adaptations of the Vero cell assays to other 
clostridial vaccines will be evaluated in the 
VAC2VAC project (see section 2.4). 
5.6.5 Human Rabies Vaccine Project
Based on the outcome of discussions held at an 
EPAA workshop in 2012, the EPAA human rabies 
vaccines group organised a collaborative study to 
identify the most suitable ELISA for quantitation 
of glycoprotein-G in rabies vaccines and possible 
replacement of the current in vivo test for 
potency testing of human rabies vaccines. 
Vaccine samples of different origin and 
composition were tested with three different 
ELISAs currently in use by manufacturers and 
control authorities. The results of the study 
and possible follow-up were discussed at a 
workshop in May 2015 (Morgeaux et al., 2017). 
One out of the three ELISAs correctly quantified 
the antigen content of all vaccine samples 
including degraded samples (Morgeaux et al., 
2017). After additional work carried out during 
2016, the EDQM BSP accepted this ELISA 
for full validation and the BSP148 project 
"Validation of a rabies in vitro potency assay" 
was launched in 2017. 
5.6.6 Harmonisation on Biologicals
This EPAA project aims at progressing 
harmonisation of requirements for batch testing 
of vaccines and other biological products at a 
global level. Due to evident differences in the 
current regional requirements, manufacturers 
may need to carry out animal tests which are 
no longer required in Europe, if they want to 
market their products outside of Europe. EURL 
ECVAM is a member of the project team.
At an international workshop, held in September 
2015 (see Box 5.5), representatives from 
regulatory bodies and manufacturers discussed 
steps towards deletion of general safety tests 
and identified means towards implementation 
of in vitro methods for potency testing of 
human and veterinary vaccines94.
The major recommendation, agreed by all 
participants, is the deletion of general safety 
tests, e.g., abnormal toxicity test, target animal 
batch safety, from regulatory requirements 
at a global level. Nowadays, these tests lack 
scientific relevance and their omission does not 
compromise the safety of vaccines, or any other 
pharmaceutical, since more adequate quality 
control measures are in place. 
The project team is following up the 
recommendations in collaboration with workshop 
participants and relevant stakeholders (Schutte et 
al., 2017). For example, requests for revision have 
been presented to the European Pharmacopoeia 
Commission via the German Pharmacopoeia and 
drafted by the Paul-Ehrlich Institut in Germany. 
The revised 49 monographs have been published 
in Pharmeuropa for public consultation.
 
9 https://circabc.europa.eu/sd/a/4a081e45-f19f-
47f7-8d8d-65f4f10fccff/ihb%20sept %20
2015%20report.pdf
Figure 5.4: Clostridium septicum.
READ MORE
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Recommendations to delete or replace 
animal tests for quality control of 
biologicals 
Due to their complexity of composition and 
heterogeneity, biologicals undergo legally required 
quality control (QC) before they are released on 
the market. Some of these QC tests involve testing 
on animals. However, legal requirements for the 
QC are not harmonised at global level, which may 
lead to unnecessary animal testing. For example, 
specific animal tests may have been deleted from 
requirements or replaced by non-animal approaches 
in Europe, whilst the same animal tests are still 
required outside of Europe.
In September 2015, the European Partnership for 
Alternative Approaches to Animal Testing (EPAA) 
convened an international workshop "Modern 
science for better quality control of medicinal 
products: Towards global harmonization of 3Rs in 
biologicals", which took place in Egmond aan Zee, The 
Netherlands, to discuss with 45 invited international 
experts the relevance of current animal tests and the 
promotion and acceptance of non-animal methods.
In particular, the usefulness of general safety tests 
(e.g., abnormal toxicity test, target animal batch 
Box 5.5
safety test) has been discussed and participants agreed that these tests are no 
longer useful to ensure the safety of biologicals for human or veterinary use. 
Therefore, they recommended their deletion from all legal requirements and 
guidance documents at a global level.
Workshop participants further addressed batch potency testing of e.g., diphtheria, 
tetanus and erysipelas vaccines. Potency tests are performed to demonstrate that 
the given vaccine batch induces protective immunity. It was acknowledged that 
non-animal methods are now available and should be used provided that they are 
appropriately validated. However, some jurisdictions may not accept non-animal 
tests. Consequently, seeking a common understanding on scientific principles of 
their use was identified as an overarching goal. Moreover, the development of 
new non-animal approaches may be an effective means to increase and facilitate 
international harmonisation (Schutte et al., 2017).
5.7 UN subcommittee on 
Globally Harmonised System of 
Classification and Labelling of 
chemicals (GHS)
On the initiative of the Netherlands and the 
United Kingdom, an informal working group was 
set up under the UN Sub-Committee of experts 
on GHS to further explore the use of non-animal 
methods for classification.
This review of the GHS would include in vitro, 
in silico and in chemico methods, as well as 
grouping and read-across, as a basis for hazard 
assessment. It was suggested to start with a 
"pilot" hazard class, which was selected to be 
skin corrosion/irritation.
The current GHS chapter was re-drafted by the 
Netherlands and is currently under discussion in 
the working group.
The activity in the UN Sub-Committee related 
to the use of non-animal testing methods for 
classification of health hazards is in the scope 
of the EURL ECVAM work programme, therefore 
EURL ECVAM has suggested to initiate the 
drafting of the chapters on skin sensitisation 
and eye damage/irritation in collaboration with 
the United Kingdom and the Netherlands with 
support from the working group.
As the work progresses and experience is 
gained on the inclusion of alternatives into 
the GHS criteria for health hazards, and 
in parallel considering further adoption 
of alternative methods and development 
of defined approaches and integrated 
approaches to testing and assessment within 
the OECD test guideline programme, further 
READ MORE
GHS implementation
www.unece.org/trans/
danger/publi/ghs/
implementation_e.
html
GHS (Rev.6) (2015)
www.unece.org/trans/
danger/publi/ghs/
ghs_rev06/06files_e.
html
OECD Guidelines for the 
Testing of Chemicals
www.oecd.org/chem-
icalsafety/testing/
oecdguidelinesforth-
etestingofchemicals.
htm
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evaluation of how (and when) to tackle other 
more complex systemic health hazards will be 
discussed with a view to developing a plan for 
consideration by the UN Sub-Committee in its 
programme 2019-2020.
5.8 Activities within the 
International Cooperation on 
Cosmetics Regulation (ICCR)
The International Cooperation on Cosmetics 
Regulation (ICCR) is a voluntary international 
group of cosmetics regulatory authorities from 
Brazil, Canada, the European Union, Japan 
and the United States founded in 2007. It 
discusses common issues on cosmetics safety 
and regulation and is in dialogue with relevant 
cosmetics industry trade associations. 
The ad hoc ICCR Joint Regulators-Industry 
Working Group (JWG) on "Integrated Strategies 
for Safety Assessments of Cosmetic Ingredients" 
aims to outline principles that underpin the 
integration of novel methods and data for the 
safety assessment of cosmetic ingredients, or 
‘Next Generation’ risk assessment.
The scope of new approach methodologies 
(NAMs) considered included in silico methods 
(such as (quantitative) structure activity 
relationships ((Q)SARs) and other computational 
modelling approaches), in chemico methods 
and in vitro tests.
EURL ECVAM has contributed and is 
continuing to contribute to the working group 
and writing of an ICCR report that is intended 
to help build integrated safety assessments 
for cosmetics-related substances without 
generating animal data.
Part 1 of the report summarises major 
overarching principles for an integrated strategy 
for risk assessment of cosmetics ingredients 
incorporating NAMs. It was adopted at the 
11th ICCR Annual Meeting in July 2017 and 
is publicly available from the ICCR website 
(Amaral et al., 2017).
The four main overriding principles are:
1) human safety risk assessment as overall goal, 
2) the assessment being exposure led,
3) hypothesis driven and 4) designed to prevent 
harm (e.g., distinguishing between adversity and 
adaptation). The other five principles describe 
how ‘Next Generation’ risk assessments should 
be conducted and documented.
Work continues on Part 2 which will illustrate 
how NAMs may be used in the cosmetic safety 
evaluation process, related to the principles, 
with examples of methods and their current 
strengths and limitations.
5.9 Nanocomput - Computational 
Models for the Regulatory 
Assessment of Nanomaterials
In March 2017, EURL ECVAM completed 
the Nanocomput project, the main aims of 
which were to review the current status of 
computational methods that are potentially 
useful for predicting the properties of engineered 
nanomaterials, and to assess the applicability of 
these approaches for regulatory purposes, with 
emphasis on REACH (Worth et al., 2017b).
The 39-month project was carried out for 
European Commission Directorate General 
Internal Market, Industry, Entrepreneurship 
and SMEs (DG GROW) and was supported by a 
steering group with representatives from DG 
GROW, DG ENV and ECHA (see Box 5.6). 
Emphasis was placed on Quantitative Structure-
Property Relationship (QSPR) and Quantitative 
Structure-Activity Relationship (QSAR) models, 
as well as grouping and read-across.
In addition, a diverse array of compartment-
based mathematical models were reviewed.
These models comprised toxicokinetic (TK), 
toxicodynamic (TD), in vitro and in vivo 
dosimetry, and environmental fate models. 
The computational models were reviewed in 
a systematic manner, with the results (model 
characteristics) being made available in the 
form of an Excel database. For the QSPR and 
QSAR models (predicting physicochemical 
properties and biological activities, respectively), 
the QSAR Model Reporting Format (QMRF) was 
used. For the compartment-based models, new 
reporting templates were developed.
Overall, it was found that the model landscape 
is sparsely populated, especially in the case 
of models that are directly predictive of 
regulatory endpoints.
In relation to grouping and read-across, a 
comprehensive review of grouping approaches 
was carried out. This was supplemented 
with two case studies on the genotoxicity of 
nano titania (TiO2) and multi-walled carbon 
nanotubes (MWCNT). 
READ MORE
ICCR - International 
Cooperation on 
Cosmetics Regulation
www.iccr-cosmetics.
org
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Review of computational models for the 
safety assessment of nanomaterials
Manufactured nanomaterials are being increasingly 
included in a variety of products because of novel 
characteristics related to their small size and surface 
properties. However, concerns have been raised about 
their potential adverse effects on environment and 
human health. This has led to an increasing interest 
in assessing the potential risks of nanomaterials, 
particularly using non-animal approaches, including 
computational methods.
Considerable scientific progress has been made 
towards the challenges of predicting the hazardous 
properties of nanomaterials using non-animal 
methods, although issues remain in translating these 
developments into regulatory practice. Therefore, 
JRC scientists carried out an extensive review of the 
current status of computational methods used for 
modelling nanomaterials.
This review, which was published in a report based on a 
39-month project, Nanocomput, was carried out by the 
JRC on behalf of DG GROW (Worth et al., 2017b). It also 
includes an assessment of the applicability of these 
computational approaches, with emphasis on the safety assessment needs of the 
REACH regulation. This was supplemented with two case studies on the genotoxicity 
of nano titania (TiO2) and multi-walled carbon nanotubes (MWCNT). They illustrate 
the applicability and usefulness of ECHA's guidance on read-across as well as the 
Read Across Assessment Framework (RAAF), which provides a systematic means of 
evaluating the uncertainties in a read-across prediction.
Overall, the report shows that that considerable progress has been made towards 
addressing the challenges of modelling nanomaterials. However, there is still a 
fragmentation in the scientific results, and limited public access to high quality 
data. A lack of detailed guidance on how to apply existing approaches is preventing 
the uptake and use of computational models in regulatory decision making. 
Recommendations for further research and development are therefore made. 
Supplementary materials are avalable at http://europa.eu/!nu77WH
Box 5.6
The case studies served to explore and illustrate 
the practical application of ECHA's guidance on 
grouping and read-across, including the possible 
use of chemoinformatic techniques to support 
a grouping hypothesis. The case studies also 
explored and illustrated the applicability of ECHA's 
Read Across Assessment Framework (RAAF) in 
analysing and documenting the uncertainties 
in read-across prediction. Finally, based on 
systematic reviews of the scientific literature, as 
well as the outputs of the EU-funded research 
projects, recommendations for further research 
and development were also made.
The results and experience gained in the project 
was well received when presented to Member 
State authorities and other stakeholders at 
the Competent Authorities Sub Group on 
nanomaterials (CASG Nano) in March 2017, 
and at the ECHA Nanomaterials Working Group 
(NMWG) meeting in May 2017. The results of 
the project should be of interest to scientists 
who are interested in the state-of-the-art in the 
field of computational nanotoxicology, as well 
as assessors and regulators who are interested 
in the practical application of different 
modelling approaches and tools.
5.10 International Life 
Sciences Institute/Health and 
Environmental Sciences Institute 
(ILSI-HESI) Update
5.10.1 Update Genetic Toxicology 
Technical Committee Activities
The aims of the ILSI/HESI Genetic Toxicology 
Technical Committee (GTTC) are to discuss 
how to: i) develop follow-up strategies for 
determining the relevance of test results to 
human health; ii) promote the development, 
integration and use of new/emerging 
technologies and scientific knowledge in genetic 
toxicology testing strategies for hazard and risk 
assessment; iii) and boost regulatory and OECD 
acceptance for new assays.
During the annual meeting that took place in 
Alexandria, USA in May 2017, the different 
working groups presented their progress. 
Among other activities, an analysis of 
most appropriate in vivo follow-up testing, 
a literature review of genotoxicity of 
nanomaterials, quantitative analyses of 
genotoxicity and the clean sheet testing 
strategy were presented. 
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This latter activity foresees the development 
of case studies for the different sectors to test 
the recently published clean sheet strategy 
for genotoxicity (Dearfield et al., 2017). A new 
working group was set up on MoA and the 
development of AOPs related to genotoxic MoA 
pathways. In this context, methods to determine 
the mode of action of genotoxic agents, and how 
to use new technologies to establish the mode of 
action of genotoxicity for new chemical entities.
5.10.2 Workshop on Advances and 
Roadblocks for Use of Genomics Data in 
Cancer Risk Assessment for Drugs and 
Chemicals
A workshop to feature multi-sector and 
international perspectives on current and 
potential applications of genomics in cancer 
risk assessment was organised by the Health 
and Environmental Sciences Institute (HESI), 
Health Canada and Mc Gill University in 
Montreal in May 2017. 
The workshop specifically addressed: areas in 
the current cancer risk assessment paradigm 
where genomics approaches will have a 
chance to add value in the future; insights 
gained through genomics data or molecular 
approaches and roadblocks for implementation 
of genomics in cancer risk assessment. 
Transcriptomics-based tests are used by 
companies for guiding internal decisions and 
huge improvements have been made in terms 
of technology and with the advent of the new 
generation of RNA sequencing. Nevertheless, 
there is still limited implementation of 
transcriptomics in regulatory decision-making. 
Several potential applications were presented, 
among which, clarification of MoA, classification, 
calculation of points of departure (PoD) 
and prioritisation. The targeted use of 
transcriptomics tests, e.g., for MoA determination 
was the preferred one. It was also underlined 
that the application may consistently differ 
whether the transcriptomics tests are applied to 
data-rich or data-poor chemicals. 
Among the roadblocks identified there was 
the fear by industry to submit data due to 
uncertainty on how these data would be used 
by regulators. This is linked to the difficulty in 
data interpretation. It was thus felt necessary 
to find a mechanism to promote submissions 
of transcriptomics data. Also validation and 
lack of regulatory guidance were considered 
as roadblocks.
A guidance document on reporting formats for 
transcriptomics data was highlighted as a priority. 
A new OECD project proposal on the construction 
of a series of guidance documents for consistent 
reporting of 'omics data from various sources, 
with an initial focus on transcriptomics, has been 
proposed by the UK/Canada in November 2017 
(see also section 5.3.4).
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6 Dissemination of Information on 
Alternatives
The availability of information on alternatives that 
is readily accessible is of fundamental importance 
both to those who use alternatives as well as 
those tasked with the evaluation of projects and 
their compliance with the Three Rs (e.g., within the 
framework of Directive 2010/63/EU).
In order to disseminate information on alternative 
approaches and enhance overall progress in their 
use, several database services are available at 
EURL ECVAM. They are described in the following 
sections and available on the EURL ECVAM website.
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on Alternatives
6.1 EURL ECVAM Databases 
6.1.1 In vitro methods: DB-ALM—
EURL ECVAM’s DataBase service 
on ALternative Methods to animal 
experimentation 
The DB-ALM provides ready-to-use and 
evaluated information on the application 
and development status of advanced and 
alternative methods in a standardised manner.
Information at various levels of detail is 
provided and defined according to pre-
determined criteria for data content by 
experts in the field.
Current focus is given to in vitro methods and 
non-experimental approaches used for safety 
assessments of chemicals and/or formulations, 
but also includes methods for testing drugs or 
biologicals or for research purposes.
Since 2015, the DB-ALM Method Summary data 
sector provides a harmonised framework for 
adequately describing alternative methods in 
an OECD recommended accepted format (OECD 
Guidance Document No. 211 (OECD, 2014d)) for 
describing non-guideline in vitro test methods.
Growing interest in the DB-ALM was 
observed in 2016 with a total of over 5000 
registrations from 82 countries with more 
than 360 new registrations. The usage 
increased by 20% compared to the year 
before with over 37,500 visits to the website 
contents and more than 3100 documents 
downloaded in 2016, being the fourth highest 
during 10 years of public access.
The DB-ALM is referenced in formal OECD 
documents; scientific books and cited in scientific 
articles. ECHA suggests the DB-ALM as useful 
information source and the OECD recommended 
it for the storage and dissemination of non-
guideline in vitro test methods and protocols of 
in vitro guideline methods. 
READ MORE
DB-ALM
ecvam-dbalm.jrc.
ec.europa.eu
JRC QSAR Model 
Database
qsardb.jrc.ec.europa.
eu
Table 6.1: The online information content originates from research projects, validation studies or individual 
submissions and covers as of June 2017.
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Further information can be obtained from 
the DB-ALM Progress Report 2014-2016 
(Janusch Roi et al., 2016).
6.1.2 In silico methods: QSAR Model 
Database
The JRC QSAR Model Database is a freely 
accessible web application that enables users 
to submit, publish, and search for peer-reviewed 
summary descriptions of QSAR Models. An 
internationally accepted format is used, known 
as the QMRF (QSAR Model Reporting Formats) 
to ensure the provision of comprehensive and 
consistent information. 
Developers and users of QSAR models 
can submit to the dedicated mailbox (JRC-
COMPUTOX@ec.europa.eu) information 
on QSARs by using a downloadable QMRF 
editor which is reviewed for adequacy and 
completeness by JRC-EURL ECVAM before 
publishing it through the JRC database.
At the time of writing (October 2017), the online 
information content of JRC QSAR Model Database 
covers 147 QSAR Model Descriptions grouped 
according to OECD defined (regulatory) endpoints 
as indicated in Figure 6.1 out of which 54 QSAR 
Reports were published during the past two years 
(2016 & 2017). A progress report summarising 
the activities of the QSAR model database during 
2016-2017 can be made available on request.
 
As an indication of usage, in the last 12 months, 
the JRC QSAR Model database had a total of 8297 
visitors, with an average of 23 per day (if a visitor 
comes the first time or visits a page more than 30 
minutes this will be recorded as a new visit). 
The public users worldwide in 2017 originate 
from North America (56%), Europe (24%), Asia 
(16%), South America, Africa, Oceania and 
Central America. 
The year 2017 shows a steady and continued 
interest in the JRC QSAR Model data base 
with a peak in May and a decrease towards 
the end of the year. 
Figure 6.1: QSAR Model Database Online Information Content.
Figure 6.2: QSAR Model Database visitors.
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Towards the end of 2017 the launch of the 
upgraded JRC QSAR Model database is expected. 
6.1.3 Tracking System for Alternative 
Test Methods towards Regulatory 
acceptance (TSAR)
The end of 2016 saw the public launch of 
the revised Tracking System for Alternative 
methods towards Regulatory acceptance (TSAR) 
on occasion of the Commission’s scientific 
conference on "Non-animal Approaches - 
The Way Forward" held on 6-7 December in 
Brussels (see Box 6.2).
The revised TSAR provides enhanced visibility 
of the progress a test method makes from first 
being proposed for validation through to its 
eventual acceptance for regulatory safety and 
efficacy testing of chemicals or biological agents.
TSAR disseminates information on test methods 
not only under consideration by EURL ECVAM but 
by all member organisations of the International 
Collaboration on Alternative Testing Methods 
(ICATM) representing the EU, Canada, USA, 
Republic of Korea, Japan, Brazil and China.
This first release of the revised TSAR includes 
the majority of methods submitted to the 
EURL ECVAM back until 2008. The remaining 
methods will progressively be made available 
for public access together with those from all 
ICATM partners.
6.1.4 Information Retrieval Guidance: 
EURL ECVAM Search Guide 
The EURL ECVAM Search Guide continues to 
encounter success in and outside Europe and is 
also applied in America, with particular emphasis 
on South America, used as a resource for higher 
education in academic institutions in life sciences 
and by national authorities for scientific project 
evaluations that might involve animal use. 
It entered the Asian region in 2014 where it 
was translated and re-published as a handbook 
and e-book in Korean. Based on the success 
reached of the Search Guide in Korea, a second 
edition was produced and published in 2016 
and included in a national survey on the 3Rs. 
It was sent to all Institutional Animal Care 
and Use Committees (IACUCs) (about 350) 
of the Animal Research Institutions together 
with government agency, Animal Protection 
Division in Korea. A total of 532 responses were 
received. The survey results were presented at 
the 10th World Congress on Animal use in Life 
sciences in Seattle, US. 
A second translated version, this time in 
Portuguese was finalised in autumn 2017 
together with Brazilian Authorities within the 
framework of ICATM.
The EURL ECVAM Search Guide has specifically 
been developed to inform and support 
untrained database users in finding high quality 
information on relevant alternative methods 
READ MORE
TSAR
tsar.jrc.ec.europa.eu
TSAR table on test 
submission
eurl-ecvam.jrc.
ec.europa.eu/test-
submission
ICATM - International 
Collaboration on 
Alternative Testing 
Methods
europa.eu/!uC38HQ
The EURL ECVAM 
Search Guide - English 
version
publications.
europa.eu/it/publi-
cation-detail/-/pub-
lication/8835aa05-
f780-454a-ac43-
7752b38b394e
The EURL ECVAM 
Search Guide - 
Portuguese version
publications.europa.
eu/it/publication-de-
tail/-/publication/
d0f0aaa7-a19d-
11e7-b92d-01aa75e-
d71a1
Figure 6.3: QSAR Model Database visitors in 2016 and 2017 per month.
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and strategies from the large amount of 
available information resources in an easy, yet 
systematic, and efficient way during project 
preparations in biomedical sciences.
6.1.5 EURL ECVAM Genotoxicity and 
Carcinogenicity Database of Ames 
Positive Chemicals 
The EURL ECVAM Genotoxicity and 
Carcinogenicity Consolidated Database of 
Ames positive chemicals, launched at the end 
of 2014, is a structured and highly curated 
database compiling available genotoxicity and 
carcinogenicity data for 726 Ames positive 
chemicals originating from different sources 
(Kirkland et al., 2014). 
In 2016 and 2017, the database was again 
used in a wide field of applications by third 
party actors (see below). The database was 
constructed following a recommendation of 
an EURL ECVAM Workshop on “Can in vitro 
mammalian cell genotoxicity test results be 
used to complement positive results in the 
Ames test and help predict carcinogenic or 
in vivo genotoxic activity?” (Kirkland et al., 
2014). Its development implemented part of 
the published EURL ECVAM strategy aimed 
at avoiding and reducing animal use in 
genotoxicity testing (Corvi et al., 2013). 
By using a harmonised format to gather the 
information, this database is representing 
a powerful resource for data analysis that 
is meant to be used to guide a thorough 
evaluation of genotoxicity and carcinogenicity: 
1) as a resource for evaluating the predictivity 
of the Ames test for in vivo genotoxicity and 
carcinogenicity when considered alone or 
in association with in vitro mammalian cell 
assays (gene mutation and clastogenicity/
aneugenicity) and for a better characterisation 
of those cases where the Ames test leads 
to irrelevant ('false positive') results; but 
also, 2) as a platform for detailed structural 
characterisation of specific groups of 
compounds with or without carcinogenic 
or genotoxic activity. Inconsistencies (e.g., 
contradictory data derived from different 
sources) and poor data quality have been 
addressed through rigorous curation which 
included expert peer review.
Since its launch in late 2014, the EURL ECVAM 
Genotoxicity and Carcinogenicity Database 
serves as a reference database for both 
the regulatory and scientific communities 
as demonstrated by a number of on-going 
activities. The database has 1) contributed to 
various activities of the Genetic Toxicology 
Technical Committee of ILSI/HESI on in 
vivo follow up studies and more recently 
to the genotoxicity project on Clean Sheet-
Industrial Chemicals Case Study Subgroup; 
2) been considered the starting point for a 
major project launched by the Cefic Long-
Range Research Initiative (LRI-B18); 3) been 
considered for a recent re-evaluation of the 
TTC values for compounds that are genotoxic 
and/or carcinogenic (Boobis et al., 2017); 4) 
been the basis to perform analysis of the 
sensitivity of unscheduled DNA synthesis 
(UDS), transgenic and comet genotoxicity assays 
to detect carcinogens to support the recent 
Scientific Opinion drafted by EFSA on "Reflection 
on interpretation of some aspects related to 
genotoxicity assessment" (EFSA, 2017).
Genotoxicity and carcinogenicity results from 
the DB have been also considered for a recent 
research project aimed at testing the sensitivity 
of a transcriptomic biomarker for classifying 
agents as genotoxic (DNA damaging) and non-
genotoxic in human lymphoblastoid TK6 cells 
(Yauk et al., 2016).
The related publication is still among the most 
downloaded articles from Mutation Research 
- Genetic Toxicology and Environmental 
Mutagenesis Journal since its first appearance 
(Kirkland et al., 2014).
The database has been linked to two other JRC 
databases, CheLIST (see 6.1.7) and ChemAgora 
(see 6.1.8) and, in the past year, to information 
published in the updated recommended list 
of genotoxic and non-genotoxic chemicals 
(Kirkland et al., 2016). This allows retrieving 
additional information on the chemicals of 
interest using a single platform. 
The DB is a living project with possibilities of 
continuous update as new genotoxicity and 
carcinogenicity data are made available. A 
major extension of the database will be soon 
available with an enrichment of curated data 
from more than 200 new chemicals with Ames 
negative results. 
An Ad hoc EURL ECVAM Expert Meeting was 
held at JRC Ispra on 14-15 September for the 
finalisation and expert review of the data.
READ MORE
EURL ECVAM 
Genotoxicity & 
Carcinogenicity 
Consolidated Database
europa.eu/!JP67xK
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6.1.6 EURL ECVAM Skin Sensitisation 
Database
The EURL ECVAM Skin Sensitisation Database 
is a collection of 269 organic chemicals with 
corresponding skin sensitisation-related results. 
These include data from in chemico (Direct 
Peptide Reactivity Assay, DPRA, OECD TG 
442C) and in vitro methods (KeratinoSens™, 
OECD TG 442D and human Cell Line Activation 
Test, h-CLAT, OECD TG 442E), Local Lymph 
Node Assay (LLNA) and human classifications 
(according to Basketter et al., 2014) assorted 
molecular descriptors and other QSAR 
predictions (e.g., from Dragon, TIMES, etc.).
The source for the Skin Sensitisation Database 
includes submissions to EURL ECVAM and 
information available in the public domain.
The data currently held in the EURL ECVAM Skin 
Sensitisation Database are stored locally in an 
Excel sheet, where they will be supplemented 
with assorted links to other Databases (e.g., 
CheLIST and ChemAgora).
Ultimately, the DB will be published on the JRC 
Science Hub. 
6.1.7 Update on CheLIST 
A key requirement for the development, 
characterisation and eventual validation of 
alternative (non-animal) methods for use in 
biomedical research and regulatory safety 
assessment is the availability of suitable 
reference or benchmark chemicals for which 
reliable structural, physicochemical and 
biological property data are available. 
However, the type of information needed to 
select such reference chemicals is typically 
scattered across a plethora of heterogeneous 
databases, project websites and peer-
reviewed literature. 
To tackle this issue, EURL ECVAM has published 
the "Chemical Lists Information System" 
(CheLIST) that provides a means of identifying 
whether a chemical (or chemical group) has 
been tested in a major EU or international 
research project and whether the chemical 
appears on a specific regulatory inventory. 
Information is provided on chemical identifiers 
(e.g., name, CAS number) and chemical 
structure, and the database can be searched 
according to these types of information. 
The various datasets and inventories can also 
be compared in order to identify overlaps 
in chemical membership and to generate 
customised lists. All lists can be downloaded 
and the references provided for each list allow 
traceability back to the source.
Using CheLIST, alternative methods can 
be developed faster as information about 
reference chemicals (for method validation) is 
available more easily.
In the reporting period CheLIST continued 
to grow, with EURL ECVAM monitoring the 
chemical programme landscape to identify 
more lists to add to CheLIST.
6.1.8 Update on ChemAgora 
People in need of a comprehensive overview of 
what information is available about a certain 
chemical often struggle with the heterogeneity 
of that information, scattered across numerous 
locations, in different formats and stored under 
often conflicting identifiers.
ChemAgora, the chemical information portal 
maintained by EURL ECVAM, facilitates the 
online retrieval of available information on a 
certain chemical substance. Chemicals can be 
searched by their name (or parts of it), CAS 
Registry number, InChIKey or chemical structure 
in a series of public repositories. Hyperlinks to 
the exact third party pages are provided, where 
more information about the chemical can be 
found. The tool also provides a list of synonyms 
the chemical is known under. 
Using ChemAgora, third party databases can be 
searched by an identifier originally not available 
in these repositories. Thus, ChemAgora is not 
only useful for getting an overview of what is 
currently known about a substance, but also 
adds value to third party systems.
Making access to information about chemical 
substances easier across heterogeneous 
platforms raises the public awareness about 
chemical knowledge. Stakeholders in the chemical 
community can take more informed decisions 
when being fully aware of the information 
available about a certain substance, and people 
using ChemAgora have a head start when it comes 
to finding out many details about a chemical.
READ MORE
CheLIST
chelist.jrc.ec.europa.
eu
ChemAgora
chemagora.jrc.
ec.europa.eu
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In the reporting period, the following activities 
led to improvements of ChemAgora: 
• A similarity search option was added, which 
can be started from the structure editor page. 
The feature is based on the ChEMBL Data Web 
Services with the possibility to choose between 
90%, 80% and 70% Tanimoto similarity cut offs.
• The user interface was adapted to user 
feedback.
• The third-party repositories were extended 
including:
- CREST (Chemical attributes, Regulatory 
approaches and Experimental STudies 
from a mixture toxicology perspective)
- CompTox Chemistry Dashboard from 
US-EPA
6.1.9 Endocrine Active Substances 
Information System (EASIS)
The term "endocrine active substance" (EAS) is 
used to describe any chemical that can interact 
directly or indirectly with the endocrine system, 
and subsequently result in an effect on the 
endocrine system, target organs and tissues. 
Whether the effect is adverse (“disruptive”) 
or not will depend on the type of effect, the 
dose and the background of the physiological 
situation (EFSA, 2010).
EASIS, the Endocrine Active Substances 
Information System, is a web-based application 
open to the public for query and review of 
results from scientific studies on chemicals 
related to endocrine activity or adverse 
effects (considered in relation to an endocrine 
disrupting mode of action). It deals generally 
with Endocrine Active Substances, e.g., not only 
with Endocrine Disruptors.
The starting point of EASIS was a database 
created by DG ENV in 2006. A new application, 
EASIS, was developed and the data from the DG 
ENV database were migrated into EASIS. More 
data to cover the period after 2006 were added. 
There are currently data from around 9000 
studies across 513 compounds in EASIS.
On 3 October 2016, EASIS was officially 
launched and is now available at https://easis.
jrc.ec.europa.eu.
JRC staff presented and promoted EASIS in 
numerous workshops and conferences, and 
has now started to identify more relevant data 
that can be managed and made available 
through EASIS.
6.2 Knowledge Sharing Activities 
During 2016, the JRC's EURL ECVAM carried 
out a study (Holley et al., 2016) of available 
knowledge on the 3Rs to understand how supply 
of such knowledge can better meet demand. 
The work undertaken in this study underpins the 
first of four actions which were identified by the 
Commission in response to the European Citizens' 
Initiative (ECI) "Stop Vivisection" and set out to 
assess the current situation regarding the sharing 
of knowledge relevant to the 3Rs between 
various sectors and communities with a view to 
accelerate the development and uptake of non-
animal approaches in research and testing. 
The results of this study were presented at the 
Commission’s scientific conference on "Non-
animal Approaches - The Way Forward" held on 
6-7 December in Brussels (see Box 6.2).
In order to map available knowledge, the 
JRC profiled over 800 knowledge sources 
relevant for the 3Rs and compiled them 
into an inventory covering different types of 
knowledge sources both explicit (e.g., websites, 
publications, databases, etc.) and more tacit 
(e.g., organisations, events, expert groups, etc.). 
A public survey was also conducted which 
aimed to elicit input from people working in 
areas related to the 3Rs to understand what 
knowledge sources they use, how they access 
them, and how they are currently being used 
to further the 3Rs. The wealth of information 
provided by the 351 survey respondents, 
a third of which replied on behalf of their 
organisations, has been invaluable to identify 
READ MORE
EASIS - Endocrine 
Active Substances 
Information System
easis.jrc.ec.europa.eu
Stop Vivisection
ec.europa.eu/
citizens-initiative/
public/initiatives/
successful/
details/2012/000007
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Reducing animal testing through better knowledge sharing
The JRC carried out a study of available knowledge on the replacement, reduction 
and refinement (the 3Rs) of animal procedures used in research and testing to 
understand how supply of such knowledge can better meet demand.
Findings show that although much 3Rs knowledge exists, its sharing can be 
improved through better coordination, communication and outreach, and by more 
emphasis on targeted education and training initiatives.
In 2015, the Commission identified four actions to accelerate the development 
and uptake of non-animal approaches, in response to the European Citizens' 
Initiative (ECI) "Stop Vivisection". The work undertaken in this study underpins 
the first action that set out to assess the current situation regarding the 
sharing of knowledge relevant to the 3Rs between various sectors and 
communities with a mind to accelerate the development and uptake of non-
animal approaches in research and testing.
Inventory of knowledge sources
In order to map available knowledge, the JRC profiled over 800 knowledge sources 
relevant for the 3Rs and compiled them into an electronic inventory.
The inventory covers different types of knowledge sources both explicit (e.g., 
websites, publications, databases, etc.) and more tacit (e.g., organisations, events, 
expert groups, etc.) and identifies who they typical target and how they share their 
content. Such a structured inventory has also allowed a comprehensive meta-
analysis of potential knowledge gaps and redundancies.
Public survey
The public survey aimed to elicit input from people working in areas related to the 
3Rs to understand what knowledge sources they use, how they access them, and 
how they aid them in their activities to further the 3Rs.
The wealth of information provided by the 351 survey respondents, a third of 
which replied on behalf of their organisations, has been invaluable to identify 
current practice, preferences and opportunities for enhancing knowledge sharing. 
Notably, many of the survey respondents stated that the available means of 
knowledge exchange are adequate, whilst two thirds stated that knowledge 
sources are lacking in their area.
Room for improvement
As described in the JRC report, although there are many 3Rs relevant knowledge 
sources available, their impact could be greater. There needs to be better 
awareness and coordination between existing 
knowledge sources. In addition, much of the vast 
amount of relevant information needs to be better 
structured and curated.
The knowledge sources also need to have a greater 
outreach, to increase the beneficiaries of the 
knowledge and to bring about more dialogue across 
sectors and between different groups working with 
animals and alternative methods.
Education and training opportunities relating to the 3Rs 
need to be increased and improved, extending across 
three levels of learning: professional, undergraduate 
and school-goers. Educators need more dedicated 
teaching resources and these should be freely 
available to them and their students.
What knowledge exists and how it can be best 
exploited can be better communicated to wider 
sections of potential users. And although there 
are many examples of good practice of knowledge 
exchange, in general people require more guidance 
and trust in the sources which are available.
Findings will feed strategies to accelerate uptake 
of 3Rs
The findings provide a strong evidence-base on 
which to formulate collaborative strategies to 
accelerate the uptake of the 3Rs and reduce 
the reliance on animal testing via enhanced 
knowledge sharing. This is important since 
most focus and investment until now has been 
in knowledge generation (e.g., via research 
programmes) rather than in better exploitation of 
already existing knowledge.
The results of this study inform knowledge providers 
on how their knowledge can be shared more 
effectively to accelerate progress in the 3Rs, as well 
as knowledge-users on the many existing knowledge 
sources that they might not be familiar with but 
which could help them in their daily work.
This report also provides a strong basis for the 
formulation of further activities underpinning 
the actions in the Commission Communication 
in response to the ECI, some of which may be 
supported as part of a one million euro EU pilot 
project adopted by the European Parliament which 
seeks to promote the use of alternatives to animal 
testing in the EU through information sharing and 
education activities.
Box 6.1
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European Commission Scientific Conference: Non-Animal 
Approaches - The Way Forward
On 6-7 December 2016, the European Commission held a scientific conference 
in Brussels to engage the scientific community and relevant stakeholders in a 
debate on how to exploit cutting edge advances in biomedical and other research 
in the development of scientifically valid non-animal approaches (alternatives to 
animal testing).
The event was one of the four actions announced in the European Commission 
Communication responding to the European Citizens' Initiative "Stop Vivisection".
Over 400 scientists from different countries, disciplines and sectors engaged in a 
dialogue to explore the current benefits and limitations of different models, and to 
consider how to improve the quality and predictivity of models used in research, 
including approaches to accelerate non-animal alternatives. Speakers from a range 
of backgrounds delivered short introductory presentations which were followed by 
discussion panel sessions. During these sessions, participants were invited to discuss 
the validity of animal models today in different sectors and the current state of play 
and ways forward for non-animal approaches in different areas of research and testing.
Maurice Whelan, head of EURL ECVAM, discussed validation as a step towards 
regulatory acceptance and uptake of alternative methods. The agenda also 
included reports on the progress of the other three actions: (1) accelerating 
progress in the Three Rs through knowledge sharing, 
(2) development, validation and implementation 
of new alternative approaches, (3) enforcement of 
compliance with the Three Rs principle and alignment 
of relevant sector legislation. Action 1 has been led 
by the JRC and this was presented by Tracey Holley 
(EURL ECVAM) whilst the Director of Directorate 
F - Health, Consumers and Reference Materials, 
Elke Anklam, participated in the panel discussion on 
knowledge sharing.
Box 6.2
current practice, preferences and opportunities 
for enhancing knowledge sharing.
The main conclusions of the study show 
that although much 3Rs knowledge exists, 
its sharing can be improved through better 
coordination, communication and outreach, 
and by more emphasis on targeted education 
and training initiatives. The findings provide a 
strong evidence-base on which to formulate 
collaborative strategies to accelerate the uptake 
of the 3Rs and reduce the reliance on animal 
testing via enhanced knowledge sharing.
6.3 JRC Summer School on 
Alternative Approaches for Risk 
Assessment 
On 16 to 19 May 2017, EURL ECVAM hosted 
a Summer School on alternative approaches 
for risk assessment with the aim of providing 
comprehensive training on state-of-the-art 
alternative (non-animal) approaches to predictive 
toxicology and to promote their use within 
modern chemical risk assessment practice.
The programme was tailored for post-graduate 
students (PhD/Master) and early-career 
scientists working in relevant fields. Over 100 
students from 29 countries (universities located 
in 19 countries) aged between 22 and 42 
years participated. All together there were 146 
registered participants.
EURL ECVAM also established a JRC summer 
school alumni group to keep the momentum 
going and to maintain the established 
professional network.
6.4 Training Activities on Read-
Across 
As part of the dissemination of information 
on alternative approaches, EURL ECVAM 
contributes to training activities related to the 
principles and application of these methods.
EURL ECVAM was involved in the Society of 
Toxicology (SOT) Continuing Education Course 
"Read-Across: Case Studies, New Techniques, 
and Guidelines for Practical Application", with 
a presentation on applying the Read-Across 
Assessment Framework to identify and 
address uncertainty. The outreach includes 
over 200 registered participants at the course 
on site at the 56th SOT Annual Meeting on 12 
March 2017 and continued availability for 
training as a recording in the SOT CEd-Tox 
online courses programme.
Similarly, EURL ECVAM contributed with a 
presentation on the principles and application 
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of read-across to the training event on health-
based guidance value development which was 
held in connection with the WHO Chemical 
Risk Assessment Network meeting on 19 June 
2017 at EFSA in Parma, Italy (see section 7.3). 
6.5 Training Activities on Adverse 
Outcome Pathways 
EURL ECVAM is strongly committed to the 
development and dissemination of AOPs. As a 
part of the OECD AOP training subgroup involved 
in the preparation of training material and 
various training activities, it continued with the 
planned AOP training courses for EFSA (via a 
Service Level Agreement), for both EFSA staff 
and external experts at EFSA premises in Parma. 
During the reporting period, three such courses 
were held in November 2016 and in April and 
June 2017 for a total of 49 participants. The 
last course is foreseen in November 2017. 
The courses aim at creating awareness of the 
AOP framework, the principles and practices 
underlying AOP development, description, and 
evaluation, and to provide the participants with 
the theory and hands-on skills to facilitate use 
and application of AOPs.
Equally important is to get valuable feedback 
from risk assessors that in turn can shape 
further development of the concept to increase 
the utility for regulators. The courses are 
consistently highly rated by attendees and 
EFSA organisers.
Further, EURL ECVAM has established strong 
ties with the EU-ToxRisk project (see section 
2.2) and has provided several training modules 
on SOP design, validation, and AOPs at their 
summer school for PhD students, postdoc 
collaborators, and principal investigators (see 
section 6.3 and Box 6.3).
In September 2016, a two-day AOP training 
course has been given for EU-ToxRisk project 
collaborators (principal investigators, Postdocs, 
and PhD students) in collaboration with the 
OECD AOP training group. 
6.6 European School Traineeship 
In 2017, EURL ECVAM offered a project to the 
students of the European School in Varese, Italy. 
The project, "Bringing scientific alternatives 
to animal testing to your classroom", helped 
students to explore the science behind 
alternatives to animal testing and, using what 
they had learnt, to develop an exciting learning 
activity to engage and inform fellow students. 
JRC Summer School on Alternative Approaches for Risk 
Assessment
From 16 to 19 May 2017, the JRC hosted in Ispra (Italy) 101 postgraduate students 
and early-career scientists from 29 countries worldwide for the JRC Summer School 
on Alternative Approaches for Risk Assessment.
During four intensive days, around 40 speakers provided the participants of 
the summer school with an overview on the whole process of chemical risk 
assessment. Lectures spanned various sectors, such as regulatory toxicology, 
in vitro methods, new concepts and approaches, computational modelling 
applications, test method validation principles and practices, and other hot topics.
Afternoons were dedicated to interactive sessions to 
facilitate knowledge exchange. In addition to two poster 
sessions, marketplaces for hands-on demonstration of 
various databases and tools for toxicology, World Café–
type discussion sessions, as well as visits to EURL ECVAM 
laboratory and an AOP game were part of the programme.
During the poster sessions, participants shared and 
discussed their research projects which covered 
a wide variety of topics mostly related to non-
animal approaches and 3Rs (replacement, reduction, 
refinement). From all the submitted poster abstracts, 
Box 6.3
20 were selected by the scientific committee for 
flash presentations. The poster prizes, however, were 
nominated by the participants themselves and were 
awarded to four outstanding pieces of work.
The summer school ended at the JRC Ispra Visitor's 
Centre where the participants got information on the 
Joint Research Centre, career opportunities within the 
EU and beyond, and checked their knowledge with the 
JRC Science Quiz.
READ MORE
SOT Continuing 
Education (CE) Program
www.toxicology.org/
events/am/AM2017/
program.asp#CE 
CEd-Tox: SOT 
Continuing Education 
Courses Online
www.toxicology.
org/education/ce/
onlineCourses.asp
Second Meeting of the 
WHO Chemical Risk 
Assessment Network
www.who.int/
ipcs/network/
meeting2017/en
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Covering chemistry, biology and toxicology 
in the context of alternatives, the students 
discovered what chemicals are used in everyday 
products, why they need to be tested and 
how in vitro cell systems and computational 
methods can be used instead of animals. 
The students also had the opportunity to see 
how EURL ECVAM assesses the reliability of 
these methods and were introduced to the 
scientific research that is important to develop 
them. At the end, they produced a poster which 
could be used to inform other students and 
gave feedback on the traineeship.
The project was a good opportunity as well for 
EURL ECVAM to increase its outreach activities 
and to engage with a different target audience. 
Many colleagues participated in this traineeship 
and gained valuable insight into how we can 
work to improve our communications with young 
scientists and to present our work in a way 
which is more understandable to non-scientists.
6.7 Dissemination Activities of 
EPAA
6.7.1 EPAA 3Rs Prizes
The EPAA Awards are granted to young 
scientists (3Rs Science Prize) or laboratory 
technicians and animal caretakers (3Rs 
Technician Prize), respectively, whose work 
has brought an outstanding contribution 
to the development and implementation 
of alternatives to animal testing. Both, the 
Science and the Laboratory Technician Prize are 
awarded alternating every other year.
In 2016, the EPAA granted the 3Rs Science 
Prize to a scientist from Wageningen University 
(former grant holder at EURL ECVAM), for his 
work on a reverse dosimetry approach using 
Physiological based kinetic (PBK) modelling. 
Through this technique, a known tissue 
concentration can be converted to an external 
dose as applied to the organism in question, 
e.g., a human, enabling the translation of 
in vitro concentrations to an exposure in 
vivo. While so far this approach has been 
successfully applied to the prediction of toxic 
effects of several chemicals in rodents based 
on in vitro data produced in rodent embryonic 
stem cells, future studies will investigate the 
prediction of effects in humans.
6.7.2 Other Dissemination Activities
In 2016 EPAA launched a process to identify 
the most important scientific challenges to 
the wider development and adoption of non-
animal methods and engaged in a discussion 
on possibilities to overcome these challenges 
in progressing towards the ultimate goal of full 
replacement of animal testing. 
The main results of this process were presented 
and further discussed at EPAA's Annual 
Conference in December 2016, of which the 
report is available online. The process will lead 
to an amendment of the current EPAA Action 
Programme (2016 - 2020), which presumably 
will be published by the end of 2017, and 
possibly to new activities within EPAA.
In the reporting period, EPAA presented its work 
and projects in a number of events, such as 
the 2016 annual conferences of the Federation 
of Laboratory Animal Science Associations 
(FELASA) and the European Society for 
Alternatives to Animal Testing (EUSAAT) as well 
as at the Danish 3Rs Symposium (September 
2016) and the 10th Congress on Alternatives 
and Animal Use in the Life Sciences (Seattle, 
USA, August 2017).
READ MORE
EPAA's Annual 
Conference in 
December 2016
ec.europa.eu/growth/
content/12th-epaa-
annual-conference-
science-based-
regulation-0_en
EPAA Action 
Programme (2016 - 
2020)
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action-pro-
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pdf
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7 International Cooperation on 
Alternative Test Methods
It is essential to maintain and strengthen 
international cooperation on alternative test 
methods in the areas of validation studies, 
independent peer review, and development of 
harmonised recommendations and test guidelines 
in order to ensure that alternative methods/
strategies are more readily accepted for regulatory 
purposes worldwide.
International cooperation is also necessary 
to ensure that new alternative test methods/
strategies adopted for regulatory use will provide 
equivalent or improved protection for people, 
animals, and the environment, while replacing, 
reducing or refining animal use whenever 
scientifically feasible. This chapter updates on 
EURL ECVAM involvement in various international 
cooperation initiatives.
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7 International Cooperation on 
Alternative Test Methods
7.1 ICATM Workshop and Meeting 
2016 
EURL ECVAM, in collaboration with the 
International Cooperation on Alternative Test 
Methods (ICATM), hosted a two-day workshop 
on the international regulatory applicability and 
acceptance of alternative non-animal approaches 
to skin sensitisation assessment of chemicals 
used in a variety of sectors on 4 to 6 October 
2016 at the JRC in Ispra, Italy (see Box 7.1).
The workshop convened representatives from 
more than 20 regulatory authorities from 
the European Union (EU), United States (US), 
Canada, Japan, South Korea, Brazil, and China, 
to facilitate a common understanding of the 
available non-animal methods (e.g., in vitro, in 
chemico, in silico and read-across) and their 
role within Defined Approaches (DAs). Working 
together to identify potential obstacles, the 
international and cross-sector group defined a 
series of steps that should be taken to support 
the regulatory application of DAs.
The participants initially focused on the current 
regulatory requirements for skin sensitisation 
in different regions by chemical sector (e.g., 
pesticides, cosmetics, pharmaceuticals, industrial 
chemicals, etc.) that could be potentially 
satisfied with the use of non-animal approaches.
International workshop on alternative non-animal approaches to 
skin sensitisation assessment of chemicals 
On 4-6 October 2016 EURL ECVAM, in collaboration with the International Cooperation 
on Alternative Test Methods (ICATM), hosted a two day workshop on the international 
regulatory applicability and acceptance of alternative non-animal approaches to skin 
sensitisation assessment of chemicals used in a variety of sectors.
The workshop brought together regulators and alternative method experts from 
Europe, China, the United States, Brazil, Canada, South Korea and Japan, working in 
a variety of sectors, to facilitate a common understanding 
of the non-animal approaches (i.e., in vitro, in chemico, in 
silico and read-across) that are available in the area and 
their current proposed use.
The participants focused on the current regulatory 
requirements for skin sensitisation in different 
regions by chemical sector (i.e., pesticides, cosmetics, 
pharmaceuticals, industrial chemicals, etc.) that could 
be potentially satisfied with the use of non-animal 
approaches. Working together to identify potential 
obstacles, the international and cross-sectorial group 
was able to define initial steps which should be taken to 
support the regulatory application of these approaches.
Following the workshop, members of the International 
Cooperation on Alternative Test Methods attended a 
one-day meeting with EURL ECVAM. Representatives 
from organisations from China, Japan, Brazil, South 
Korea, the US and Canada followed up on how to 
implement the actions decided at the workshop, and 
also on how to build on current strategies to facilitate 
and accelerate global progress in the development, 
validation, acceptance and use of alternative methods 
to animal testing.
Box 7.1
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There was general consensus among the 
workshop participants that in order to maximise 
regulatory consideration and acceptance of data 
generated with DAs, international harmonisation 
and standardisation will be necessary. This 
should ideally be achieved through the 
development of an evaluation framework that 
allows an independent assessment of the 
DAs currently reported in Annex I to OECD GD 
256 (OECD, 2016f) and any other upcoming 
promising DAs.
The area of skin sensitisation has in recent 
years been at the centre of concerted efforts to 
replace animal testing. Progress has been made 
in the development, validation and regulatory 
adoption of in chemico and in vitro methods, 
and various in silico approaches (e.g., (Q)SAR 
models and expert systems) are available (see 
section 4.9.1 and section 5.2.3).
In parallel, efforts have been made to develop 
defined approaches to testing and assessment 
using data generated with these methods, and to 
derive predictions that would replace information 
traditionally generated with animal models 
that can be used in the context of Integrated 
Approaches to Testing and Assessment (IATA). 
The outcomes of the workshop will be presented 
in two peer-reviewed publications (Casati et al., 
2017; Daniel et al., 2017).
Following the workshop, members of the 
Following the workshop, members of the 
International Cooperation on Alternative Test 
Methods attended a one-day meeting with EURL 
ECVAM. Representatives from organisations 
from China, Japan, Brazil, South Korea, the US 
and Canada followed up on how to implement 
the actions decided at the workshop, and 
also on how to build on current strategies to 
facilitate and accelerate global progress in the 
development, validation, acceptance and use of 
alternative methods to animal testing.
The main action discussed and agreed upon 
was the submission to the OECD of a project 
proposal for the development of a PBTG 
for DAs for skin sensitisation testing and 
assessment. Such a proposal (co-led by the EU, 
US and Canada) was submitted to the OECD in 
November 2016 and following revision based 
on feedback from Member Countries, was 
approved on 27 April 2017 for inclusion in the 
OECD workplan (see section 5.2.10).
7.2 Overview of EURL ECVAM - 
NICNAS Training Webinar Series 
on "Alternative Approaches to 
Assessing Systemic Toxicity" 
EURL ECVAM has delivered a series of webinars 
on alternative approaches to assessing 
systemic toxicity to the National Industrial 
Chemicals Notification and Assessment Scheme 
(NICNAS) Office of Chemical Safety, Australian 
Government Department of Health. The 
following topics were presented:
7.2.1 Skin Sensitisation
The presentation provided an overview of the 
state-of-the art in the area. This included a 
description of the skin sensitisation AOP and 
of the adopted methods and other methods in 
the validation/adoption pipeline. The definitions 
and concepts of IATA and DAs including an 
overview of current discussions and activities 
 74
CHAPTER 7
at the OECD on their regulatory use and 
acceptability were provided. 
The DAs reported in Annex 1 to the OECD GD 
256 (OECD, 2016f) were briefly illustrated 
as well as the new legal requirements for the 
endpoint as established within the REACH 
legislation and how these have been addressed 
in the revised European Chemicals Agency 
(ECHA) guidance on information requirements 
and chemical safety assessment.
7.2.2 Genotoxicity Testing
Several in vitro tests are available at different 
stages of development and acceptance, yet they 
are not considered at present sufficient to fully 
replace animal tests needed to evaluate the 
safety of substances. The webinar focused on the 
presentation of recent activities that have taken 
place which aim at the overall improvement of 
the traditional genotoxicity testing paradigm 
(Corvi and Madia, 2017) (see Box 7.2).
These include the improvement of existing tests, 
the development of novel tests, as well as the 
establishment and exploration of approaches to 
optimise in vitro testing accuracy. Furthermore, 
useful tools, such as databases or reference 
chemical lists (see section 6.1.5) have been 
developed to support advances in this field.
7.2.3 Non-Animal Methods: How to 
Judge their Reliability and Relevance
The principles and process of validation were first 
established in the 1990s and gained international 
recognition with the adoption of OECD Guidance 
Document No. 34 in 2005 (OECD, 2005). If 
these principles and processes were successful 
in pioneering the regulatory acceptance of 
alternative methods for less complex endpoints, 
an evolution of current practices is needed 
to embrace emerging technologies and the 
increased complexity of endpoints.
Indeed, validation needs to keep pace with 
scientific progress, the availability of new tools 
and techniques, the need for data integration 
to address complex endpoints, and the growing 
demands for better protection of human health 
and the environment, to ensure that it continues 
to be fit for purpose and to add value rather 
than hindering progress. 
In 2004, a “Modular Approach to the ECVAM 
Principles on Test Validity” was proposed with 
the objective of making the validation process 
more flexible by breaking down its various steps 
into seven independent modules, and defining 
for each module the information needed 
for assessing the scientific validity of a test 
method (Hartung et al., 2004). 
Improved performance of in vitro genotoxicity testing?
The evaluation of genotoxicity is an essential component of the safety assessment 
of all types of substances (industrial chemicals, pharmaceuticals, pesticides, food 
additives, cosmetics ingredients, etc.) for the protection of human and animal 
health. In general, the assessment of genotoxic hazards to humans begins with 
non-animal (in vitro) tests followed in some cases by animal testing.
A variety of well-established in vitro assays are available at different stages of 
development and regulatory acceptance. However, they are not considered at 
present sufficient to fully replace animal tests currently used to evaluate the 
safety of substances for regulatory purposes.
A strategy to reduce and avoid animal use in genotoxicity testing had previously 
been described by the JRC-hosted EU Reference Laboratory for Alternatives to 
Animal Testing (EURL ECVAM), based on the regulatory needs across different 
EU legislations, state of the science, and recent efforts undertaken by various 
organisations. Moreover, considerable activities have been carried out in the last 
decade worldwide with the aim of optimising strategies for genotoxicity testing. 
These recent achievements together with the implementation of the EURL ECVAM 
strategy plan are described in this review.
They include the improvement of existing tests, the development of novel tests, 
as well as the establishment and exploration of approaches to optimise in vitro 
testing accuracy (Kirkland et al., 2014a, Kirkland et al., 
2014b). Furthermore, useful tools, such as databases 
or reference chemical lists, have been developed 
by the JRC in collaboration with other scientists 
to support advances in this field. Some of these 
activities have also led to the revision of OECD Test 
Guidelines and regulatory guidance (Corvi and Madia, 
2017).
Box 7.2
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This modular approach to validation should be 
further exploited to encourage more innovation 
and flexibility in study design and to increase 
efficiency in validation. A more systematic 
consideration of the uncertainty associated 
with both in vivo and non-animal data is also 
an important step in building further confidence 
in the validation of alternative approaches and 
their regulatory acceptance. 
This webinar provided a historical overview 
of the establishment of the principles of the 
scientific validation of alternative methods for 
toxicity testing as well as the challenges and 
opportunities for adapting the validation practices 
to keep pace with scientific progress whilst 
ensuring the protection of human health and the 
environment and best serve the needs of society.
7.2.4 SEURAT-1 Read-Across Case 
Studies and ab initio Case Study
The presentation started with a brief 
introduction to the EU FP7 research initiative 
SEURAT-1 (see section 2.1), which focused on 
the complex area of alternative approaches 
to repeated dose toxicity testing, and the 
conceptual framework for safety assessment 
developed. It was followed by two more detailed 
presentations that covered the cross-cluster 
SEURAT-1 read-across case studies (Berggren 
et al., 2015; Schultz et al., 2015, Mellor et al., 
2017; Przybylak et al., 2017; Schultz and Cronin, 
2017; Schultz et al., 2017a,b) and the SEURAT-1 
ab initio case study (Berggren et al., 2017).
7.2.5 Exposure Assessment - Route to 
Route extrapolation
The webinar introduced the concept of exposure 
assessment. To assess risk, exposure and 
hazard factors are needed. For estimation 
of exposure factors the following steps were 
highlighted: (i) data collection (of diaries, 
monitoring of environment, biomonitoring); (ii) 
organisation of knowledge by using defined 
frameworks like Aggregate Exposure Pathways 
(AEP) and hazard Adverse Outcome Pathways 
(AOPs); (iii) simulation of chemicals fate and 
transport and human exposure by predictive 
models; Finally, (iv) route to route extrapolation 
was explained by means of an approach 
applicable to cosmetics compounds, called the 
margin of internal exposure (MOIE).
In the MOIE approach PBK models developed 
for human and rodents for simulating caffeine 
exposure via oral and dermal route were applied 
(Bessems et al., 2017). The models developed 
as part of the COSMOS Project within the 
SEURAT-1 research initiative, were implemented 
as KNIME workflows and are freely available . 
Furthermore, the evaluation of the applicability 
of the Threshold of Toxicological Concern 
(TTC) concept to cosmetics-related substances 
was discussed, including building of a 
cosmetics-ingredient enriched TTC dataset and 
extrapolation to the dermal route of exposure 
relevant to cosmetics (Williams et al., 2016; 
Yang et al., 2013; Yang et al., 2017).
7.2.6 EU Activities relevant to the 
Identification and Assessment of 
Endocrine Disruptors
The webinar started with the need for assessing 
EDs in general, followed by past and present 
activities in the EU regarding endocrine 
disruptors and the scientific criteria for EDs. 
This was followed by the JRC work (Munn 
et al., 2016) on the ED impact assessment, 
explaining the way the data has been captured 
and codified, and the automatically generated 
matrix can be used to get an easy overview of 
the available evidence. This is really useful in 
assessing whether a compound is likely to be 
an ED or not and to identify clear data gaps. 
Next, the AOP framework (and its practical 
applications) was presented, including IATA and 
the use of AOPs for hazard identification (as 
was done for the EDs). 
An overview of the test methods that 
are available to predict the ED potential 
of chemicals was presented, focusing on 
the methods listed in the OECD Guidance 
Document 150 (as part of the OECD Conceptual 
Framework for Testing and Assessment of 
Endocrine Disruptors (OECD, 2012b)); these 
methods range from simple (Q)SAR and in vitro 
tests to multigenerational in vivo tests. The 
webinar ended with an overview of the activities 
by the US EPA, including the recent analysis of 
the Endocrine Disruptor Screening Programme 
(EDSP) and the ED work covered by ToxCast 
with the development of the ER and AR models 
(to predict level 3 mechanistic in vivo assays) 
(Browne et al., 2015).
7.3 World Health Organisation 
Chemical Risk Assessment 
Network
The World Health Organisation (WHO) Chemical 
Risk Assessment Network (CRAN) within the 
International Programme on Chemical Safety 
READ MORE
SEURAT-1 - Towards 
the Replacement of in 
vivo Repeated Dose 
Systemic Toxicity 
Testing
www.seurat-1.eu
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(IPCS) is a collaborative initiative aiming at 
improving chemical risk assessment globally, 
through facilitating interaction and exchange 
of experience about risk assessment topics 
and activities between institutions engaged 
in chemical risk assessment activities around 
the world. It was established at the end of 
2013 and comprises 85 institutions from 45 
countries, including government departments, 
academia, WHO Collaborating Centres and 
professional societies. 
The WHO Network promotes the objectives 
of the Strategic Approach to International 
Chemicals Management (SAICM). It is 
coordinating projects that can be international, 
regional, multilateral or bilateral in 
scope, resulting for example in guidance 
documentation, training sessions or materials, 
tools or databases. An important focus is 
developing countries' perspectives on risk 
assessment. EURL ECVAM is involved as an 
observer, and contributes to the Network 
Coordination Groups on Mode of Action (MoA) 
and Combined Exposures. 
The MoA Human Relevancy Framework was 
developed by WHO/IPCS as a tool for Weight of 
Evidence analysis and was updated in 2013 (Meek 
et al., 2014), including a MoA roadmap showing 
the use of MoA knowledge in human health risk 
assessment as well as MoA analysis templates . 
WHO/IPCS further follows up work on MoA and is 
planning activities for training purposes.
The Network Coordination Group on Combined 
Exposures was set up at the first WHO CRAN 
meeting in Paris in 2014. It has compiled 
an inventory with information on combined 
exposure activities of the Network participants 
to find synergies and opportunities for 
cooperation between Group members and is 
further monitoring ongoing developments. 
The Second Meeting of the WHO CRAN was 
hosted by the European Food Safety Authority 
(EFSA) on 20-22 June 2017, with attendants 
from 63 chemical risk assessment institutions 
from 39 countries. It addressed themes 
including combined exposures to multiple 
chemicals, human biomonitoring, identifying 
new and emerging risks, interplay of existing 
methodologies, new scientific approaches 
for regulatory safety assessment as well as 
prioritising chemicals and settings of concern 
for risk assessment. The draft strategic plan for 
enhancing chemical risk assessment capacity in 
the Network was discussed.
EURL ECVAM contributed to the meeting with 
a keynote presentation on establishing the 
credibility of predictive toxicology approaches 
for regulatory safety assessment, as well as 
providing a thought starter document on new 
science in chemical risk assessment for one of 
the break-out discussions.
The meeting concluded with plans for future 
activities, including scoping activities on 
emerging risks, raising awareness of new 
approaches for chemical risk assessment and 
sharing experience to promote harmonised 
approaches, as well as developing training and 
case studies in order to foster integration of the 
use of new methods and existing methods.
READ MORE
WHO Chemical Risk 
Assessment Network 
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8 Conclusions
Current EU-funded projects such as EU-ToxRisk aim 
for animal-free toxicological assessments for complex 
areas such as repeated dose and reproductive toxicology. 
These assessments are based on human cell responses 
and a comprehensive mechanistic understanding of 
cause-consequence relationships of chemical adverse 
effects. These projects try to integrate cell biology, 
'omics technologies, systems biology and computational 
modelling for the risk assessment of chemicals without 
relying on animal testing. 
Similarly, other EU projects investigate the applicability 
of these novel, non-animal tools in the assessment 
of combined effects of chemicals on humans and the 
environment. New approaches and methods, such as 
the AOP concept, in vitro methods, 'omics techniques, 
quantitative structure activity relationships (QSARs), 
read-across, toxicokinetic and dynamic energy budget 
(DEB) modelling, and IATA contribute to a more 
mechanistically based prediction of mixture effects and 
at the same time reduce the reliance on animal testing.
Besides R&D projects that are focused on human 
health effects, other projects related to fish toxicity and 
bioaccumulation are currently ongoing such as e.g., the 
development of AOPs for chronic fish toxicity testing, the 
potential use of the eco-TTC concept for environmental 
risk assessment and the development of a tiered testing 
strategy for fish bioaccumulation testing based on in 
vitro approaches. 
In the area of acute systemic toxicity, activities are 
dedicated to the collection and evaluation of mechanistic 
information on eight potential organs identified as 
relevant for acute systemic toxicity. The overall aim is 
to identify properties that are required for in vitro test 
methods for target organ toxicity testing which are not 
covered by cytotoxicity assays. An improved understanding 
of toxicological mechanisms in this area will allow the 
development of IATA for acute systemic toxicity.
In the area of carcinogenicity, the current efforts focus 
on providing insight into carcinogenicity mechanisms and 
the integration of all available information on relevant 
endpoints, including from epidemiology, traditional and 
alternative toxicology test systems, and from novel data 
streams (e.g., 'omics, high through technologies).
IATA have been developed and internationally approved 
in the areas of skin irritation/corrosion, serious 
eye damage/eye irritation and skin sensitisation. 
For the latter, a number of DAs integrating data 
from internationally adopted in vitro methods with 
other relevant information have been proposed and 
documented by the OECD under the leadership of JRC's 
EURL ECVAM.
With the aim to further enhance regulatory consideration 
and adoption of DAs, EURL ECVAM in collaboration with 
ICATM hosted a workshop on the international regulatory 
applicability and acceptance of alternative non-animal 
approaches, e.g., DAs, to skin sensitisation assessment 
of chemicals used in a variety of sectors. The workshop 
led to the conclusion that international harmonisation 
and standardisation of DAs are needed. EURL ECVAM 
therefore submitted together with US and Canada, a 
new project proposal to the OECD on the development 
of a PBTG on DAs and individual methods for skin 
sensitisation testing.
In the area of toxicokinetics, EURL ECVAM focuses 
its efforts on the development of an OECD GD to 
characterise and describe in vitro methods for measuring 
hepatic metabolic clearance, since the latter represents 
in many cases the main driving process of kinetics and 
several in vitro methods exist in that area. In parallel, 
another OECD GD on Physiologically Based Kinetic (PBK) 
models is currently being prepared with a view to provide 
harmonised guidance to model developers, reviewers, 
and risk assessors.
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In the area of vaccines, projects like "Vaccine batch 
to vaccine batch comparison by consistency testing" 
(VAC2VAC) focus on the development, optimisation and 
evaluation of non-animal methods, e.g., physicochemical 
and immunochemical methods, cell-based and other 
assays for routine batch quality, safety and efficacy 
testing of vaccines in order to avoid severe animal testing.
At international level, efforts are focused on the 
development and adoption of VICH guidelines on 
harmonisation of criteria to waive the target animal 
batch safety testing for inactivated and live vaccines for 
veterinary use. 
Information on in vitro and in silico data as well as on test 
methods are disseminated through a variety of databases 
hosted by JRC-EURL ECVAM.
EURL ECVAM also invested in communication, education 
and training activities on alternatives for young scientists 
during the JRC Summer School and the European School 
traineeship with the aim to raise awareness of new modern 
risk assessment approaches to post-graduate students and 
early-career scientists.
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Annexes
Annex 1 —Summary status of the adoption of Test Guidelines based on Alternative 
Methods in the OECD TG programme (2011-2017)
Table 1. summarises the status of adoption of OECD test guidelines on alternative methods from 2011 to 2017. It should be noted that beside TGs, also Guidance Documents and new projects 
on alternative methods were respectively adopted and included in the OECD Work programme during that period. For additional information, please consult the OECD website of the Test 
Guideline Programme: http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelateddocuments.htm
Table 1. Status of adoption of OECD Test Guidelines based on alternative methods 2011-2017
Nr. Toxicity area Test method description Acceptance status
1 Skin corrosion Reconstructed human Epidermis (RhE) test methods, 
as included in OECD TG 431/EU TM B.40 bis
Adopted as a new TG in 2004; updated version (sub-categorisation, inclusion of performance standards, 
inclusion of SkinEthic™ RHE and epiCS®) adopted in 2013. Revised version including sub-categorisation 
with the epiCS® test method adopted in 2014.
Updated in 2015 for the deletion of the performance standards (published separately on the Series on 
Testing and Assessment No. 219), inclusion of paragraphs referring to the IATA for Skin Corrosion and 
Irritation (OECD GD No. 203) and inclusion of the use of HPLC/UPLC-spectrophotometry as an alternative 
procedure to measure tissue viability (increasing the applicability domain of the test methods to coloured 
substances interfering with the measurement of MTT-formazan).
Updated in 2016 for improving the predictive capacity of the three validated in vitro skin corrosion test 
methods (EpiDermTM, SkinEthicTM and EpiCS®) for the correct prediction of Sub-Cat.1A.
2 Skin corrosion Transcutaneous Electrical Resistance (TER) test 
method, as included in OECD TG 430/EU TM B.40
Adopted as a new TG in 2004; updated version (inclusion of performance standards) adopted in 2013
Updated in 2015 for the deletion of the performance standards (published separately in the Series on 
Testing and Assessment No. 218) and the inclusion of paragraphs referring to the IATA for Skin Corrosion 
and Irritation (OECD GD No. 203)
3 Skin corrosion In vitro Membrane Barrier Test Method for Skin 
Corrosion, as included in OECD TG 435/EU TM B.40
Adopted as a new TG in 2006; Updated in 2015 for the inclusion of the Corrositex® prediction model, 
the deletion of the performance standards (to be published separately on the Series on Testing and 
Assessment), the inclusion of paragraphs referring to the IATA for Skin Corrosion and Irritation and the 
updating of the list of proficiency substances (OECD GD No. 203)
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4 Skin irritation Reconstructed human Epidermis (RhE) test methods, 
as included in OECD TG 439/EU B.46
Adopted as a new TG in 2010; updated version (inclusion of LabCyte EPI-model24 SIT) adopted in 2013
Updated in 2015 for the deletion of the performance standards (published separately on the Series on 
Testing and Assessment No. 220), inclusion of paragraphs referring to the IATA for Skin Corrosion and 
Irritation (OECD GD No. 203) and inclusion of the use of HPLC/UPLC-spectrophotometry as an alternative 
procedure to measure tissue viability (increasing the applicability domain of the test methods to coloured 
substances interfering with the measurement of MTT-formazan)
5 Serious eye damage/eye 
irritation 
Fluorescein Leakage (FL) test method, as included 
in OECD TG 460
Adopted as a new TG in 2012; updated version to include a new reference to OECD GD 236 on an IATA 
for Serious Eye Damage and Eye Irritation adopted in 2017
6 Serious eye damage/eye 
irritation
Bovine Corneal Opacity and Permeability (BCOP) 
test method, as included in OECD TG 437/EU TM 
B.47
Adopted as a new TG in 2009; updated version (revision of positive controls, use to identify non-classified 
chemicals and several other revisions) adopted in 2013; updated version to include a new reference to 
OECD GD 236 on an IATA for Serious Eye Damage and Eye Irritation adopted in 2017
7 Serious eye damage/eye 
irritation
Isolated Chicken Eye (ICE) test method, as included 
in OECD TG 438/EU TM B.48
Adopted as a new TG in 2009, updated version (use to identify non-classified chemicals and several 
other revisions) adopted in 2013; updated version to include a new reference to OECD GD 236 on an 
IATA for Serious Eye Damage and Eye Irritation adopted in 2017
8 Serious eye damage/eye 
irritation
Cytosensor Microphysiometer (CM) test method New draft TG first discussed at WNT in 2013 but not adopted, pending further clarification on its use 
to identify non-classified chemicals. The additional data requested by the WNT that should have been 
submitted by US to support the project were not received and thus the project has been discontinued 
because of lower priority for the EC
9 Serious eye damage/eye 
irritation
Short Time Exposure (STE) test method for the 
detection of chemicals causing serious eye damage 
and chemicals not requiring classification for 
serious eye damage or eye irritation, as included in 
OECD TG 491
Adopted as a new TG in 2015; updated version to include a new reference to OECD GD 236 on an IATA 
for Serious Eye Damage and Eye Irritation adopted in 2017
10 Serious eye damage/eye 
irritation
Reconstructed human Cornea-like Epithelium 
(RhCE) test methods for the detection of chemicals 
not requiring classification and labelling for eye 
irritation or serious eye damage, as included in 
OECD TG 492
Adopted as a new TG in 2015; updated version to include SkinEthic™ HCE EIT and a new reference to 
OECD GD 236 on an IATA for Serious Eye Damage and Eye Irritation adopted in 2017
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11 Skin sensitisation In chemico skin sensitisation: Direct Peptide Reactivity 
Assay (DPRA), as included in OECD TG 442C
Adopted as a new TG in 2015
12 Skin sensitisation In vitro skin sensitisation: ARE-Nrf2 Luciferase test 
method (KeratinoSens™), as included in OECD TG 
442D
Adopted as a new TG in 2015
13 Skin sensitisation In vitro Skin Sensitisation assays addressing the 
Key Event on activation of dendritic cells on the 
Adverse Outcome Pathway for Skin Sensitisation, 
as included in OECD TG 442E
Adopted as a new TG in 2016 as "In vitro Skin Sensitisation: human Cell Line Activation Test (h-CLAT)"; 
updated version to include U-SENS™ and IL-8 Luc test methods adopted in 2017. The TG was revised to 
an "OECD Test Guideline for the Testing of Chemicals Based on Key events", grouping the three adopted 
test methods addressing key event 3 within the existing AOP into one single TG
14 Carcinogenicity In vitro Syrian Hamster Embryo (SHE) Cell 
Transformation Assay (CTA) as included in OECD GD 
No. 2141
Adopted as a new GD in 2015
15 Carcinogenicity In vitro Bhas 42 Cell Transformation Assay (CTA) as 
included in OECD GD no 2311
Adoption as a new GD in 2016
16 Genotoxicity In vitro Mammalian Chromosome Aberration Assay 
as included in OECD TG 473
Updated OECD TG 473 (originally adopted in 1983) adopted in 2014. Updated in 2016 to reference the 
Guidance Document on genetic toxicology Test Guidelines
17 Genotoxicity In vitro Mammalian Cell Micronucleus Assay as 
included in OECD TG 487 
Updated OECD TG 487 (originally adopted in 2010) adopted in 2014. Updated in 2016 to reference the 
Guidance Document on genetic toxicology Test Guidelines
18 Genotoxicity In vitro Mammalian Cell Gene Mutation Test using 
Hprt and xprt genes as included in OECD TG 476 
OECD TG 476 (originally adopted in 1984) "In vitro Mammalian Cell Gene Mutation Test" has been split 
up into two TGs: 
1. The updated TG 476 now using the Hprt and xprt genes was adopted in 2015;
2. OECD TG 490 using thymidine kinase Gene was adopted in 2015. Both TGs were updated in 2016 to 
reference the Guidance Document on genetic toxicology Test Guidelines and TG 490 was also corrected 
(see below)
19 Genotoxicity In vitro Mammalian Cell Gene Mutation Tests Using 
the Thymidine Kinase Gene as included in OECD TG 
490
Adopted as TG 490 in 2015 (see above). Updated in 2016 to reference the Guidance Document on 
genetic toxicology Test Guidelines and to correct a paragraph related to the maximum concentration 
that is based on cytotoxicity. 
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20 Endocrine disruption H295R Steroidogenesis Assay Adopted as TG 456 in 2011
21 Endocrine disruption Estrogen receptor transactivation assay (BG1Luc ER 
TA; agonist and antagonist protocols) as included in 
OECD TG 457
Adopted in 2012
OECD TG 457 was deleted in 2015. The method was included in OECD TG 455 in 2012 (agonist part) 
and 2015 (antagonist part) (see table entry below)
22 Endocrine disruption Performance-Based Test Guideline for Stably 
Transfected Transactivation In vitro Assays to 
Detect Estrogen Receptor Agonists and Antagonists 
as included in OECD TG 455
OECD	455	adopted	in	2009	(STTA	assay	using	the	hERα-HeLa-9903	cell	line);	updated	version	(PBTG,	
inclusion of VM7Luc ER TA assay using the VM7Luc4E2 cell line) adopted in 2012; Second updated 
version, including the antagonist part of both methods was adopted in 2015.
This update led to the deletion of OECD TG 457 in parallel as it is no longer needed (see above).
Third updated version to include the ER-CALUX method (using a U2OS cell line) was approved in 2016
23 Endocrine disruption Performance-Based Test Guideline for Human 
Recombinant Estrogen Receptor (hrER) In vitro 
Assays to Detect Chemicals with ER Binding Affinity 
as included in OECD TG 493
Adopted as new TG in 2015. It includes two reference test methods:
• In vitro	Estrogen	Receptor	(ER)	Binding	Assay	Using	a	Full	Length	Human	Recombinant	ERα;
• In vitro Estrogen Receptor Binding Assay Using a Human Recombinant Ligand Binding Domain 
Protein
24 Endocrine disruption Stably Transfected Human Androgen Receptor 
Transcriptional Activation Assay for Detection of 
Androgenic Agonist and Antagonist Activity as 
included in OECD TG 458
Adopted as new TG in 2016
The method uses the AR-EcoScreen™ cell line
25 Acute fish toxicity Fish Embryo Acute Toxicity (FET) Test as included in 
OECD TG 236
Adopted in 2013
 
1 These test methods were initially proposed to be included in Test Guidelines. It was later decided to include them in Guidance Documents.
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Annex 2 — ICATM Alternative Test Methods Validation and Status of Regulatory 
Acceptance
Table 2. ICATM Alternative Test Methods Validation and Status of Regulatory Acceptance
Method Current Status Lead 
Organisation
International Acceptance
Dermal Corrosion Test Methods
CORROSITEX Skin Corrosion 
Test
Completed OECD TG 435 (2006)
Updated version (including the Corrositex® prediction model, the deletion of the performance 
standards (to be published separately on the Series on Testing and Assessment), including 
paragraphs referring to the IATA for Skin Corrosion and Irritation in OECD GD No. 203 and 
the updating of the list of proficiency substances) adopted in 2015.
EpiSkin™, EpiDerm™ SCT, 
SkinEthic™ RHE, epiCS® Skin 
Corrosion Tests
Completed OECD TG 431 (2004)
Updated version (sub-categorisation, inclusion of performance standards, inclusion 
of SkinEthic™ RHE and epiCS™) adopted in 2013. Revised version including the sub-
categorization with the epiCS™ test method adopted in 2014.
Updated version [deleting the performance standards (published separately on the Series 
on Testing and Assessment No. 219), including paragraphs referring to the IATA for 
Skin Corrosion and Irritation in OECD GD No. 203 and including the use of HPLC/UPLC-
spectrophotometry as an alternative procedure to measure tissue viability (increasing 
the applicability domain of the test methods to coloured substances interfering with the 
measurement of MTT-formazan)] adopted in 2015. Updated in 2016 for improving the 
predictive capacity of the three validated in vitro skin corrosion test methods (EpiDermTM 
SCT, SkinEthicTM RHE and epiCS®) for the correct prediction of Sub-Cat.1A.
Rat TER Skin Corrosion Test Completed OECD TG 430 (2004)
Updated version (inclusion of performance standards) adopted in 2013.
Updated version [deleting the performance standards (published separately on the Series 
on Testing and Assessment No. 218) and including paragraphs referring to the IATA for Skin 
Corrosion and Irritation in OECD GD No. 203] adopted in 2015.
In vitro Reconstructed human 
Epidermis (RhE) test methods:  
LabCyte EPI-MODEL24 SCT
JSAAE sponsored validation study is 
ongoing. The experimental part was 
finalised in autumn 2017
JaCVAM
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Organisation
International Acceptance
Dermal Irritation Test Methods
In vitro Reconstructed human 
Epidermis (RhE) test methods: 
EpiSkin™, EpiDerm™ SIT, 
SkinEthic™ RHE and LabCyte 
EPI-MODEL24 SIT 
Completed OECD TG 439 (2010)
Updated version (including the LabCyte EPI-MODEL24 SIT) adopted in 2013.
Updated version [deleting the performance standards (published separately on the Series 
on Testing and Assessment No. 220), including paragraphs referring to the IATA for 
Skin Corrosion and Irritation in OECD GD No. 203 and including the use of HPLC/UPLC-
spectrophotometry as an alternative procedure to measure tissue viability (increasing 
the applicability domain of the test methods to coloured substances interfering with the 
measurement of MTT-formazan)] adopted in 2015.
In vitro reconstructed human 
epidermis (RhE) test methods: 
Korean epidermis model
KoCVAM sponsored validation study is 
ongoing
KoCVAM
In vitro reconstructed human full-
thickness model test methods: 
LbL model
JSAAE sponsored validation study is 
ongoing
JaCVAM
Phototoxicity Test Methods
3T3 NRU Phototoxicity Test Completed OECD TG 432 (2004)
ICH S10 (2014)
Test method battery to predict 
phototoxicity (yeast growth 
inhibition phototoxicity assay and 
red blood cell photohemolysis 
assay)
Japanese Regulatory Acceptance Board 
recommended additional work be 
performed
JaCVAM
In vitro test method based on 
reactive oxygen species (ROS) 
and photostability 
Completed ICH S10 (2014)
Included in the OECD TGP work plan in 2016.
Ocular Toxicity Test Methods
Bovine Corneal Opacity and 
Permeability (BCOP) Test 
Method
Completed OECD TG 437 (2009)
Updated version (positive control, use in a bottom-up approach to identify non-classified 
chemicals and several other revisions) adopted in 2013. Updated version to include a new 
reference to OECD GD 236 on an IATA for Serious Eye Damage and Eye Irritation adopted in 
2017. Updated version under consideration to include a laser light-based opacitometer.
101
Method Current Status Lead 
Organisation
International Acceptance
Isolated Chicken Eye (ICE) Test 
Method
Completed OECD TG 438 (2009)
Updated version (use in a bottom-up approach to identify non-classified chemicals and 
several other revisions) adopted in 2013.
Updated version to include a new reference to OECD GD 236 on an IATA for Serious Eye 
Damage and Eye Irritation adopted in 2017. Updated draft under consideration to include 
histopathology and modified decision criteria.
Use of Histopathology as an 
additional endpoint in Ocular 
Safety Testing
Completed  OECD GD 160 (2011)
Updated version [including: (i) the recommendation for having an internal peer-review 
process when evaluating histopathological effects, (ii) the use of semi-quantitative scoring 
systems for e.g.,. the ICE histopathology, and (iii) inclusion of an Atlas describing typical ICE 
histopathological effects] adopted in 2017.
Cytotoxicity test: SIRC CVS Peer review coordinated by JaCVAM is 
ongoing
JaCVAM 
Cytotoxicity test: three-dimensional 
dermal model (MATREX)
JaCVAM-sponsored validation study in 
the planning stage
JaCVAM 
Cytotoxicity test: Short Time 
Exposure (STE) test
Completed OECD TG 491 (2015)
Updated version to include a new reference to OECD GD 236 on an IATA for Serious Eye 
Damage and Eye Irritation adopted in 2017.
Use of anaesthetics, 
analgesics, and humane 
endpoints for routine use in 
TG 405
Completed OECD updated TG 405 (2012)
Updated version to delete the "Testing and Evaluation Strategy for Eye Irritation/Corrosion" 
and include a new reference to OECD GD 236 on an IATA for Serious Eye Damage and Eye 
Irritation adopted in 2017.
In vitro approach for 
categorisation of anti-
microbial cleaning products: 
recommendations for further 
studies
Completed. EPA/OPP2 has concluded from 
submission and review of alternative eye 
irritation tests conducted on antimicrobial 
pesticide products with cleaning claims 
(AMCPs) that the proposed testing 
approach is acceptable for determining 
the appropriate eye hazard classification 
and labelling for AMCPs (see https://www.
epa.gov/pesticides for the details of the 
scope of the policy).
ICCVAM
2 Environmental Protection Agency/Office of Pesticide Programme
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Method Current Status Lead 
Organisation
International Acceptance
Cytosensor Microphysiometer® 
(CM) Test method
The draft TG was submitted to OECD 
for comments including a set of 
Performance Standards
EURL ECVAM New draft TG discussed at WNT in 2013, 2015 and 2016 but not adopted. The additional 
data requested by the WNT that should have been submitted by US to support the project 
were not received and thus the project has been discontinued because of lower priority for 
the EC. The project is no longer on the OECD Work Plan.
Fluorescein Leakage (FL) test 
method
Completed OECD TG 460 (2012)
Updated version to include a new reference to OECD GD 236 on an IATA for Serious Eye 
Damage and Eye Irritation adopted in 2017
Reconstructed human Cornea-
like Epithelium (RhCE)
EpiOcular™ EIT; SkinEthic™ 
HCE EIT
Completed OECD TG 492 (2015)
Updated version to include SkinEthic™ HCE EIT and a new reference to OECD GD 236 on an 
IATA for Serious Eye Damage and Eye Irritation adopted in 2017.
Vitrigel-EIT Validation and peer review coordinated 
by JaCVAM completed
JaCVAM Included in the OECD TGP work plan in 2017
Reconstructed human Cornea-like 
Epithelium (RhCE) for eye irritation
LabCyte Cornea-model
Validation and peer review coordinated 
by JaCVAM completed. Undergoing 
commenting at OECD level for inclusion 
in TG 492.
JaCVAM Included in the OECD TGP work plan in 2017
OptiSafe Validation Study coordinated by 
NICEATM. Phase I (qualification 
and training of naïve laboratories) 
completed. Phase II partially completed: 
inter-laboratory study with 30 
chemicals completed; testing of 60 
chemicals in the lead laboratory 
ongoing.
NICEATM 
In vitro reconstructed human 
Cornea-epithelium model (RhCE) 
test method: Korean Cornea-model
KoCVAM-sponsored validation study is 
ongoing
KoCVAM
Hen's Egg Test-Chorioallantoic 
Membrane (HET-CAM) Test 
Method 
Validation study sponsored by Brazilian 
Ministry of Science, Technology 
Innovation and Communication (MCTIC). 
Preliminary phase of validation study 
ongoing
BraCVAM
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Organisation
International Acceptance
Immunotoxicity (Allergic Contact Dermatitis) Test Methods
Murine local lymph node assay 
(LLNA) for skin sensitization
Completed OECD TG 429 (2002)
ISO (2002)
Updated Murine local lymph 
node assay (LLNA) for skin 
sensitization (20% reduction)
Completed Update to TG 429 OECD (2010)
ISO (2010)
Reduced LLNA (rLLNA) Completed Update to TG 429 OECD (2010)
Nonradioactive LLNA protocol 
(LLNA: BrdU-ELISA)
Completed OECD TG 442B OECD (2010)
Nonradioactive LLNA protocol, 
LLNA:DA
Completed OECD TG 442A OECD (2010)
Harmonized performance 
standards for the LLNA
Completed Update to TG 429 OECD (2010)
Nonradioactive LLNA protocol 
(LLNA: BrdU-Flow Cytometry)
Validation study and peer review 
coordinated by KoCVAM completed. 
Undergoing commenting at OECD level 
for inclusion in TG 442B.
KoCVAM Consideration to include the method into draft TG 442B
In vitro skin sensitisation 
assay (DPRA) 
Completed OECD TG 442C (2015)
In vitro skin sensitisation 
assay (h-CLAT)
Completed OECD TG 442E (2016). Draft updated TG442E under consideration to include an 
adaptation to use human serum/antibodies.
In vitro skin sensitisation 
assay KeratinoSens™
Completed OECD TG 442D (2015). Draft updated version under consideration to include an 
adaptation to animal-free conditions.
In vitro skin sensitisation 
assay IL-8 Luc assay
Completed OECD TG 442E (2017)
In vitro skin sensitisation 
assay U937 Cell Line 
Activation Test (U-SENS™)
Completed OECD TG 442E (2017)
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Organisation
International Acceptance
In vitro skin sensitisation assay
LuSens
ESAC peer review completed and EURL 
ECVAM Recommendation published in 
2017. Undergoing commenting at OECD 
level for inclusion in TG 442D.
EURL ECVAM SPSF to include LuSens in OECD TG 442D approved in 2017. Draft updated TG442D 
currently under consideration.
In vitro skin sensitisation assay
SENS-IS
External validation study finalised EURL ECVAM 
evaluation 
ongoing
Included in the OECD TG work plan in 2016
In vitro skin sensitisation assay
Genomic Allergen Rapid Detection
(GARDskin)
External validation study ongoing Included in the OECD TG work plan in 2016
In vitro skin sensitisation assay 
Vitrigel-SST
MAFF3-sponsored validation study is 
pending
JaCVAM
In vitro skin sensitisation assay, 
Amino acid derivative reactivity 
assay (ARDA)
JCIA4 and JSAAE5 validation study is 
ongoing; peer review of study results 
foreseen for spring 2018
JaCVAM 
IL-2 Luc assay for the evaluation 
of the immunotoxic potential of 
chemicals 
JaCVAM validation study is ongoing JaCVAM
Electrophilic allergen screening 
assay (EASA)
Validation study coordinated by 
NICEATM is currently being planned. 
Testing began in spring 2017 and will 
continue through 2018.
NICEATM 
Acute Toxicity Test Methods
Up and Down Procedure (UDP) Completed OECD TG 425 (2008)
In vitro cytotoxicity test 
methods for estimating 
starting doses for acute oral 
systemic toxicity tests
Completed OECD GD 129 (2010)
3 Ministry of Agriculture, Forestry and Fisheries
4 Japan Cosmetic Industry Association
5 Japanese Society for Alternatives to Animal Experiments
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International Acceptance
In vitro cytotoxicity test (3T3 
Neutral Red Uptake) for 
identifying substances with acute 
oral LD50 > 2000 mg/kg b.w.
EURL ECVAM ESAC peer review 
completed, and EURL ECVAM 
Recommendation published in 2013
EURL ECVAM
EpiAirway human reconstructed 
lung epithelium for identifying 
acute inhalation toxicity
Validation study currently 
being planned. ICCVAM agency 
representatives serving on the VMT
NICEATM/ICCVAM
Toxicokinetic Test Methods
In vitro hepatic biotransformation 
– CYP induction: Hepa RG and 
cryopreserved human hepatocytes
EURL ECVAM SPSF for a PBTG approved in April 2013. Draft PBTG underwent a first commenting round in 
2014. An OECD expert meeting was held in March 2015. 
Endocrine Disruptor Test Methods
Stably transfected human 
estrogen receptor-α 
transcriptional activation assay 
for detection of estrogenic 
agonist-activity of chemicals 
(STTA and BG1-Luc assays) 
Completed OECD TG 455 (2009), updated 2012 and 2015, inclusion of the antagonist protocols 
in addition to the agonist protocols, deletion of OECD TG 457 in parallel as it is no longer 
needed
H295R Steroidogenesis assay Completed OECD TG 456 (2011)
BG1Luc® human estrogen 
receptor transcriptional 
activation assay: agonist and 
antagonist protocols
Completed OECD TG 457 (2012)
TG 457 has been deleted in parallel to TG 455 updates (see previous table entry)
CertiChem MCF-7 cell proliferation 
assay for the detection of human 
estrogen receptor agonists and 
antagonists
International validation study 
completed. Protocol must be revised for 
adequate transferability.
NICEATM Not in the OECD TGP work plan anymore
CertiChem MDA-Kb2 assay for 
the detection of human androgen 
receptor agonists and antagonists
NICEATM coordinated single lab 
validation study ongoing
NICEATM
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Stably transfected CHO 
Androgen receptor-α 
transcriptional activation 
assay for detection of 
androgenic agonist and 
antagonist activity of 
chemicals (AR-STTA)
Completed OECD TG 458 (2016)
MELN® human estrogen receptor 
transcriptional activation assay: 
agonist and antagonist protocols
Validation stopped
Stably Transfected Transactivation 
in vitro Assay to detect 
Androgen Receptor Agonists and 
Antagonists
Validation study ongoing EURL ECVAM Included in the OECD TGP work plan in April 2013
Transactivation assay for the 
detection of compounds with 
(anti)androgenic potential using 
22Rv1/MMTV cells
Validation study ongoing Ministry of Food 
and Drug Safety 
(MFDS) South 
Korea 
Performance-Based Test 
Guideline for Human 
Recombinant Estrogen 
Receptor (hrER) In Vitro 
Assays to Detect Chemicals 
with ER Binding Affinity
Completed OECD TG 493 (2015)
Genetic Toxicity Test Methods
In vitro mammalian cell 
micronucleus test
Completed OECD TG 487 (2010), updated TG  adopted in 2014
In vitro mammalian cell 
chromosome aberration assay6
Completed OECD TG 473 (1997), updated TG  adopted in 2014
In vivo comet assay Completed OECD TG 489 (2014)
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International Acceptance
In vitro comet assay Validation study for the in vitro comet 
assay stopped
JaCVAM 
Genotoxicity assays (micronucleus 
and comet) in 3D skin models
Validation study ongoing Cosmetics 
Europe  (lead);
EURL ECVAM 
support
Carcinogenicity Test Methods
In vitro Bhas 42 cell 
transformation assay (CTA)
Completed JaCVAM OECD GD  231 (2016)
In vitro Syrian hamster 
embryonic cells (SHE) cell 
transformation assays (CTAs)
Completed OECD GD 214 (2015)
Reproductive Test Methods
Hand-1 Luc assay METI7 -sponsored validation is 
completed. The peer review is on-going
JaCVAM Included in the OECD TGP work plan in 2017
Acute Aquatic Toxicity Test Methods
Zebrafish Embryo Acute 
Toxicity test (ZFET)
Completed OECD TG 236 (2013)
Fish Bioaccumulation Test Methods
In vitro Fish Hepatic Metabolism - 
Two in vitro systems for deriving 
information on biotransformation 
and improving reliability of 
predicted bioconcentration factors 
(BCF); thus having the potential 
of avoiding the need of fish 
bioconcentration tests
Ring trial conducted under the auspices 
of the OECD completed; ring trial report, 
two draft test guidelines and draft 
guidance document underwent two 
WNT commenting rounds in 2017 (April, 
August) 
US and European 
Commission 
(through JRC-
EURL ECVAM)
Included in the OECD TGP work plan in April 2014 
6 The in vitro mammalian cell chromosome aberration assay has not been validated by any of the ICATM partners. It is added here for completeness as it has been adopted as an OECD TG.
7 Ministry of Economy, Trade and Industry

Joint 
Research 
Centre
W
1991 
Foundation of ECVAM, the European Centre 
for the Validation of Alternative Methods, 
at the European Commission’s Joint 
Research Centre in Ispra, Italy.
1994
ECVAM Opening Symposium “The 
Validation of Replacement Alternative 
Methods”.
1997  
First Statement of the ECVAM Scientific 
Advisory Committee on an in vitro method 
for phototoxicity testing of chemicals.
1999  
Third World Congress on Alternatives and 
Animal Use in Life Sciences organised 
by ECVAM with signing of the Three Rs 
Declaration of Bologna.
2000 
Inclusion of first in vitro replacement tests 
for skin corrosion and phototoxicity testing 
into EU law.
2002 
International recognition of ECVAM’s 
validation process at OECD conference.
2004  
ECVAM publishes its Modular Approach 
to Validation of alternative methods to 
achieve more flexibility while retaining 
scientific rigour.
2006  
Launch of DB-ALM, the ECVAM Database 
Service on Alternative Methods.
2016 
OECD endorses three Adverse Outcome 
Pathways developed by EURL ECVAM 
signalling a clear shift towards knowledge-
driven design of Integrated Approaches to 
Testing and Assessment using alternative 
methods.
Updates to REACH Regulation making in 
vitro methods the default route to satisfy 
information requirements for serious eye 
damage and eye irritation, skin corrosion 
and irritation, and skin sensitisation. 
2010 
Alternative methods for full replacement of 
skin irritation, skin corrosion, phototoxicity 
and skin penetration testing accepted as 
OECD Test Guidelines and included in the 
EU Test Methods Regulation.
2011 
ECVAM becomes EURL ECVAM, the EU 
Reference Laboratory for Alternatives to 
Animal Testing. 
Publication of 1st edition of the EURL 
ECVAM Search Guide, a means for effective 
retrieval of information on alternative 
methods.
Dedicated to 3Rs – Replacement, Reduction and 
25 years of EU Reference Laboratory
Refinement of animal experiments
 
EURL ECVAM has organised 86 workshops on the development, validation and acceptance of alternative methods & has 
validated around 50 alternative methods | There are 37 members in the network of validation laboratories | 56 Statements/
Opinions have been issued by the EURL ECVAM Scientific Advisory Committee | EURL ECVAM has led the development of 
14 OECD Test Guidelines and Guidance Documents on alternative methods | DB-ALM  has over 5000 registered users, 
from 82 countries & contains over 300 method descriptions
for Alternatives to Animal Testing
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